
<html lang="en"     class="pb-page"  data-request-id="0fb830e0-cff7-4b31-b381-7e1f59a5fa5a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b00709;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2017.60.issue-18;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders" /></meta><meta name="dc.Creator" content="Satoshi  Mikami" /></meta><meta name="dc.Creator" content="Shigekazu  Sasaki" /></meta><meta name="dc.Creator" content="Yasutomi  Asano" /></meta><meta name="dc.Creator" content="Osamu  Ujikawa" /></meta><meta name="dc.Creator" content="Shoji  Fukumoto" /></meta><meta name="dc.Creator" content="Kosuke  Nakashima" /></meta><meta name="dc.Creator" content="Hideyuki  Oki" /></meta><meta name="dc.Creator" content="Naomi  Kamiguchi" /></meta><meta name="dc.Creator" content="Haruka  Imada" /></meta><meta name="dc.Creator" content="Hiroki  Iwashita" /></meta><meta name="dc.Creator" content="Takahiko  Taniguchi" /></meta><meta name="dc.Description" content="Herein, we describe the discovery of a potent, selective, brain-penetrating, in vivo active phosphodiesterase (PDE) 2A inhibitor lead series. To identify high-quality leads suitable for optimizatio..." /></meta><meta name="Description" content="Herein, we describe the discovery of a potent, selective, brain-penetrating, in vivo active phosphodiesterase (PDE) 2A inhibitor lead series. To identify high-quality leads suitable for optimizatio..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 11, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00709" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00709" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00709" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00709" /></link>
        
    
    

<title>Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00709" /></meta><meta property="og:title" content="Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0019.jpeg" /></meta><meta property="og:description" content="Herein, we describe the discovery of a potent, selective, brain-penetrating, in vivo active phosphodiesterase (PDE) 2A inhibitor lead series. To identify high-quality leads suitable for optimization and enable validation of the physiological function of PDE2A in vivo, structural modifications of the high-throughput screening hit 18 were performed. Our lead generation efforts revealed three key potency-enhancing functionalities with minimal increases in molecular weight (MW) and no change in topological polar surface area (TPSA). Combining these structural elements led to the identification of 6-methyl-N-((1R)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (38a), a molecule with the desired balance of preclinical properties. Further characterization by cocrystal structure analysis of 38a bound to PDE2A uncovered a unique binding mode and provided insights into its observed potency and PDE selectivity. Compound 38a significantly elevated 3′,5′-cyclic guanosine monophosphate (cGMP) levels in mouse brain following oral administration, thus validating this compound as a useful pharmacological tool and an attractive lead for future optimization." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00709"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00709">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00709&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00709&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00709&amp;href=/doi/10.1021/acs.jmedchem.7b00709" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 7658-7676</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00143" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00807" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Satoshi++Mikami">Satoshi Mikami</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-3587-0343" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shigekazu++Sasaki">Shigekazu Sasaki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yasutomi++Asano">Yasutomi Asano</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Osamu++Ujikawa">Osamu Ujikawa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shoji++Fukumoto">Shoji Fukumoto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kosuke++Nakashima">Kosuke Nakashima</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hideyuki++Oki">Hideyuki Oki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Naomi++Kamiguchi">Naomi Kamiguchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haruka++Imada">Haruka Imada</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroki++Iwashita">Hiroki Iwashita</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takahiko++Taniguchi">Takahiko Taniguchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div><div class="corresp-info"><strong>*</strong>Phone: +81-466-32-1217. Fax: +81-466-29-4458. E-mail: <a href="/cdn-cgi/l/email-protection#1665776279657e7f387b7f7d777b7f5662777d7372773875797b"><span class="__cf_email__" data-cfemail="e794869388948f8ec98a8e8c868a8ea793868c828386c984888a">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00709&amp;href=/doi/10.1021%2Facs.jmedchem.7b00709" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 7658–7676</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 31, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 May 2017</li><li><span class="item_label"><b>Published</b> online</span>11 September 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 September 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00709" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00709</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7658%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSatoshi%2BMikami%252C%2BShigekazu%2BSasaki%252C%2BYasutomi%2BAsano%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D18%26contentID%3Dacs.jmedchem.7b00709%26title%3DDiscovery%2Bof%2Ban%2BOrally%2BBioavailable%252C%2BBrain-Penetrating%252C%2Bin%2BVivo%2BActive%2BPhosphodiesterase%2B2A%2BInhibitor%2BLead%2BSeries%2Bfor%2Bthe%2BTreatment%2Bof%2BCognitive%2BDisorders%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7676%26publicationDate%3DSeptember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00709"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2974</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">24</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00709" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Satoshi&quot;,&quot;last_name&quot;:&quot;Mikami&quot;},{&quot;first_name&quot;:&quot;Shigekazu&quot;,&quot;last_name&quot;:&quot;Sasaki&quot;},{&quot;first_name&quot;:&quot;Yasutomi&quot;,&quot;last_name&quot;:&quot;Asano&quot;},{&quot;first_name&quot;:&quot;Osamu&quot;,&quot;last_name&quot;:&quot;Ujikawa&quot;},{&quot;first_name&quot;:&quot;Shoji&quot;,&quot;last_name&quot;:&quot;Fukumoto&quot;},{&quot;first_name&quot;:&quot;Kosuke&quot;,&quot;last_name&quot;:&quot;Nakashima&quot;},{&quot;first_name&quot;:&quot;Hideyuki&quot;,&quot;last_name&quot;:&quot;Oki&quot;},{&quot;first_name&quot;:&quot;Naomi&quot;,&quot;last_name&quot;:&quot;Kamiguchi&quot;},{&quot;first_name&quot;:&quot;Haruka&quot;,&quot;last_name&quot;:&quot;Imada&quot;},{&quot;first_name&quot;:&quot;Hiroki&quot;,&quot;last_name&quot;:&quot;Iwashita&quot;},{&quot;first_name&quot;:&quot;Takahiko&quot;,&quot;last_name&quot;:&quot;Taniguchi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;7658-7676&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00709&quot;},&quot;abstract&quot;:&quot;Herein, we describe the discovery of a potent, selective, brain-penetrating, in vivo active phosphodiesterase (PDE) 2A inhibitor lead series. To identify high-quality leads suitable for optimization and enable validation of the physiological function of PDE2A in vivo, structural modifications of the high-throughput screening hit 18 were performed. Our lead generation efforts revealed three key potency-enhancing functionalities with minimal increases in molecular weight (MW) and no change in topological polar surface area (TPSA). Combining these structural elements led to the identification of 6-methyl-N-((1R)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (38a), a molecule with the desired balance of preclinical properties. Further characterization by cocrystal structure analysis of 38a bound to PDE2A uncovered a unique binding mode and provided insights into its observed potency and PDE selectivity. Compound 38a significantly elevated 3′,5′-cyclic guanosine monophosphate (cGMP) &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00709&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00709" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00709&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00709" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00709&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00709" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00709&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00709&amp;href=/doi/10.1021/acs.jmedchem.7b00709" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00709" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00709" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00709%26sid%3Dliteratum%253Aachs%26pmid%3D28759228%26genre%3Darticle%26aulast%3DMikami%26date%3D2017%26atitle%3DDiscovery%2Bof%2Ban%2BOrally%2BBioavailable%252C%2BBrain-Penetrating%252C%2Bin%2BVivo%2BActive%2BPhosphodiesterase%2B2A%2BInhibitor%2BLead%2BSeries%2Bfor%2Bthe%2BTreatment%2Bof%2BCognitive%2BDisorders%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D18%26spage%3D7658%26epage%3D7676%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291594" title="Silica">Silica</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/jmcmar.2017.60.issue-18/20170928/jmcmar.2017.60.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein, we describe the discovery of a potent, selective, brain-penetrating, in vivo active phosphodiesterase (PDE) 2A inhibitor lead series. To identify high-quality leads suitable for optimization and enable validation of the physiological function of PDE2A in vivo, structural modifications of the high-throughput screening hit <b>18</b> were performed. Our lead generation efforts revealed three key potency-enhancing functionalities with minimal increases in molecular weight (MW) and no change in topological polar surface area (TPSA). Combining these structural elements led to the identification of 6-methyl-<i>N</i>-((1<i>R</i>)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>38a</b>), a molecule with the desired balance of preclinical properties. Further characterization by cocrystal structure analysis of <b>38a</b> bound to PDE2A uncovered a unique binding mode and provided insights into its observed potency and PDE selectivity. Compound <b>38a</b> significantly elevated 3′,5′-cyclic guanosine monophosphate (cGMP) levels in mouse brain following oral administration, thus validating this compound as a useful pharmacological tool and an attractive lead for future optimization.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81343" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81343" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">3′,5′-Cyclic adenosine monophosphate (cAMP) and 3′,5′-cyclic guanosine monophosphate (cGMP) are ubiquitous key second messengers for intracellular signaling pathways. These signaling cascades are triggered by a wide variety of extracellular signaling molecules such as hormones and neurotransmitters. The extracellular signaling molecule binds to a specific cell-surface receptor and, in turn, activate adenylyl cyclases (ACs) or guanylyl cyclases (GCs), resulting in the production of cAMP or cGMP, respectively.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> The resulting increases in cellular cAMP and/or cGMP concentrations lead to the activation of cAMP- and/or cGMP-dependent protein kinases such as protein kinase A (PKA) and protein kinase G (PKG). Signals can be further transduced into the nucleus to affect gene transcription and numerous cellular functions.</div><div class="NLM_p">Phosphodiesterases (PDEs) are a family of enzymes that metabolically inactivate cAMP and/or cGMP. PDEs catalytically hydrolyze the 3′-cyclic phosphate bonds of the nucleotides, forming inactive 5′-AMP and/or 5′-GMP, which terminates the intracellular signals.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> There are 11 different PDE families (PDE1–11), encoded by 21 separate genes. Each family member has several different isoforms and splice variants and is characterized by a unique cellular and subcellular distribution, different mechanisms of regulation, and distinct substrate preferences for cAMP and cGMP.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> On the basis of substrate specificity, PDE families can be categorized into three groups: cAMP-specific, cGMP-specific, and dual-substrate PDEs. For example, PDE4, 7, and 8 hydrolyze only cAMP, PDE5, 6, and 9 specifically degrade cGMP, and PDE1, 2, 3, 10, and 11 hydrolyze both substrates.</div><div class="NLM_p">Because of their ability to amplify intracellular signaling cascades through increasing the concentration of cAMP and/or cGMP, PDE inhibitors have garnered a great deal of attention as therapeutic agents for a wide range of disorders. Currently, inhibitors of several classes of PDE families, including PDE3, 4, and 5, are available for treating pathophysiological dysregulation of cyclic nucleotide signaling in several peripheral diseases such as congestive heart failure, chronic obstructive pulmonary disease (COPD), erectile dysfunction, and pulmonary arterial hypertension (PAH) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Considering the widespread expression of some PDEs throughout the brain and the therapeutic success of PDE inhibitors targeting peripheral diseases, there has been significant interest in the potential of PDE inhibitors to treat central nervous system (CNS) disorders.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16-19)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0001.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selected examples of currently approved PDE inhibitors <b>1</b>–<b>13</b>. Of these, the PDE3 inhibitors milrinone, olprinone, and cilostazol have been approved for the short-term treatment of congestive heart failure<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and the treatment of intermittent claudication,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> respectively. The PDE4 inhibitor roflumilast has entered the market as an oral treatment for reducing the risk of exacerbations in patients with COPD who also have chronic bronchitis.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a> Another PDE4 inhibitors apremilast and crisaborole have been approved for the treatment of psoriasis and psoriatic arthritis<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and the treatment of atopic dermatitis,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> respectively. The PDE5 inhibitors sildenafil, tadalafil, vardenafil, avanafil, udenafil, mirodenafil, and lodenafil are now marketed for the treatment of erectile dysfunction.<a onclick="showRef(event, 'ref5 ref13'); return false;" href="javascript:void(0);" class="ref ref5 ref13">(5, 13)</a> Sildenafil and tadalafil have also been approved as treatments for PAH;<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> moreover, the latter has also been used clinically for the treatment of benign prostatic hyperplasia.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">PDE2A is a dual-substrate enzyme capable of hydrolyzing both cAMP and cGMP. It is highly expressed in the brain, where the enzyme is localized in the cortex, hippocampus, striatum, and amygdala, brain regions that govern cognitive functions such as emotion, learning, and memory.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> However, PDE2A is reported to have relatively low expression in peripheral tissues,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> which may minimize the unwanted side effects observed with some PDE inhibitors.<a onclick="showRef(event, 'ref5 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref5 ref22 ref23">(5, 22, 23)</a> Several preclinical studies have shown that PDE inhibitors demonstrated to enhance long-term potentiation (LTP) in brain slice preparations via elevations in either cAMP or cGMP.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Additionally, cGMP and cAMP have been implicated in early and late stages of memory consolidation, respectively.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> These pieces of evidence indicates that through elevation of intracellular cAMP and/or cGMP levels in brain regions associated with emotion, learning, and memory, inhibition of PDE2A could potentially ameliorate cognitive dysfunction in a range of neuropsychiatric and neurodegenerative disorders, including schizophrenia and dementia.</div><div class="NLM_p">To date, a variety of small-molecule PDE2A inhibitors have been reported by different pharmaceutical companies,<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31 ref32 ref33">(27-33)</a> as summarized in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. Janssen reported the discovery of methyl-[1,2,4]triazolo[4,3-<i>a</i>]quinoxaline analogue <b>14</b> as a selective and brain penetrating PDE2A inhibitor (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). In addition, Pfizer recently disclosed the clinical candidate <b>15</b> (PF-05180999), which demonstrated potent PDE2A inhibitory activity, excellent PDE selectivity, and good brain permeability.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Consequently, compound <b>15</b> was advanced into phase I clinical trials for the treatment of schizophrenia and, subsequently, migraines. Very recently, Dart Neuroscience also reported the novel PDE2A inhibitor <b>16</b> (DNS-8254) with balanced drug-like properties.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Compound <b>17</b> (BAY 60–7550), the first PDE2A inhibitor disclosed in a 2002 patent application from Bayer,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> has been the most thoroughly characterized preclinical compound and is a critical pharmacological tool in the research field.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> However, a recent study revealed the extremely poor ability of <b>17</b> to cross the blood–brain barrier in rats after oral administration, bringing into question whether the observed in vivo effects were truly mediated by PDE2A inhibition in the brain.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative structures and profiles of reported selective PDE2A inhibitors <b>14</b>–<b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering the limited availability of other high-quality tool compounds at the beginning of our program and the potential physiological role of PDE2A and its unique expression pattern, we embarked on a campaign to search for small-molecule PDE2A inhibitors. Our primary goal was to deliver a tool compound that would enable us to confirm the biological rationale of PDE2A inhibition and, simultaneously, to identify a promising lead molecule that could facilitate optimization toward an orally bioavailable and brain-penetrating clinical candidate with suitable drug-like properties.</div><div class="NLM_p last">In this article, we describe our lead-generation approach, starting from the high-throughput screening hit <b>18</b> and elucidate the structure–activity relationships (SAR) for this series that ultimately led to the discovery of 6-methyl-<i>N</i>-((1<i>R</i>)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>38a</b>), a promising lead that achieved a good alignment of potency, PDE selectivity, and PK profile (including brain penetration) while also possessing favorable physicochemical properties. In addition, we report the X-ray crystal structure of <b>38a</b> complexed with PDE2A, which uncovered key and unique interactions with the PDE2A enzyme. We also report in vivo effects of <b>38a</b> on cyclic nucleotides by oral dosing, which will help us understand the physiological role of the PDE2A enzyme.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81037" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81037" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the search for attractive chemical matter to serve as starting points for drug-like lead generation, a diverse set of compounds from our corporate sample collection were screened for PDE2A inhibitory activity. This effort identified pyrazolo[1,5-<i>a</i>]pyrimidine hit <b>18</b> with an IC<sub>50</sub> of 3.8 μM. Although <b>18</b> was not sufficiently potent or selective to develop, it was attractive due to its modular structure, which was amenable to rapid analogue preparation and SAR exploration. The compound also had a low MW and calculated TPSA value (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A), allowing for latitude to optimize potency and physicochemical properties in both the lead generation and ensuing optimization stages. In addition, we envisioned that the potential of <b>18</b> to form an intramolecular hydrogen bond would impart a benefit of reducing the number of exposed hydrogen bond donors (HBDs) (the NH of the amide) and attenuating the p<i>K</i><sub>a</sub> of the pyrazolo[1,5-<i>a</i>]pyrimidine N4 nitrogen atom, resulting in further increased CNS drug-likeness. These properties motivated us to initiate hit-to-lead studies with the main goal of enhancing the in vitro PDE2A inhibitory activity of <b>18</b>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Structure and profile of pyrazolo[1,5-<i>a</i>]pyrimidine hit <b>18</b> from a high-throughput screen. The intramolecular hydrogen bond is indicated in red. (B) SAR approach.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At the outset of this program, an X-ray crystal structure of PDE2A in complex with a selective inhibitor had not been reported, except for one using a complex with the weak, nonspecific PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Moreover, our initial attempts to predict the binding mode of <b>18</b> by employing molecular modeling provided too many plausible and low-scoring options, which limited our ability to utilize structure-based drug design (SBDD) techniques effectively during the early lead-generation phase. Thus, we decided to implement a classical medicinal chemistry approach.</div><div class="NLM_p">The SAR of <b>18</b> was systematically investigated according to three main parts of the molecule, namely the pyrazolo[1,5-<i>a</i>]pyrimidine core, central amide linker, and α-branched benzylamine portion as shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B.</div><div class="NLM_p">An initial SAR study involved substitutions on the pyrazolo[1,5-<i>a</i>]pyrimidine core (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Incorporation of a methyl group into the 2-position (<b>19</b>) led to a significant loss in inhibitory activity, while methyl substitution at the 5-position in compound <b>20</b> retained potency relative to compound <b>18</b>. One possible explanation for the loss of potency with <b>19</b> is that steric hindrance of the methyl group at the 2-position with the nearby carbonyl group of the amide moiety induces a conformational change of the molecule into an energetically less favorable conformation. A substantial enhancement in the potency of <b>21</b> was accomplished, coupled with an improvement in ligand efficiency (LE = 0.36), by methyl substitution at the 6-position. However, methyl substitutions at both the 5- and 7-positions (<b>22</b>) decreased inhibitory activity. Considering that the 5-methyl derivative <b>20</b> retained potency, it appears that the methyl group at the 7-position in <b>22</b> has a detrimental effect on inhibitory activity, and, therefore, the loss of potency of <b>22</b> can be explained by the limited and/or hydrophilic space in the binding pocket of PDE2A around the 7-position. Taking into account the enhanced inhibitory activity of compound <b>21</b>, we next directed our attention to variations of substituents at the 6-position. More lipophilic and bulkier substituents such as chloro, cyclopropyl, and phenyl groups were incorporated; however, all compounds (<b>23</b>, <b>24</b>, and <b>25</b>) exhibited decreased potency. These results indicated that the space in the binding pocket around the 6-position is not very large and is roughly the size that a methyl group can fully occupy. Altogether, the SAR studies around the core ring revealed that the introduction of a methyl group at the 6-position (<b>21</b>) yielded the most promising potency enhancement while maintaining good ligand efficiency.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Activities for Substituted Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0014.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>5</sup></th><th class="colsep0 rowsep0" align="center">R<sup>6</sup></th><th class="colsep0 rowsep0" align="center">R<sup>7</sup></th><th class="colsep0 rowsep0" align="center">PDE2A IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">LE<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">3.8 (3.0–4.7)</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="center">Me</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">16 (13–19)</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">Me</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">2.2 (1.8–2.7)</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">Me</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">0.49 (0.43–0.57)</td><td class="colsep0 rowsep0" align="char" char=".">0.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">Me</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">Me</td><td class="colsep0 rowsep0" align="center">7.0 (4.8–10)</td><td class="colsep0 rowsep0" align="char" char=".">0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">Cl</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">1.4 (1.3–1.7)</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center"><i>c</i>-Pr</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">1.0 (0.92–1.1)</td><td class="colsep0 rowsep0" align="char" char=".">0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">Ph</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">23 (18–31)</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values (95% confidence intervals given in parentheses) were calculated from percent inhibition data (duplicaate, <i>n</i> = 1). All values are rounded to two significant digits.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Ligand Efficiency (LE) = −1.37 Log IC<sub>50</sub>/number of heavy atoms.</p></div></div></div><div class="NLM_p">We next investigated the SAR of the amide linker region. As shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, all modifications, including removal of the amide carbonyl group (<b>26</b>), <i>N</i>-methylation of the amide (<b>27</b>), and replacement with the corresponding sulfonamide group (<b>28</b>), resulted in markedly reduced inhibitory activities. From these results, we assumed that the carbonyl group is most likely engaged in a key interaction with an amino acid residue in the PDE2A enzyme while the amide NH plays a crucial role in constraining the binding conformation via intramolecular hydrogen bonding to the N4 nitrogen atom on the pyrazolo[1,5-<i>a</i>]pyrimidine core. To examine the effect of this presumed internal hydrogen bond on the potency, two analogues, <b>29</b> and <b>30</b>, were prepared, wherein the nitrogen atom at the N4 position of the core was replaced with a CH group with the aim of disrupting the internal hydrogen bonding (<b>29</b>), or a new ring was constructed between the amide NH and the N4 position of the core (<b>30</b>). As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, the potency of compound <b>29</b> dropped sharply, while compound <b>30</b> partially maintained inhibitory activity, suggesting that structural rigidity conveyed by the intramolecular hydrogen bond is critical for PDE2A inhibitory activity in this series. An approximately 5-fold decrease in potency noted with <b>30</b> relative to acyclic analogue <b>18</b> could be attributed to the conformational change of the right-hand side (RHS) α-branched benzylamine moiety by the new ring formation.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of the amide linker connecting the pyrazolo[1,5-<i>a</i>]pyrimidine core and <i>p</i>-methoxyphenyl moiety on PDE2A inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Analogue designed to test the involvement of intramolecular hydrogen bonding in PDE2A inhibitory activity. The intramolecular hydrogen bond is depicted as a red arc in compound <b>18</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next focused on exploring the RHS amine part while keeping the secondary amide group constant, taking into account the importance of the intramolecular hydrogen bond. Some key SAR features are shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Reference data for <i>p</i>-methoxyphenyl derivative <b>21</b> is also included in the table. Removal of the <i>p</i>-methoxy group from compound <b>21</b> resulted in a 7-fold decrease in potency (<b>31</b>), suggesting that the substituent at this position contributes to space filling in the neighboring binding pocket and/or to assisting the interaction of the attached phenyl group with the protein by its electron donating nature. In the case of the branched alkyl group, truncation of the ethyl group (<b>31</b>) to form a methyl group (<b>32</b>) resulted in a 6-fold decrease in potency, while complete deletion of the ethyl group (<b>34</b>) led to a marked erosion in potency (>100-fold), when compared to compound <b>21</b>. Furthermore, a 9-fold loss in potency was observed with cyclization of the ethyl moiety into the <i>ortho</i>-position of the adjacent phenyl ring (<b>33</b>). These results indicate that the branched alkyl group is likely essential to obtaining potent PDE2A inhibitory activity. We speculated that the branched alkyl group not only fills the binding pocket but also serves to direct the phenyl group into a favorable orientation. The substitution pattern on the phenyl ring also appeared to be important. Migration of the methoxy group from the <i>para</i>-position to the <i>meta</i>- (<b>35</b>) or <i>ortho</i>-positions (<b>36</b>) was detrimental to activity. Replacement of the methoxy group at the <i>para</i>-position (<b>34</b>) with a trifluoromethoxy group (<b>37</b>) boosted potency by nearly 9-fold. This large activity discrepancy (<b>34</b> vs <b>37</b>) may be explained by a difference in conformational preferences between the methoxyphenyl and trifluoromethoxyphenyl groups. It has been reported that a trifluoromethoxy group attached to an aromatic ring generally prefers an orthogonal orientation to the aromatic plane and, in contrast, methoxy groups tend to lie in the plane of the aromatic ring.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> We postulated, therefore, that the propensity of the O–CF<sub>3</sub> bond to adopt an orthogonal alignment would help mimic the bound conformation, which may result in a less entropic cost of binding and, consequently, enhanced potency.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Representative RHS Amines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0015.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0016.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values (95% confidence intervals given in parentheses) were calculated from percent inhibition data (duplicate, <i>n</i> = 1). All values were rounded to two significant digits.</p></div></div><div></div></div><div class="NLM_p">These promising results from the preliminary SAR studies described above prompted us to prepare <b>38</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), which combined the key potency enhancing elements, i.e., the methyl group at the 6-position of the pyrazolo[1,5-<i>a</i>]pyrimidine core and the distal trifluoromethoxy group. As expected, an additive effect on inhibitory activity was observed for this compound (PDE2A IC<sub>50</sub> = 53 nM). Encouraged by this result, chiral separation was performed to determine the effect of chirality on PDE2A inhibitory activity and selectivity against other PDEs. Eutomer <b>38a</b> was found to be approximately 2-fold more potent than racemic compound <b>38</b>, while distomer <b>38b</b> was inactive with a PDE2A IC<sub>50</sub> > 10000 nM, indicating that most of the activity of <b>38</b> resided in a single enantiomer. In addition, eutomer <b>38a</b> demonstrated 180-fold selectivity with respect to PDE3A and more than 300-fold selectivity toward the remaining PDE family proteins (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Activity Profiles of <b>38</b> and Its Enantiomers <b>38a</b> and <b>38b</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0017.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">stereo</th><th class="colsep0 rowsep0" align="center">PDE2A IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="center"><i>rac</i></td><td class="colsep0 rowsep0" align="center">0.053 (0.047–0.059)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38a</b></td><td class="colsep0 rowsep0" align="center"><i>R</i><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">0.024 (0.022–0.027)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38b</b></td><td class="colsep0 rowsep0" align="center"><i>S</i><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">>100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values (95% confidence intervals given in parentheses) were calculated from percent inhibition data (duplicate, <i>n</i> = 1). All values are rounded to two significant digits.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Absolute configuration assigned based on the stereochemistry of the bound conformation in the crystal structure of <b>38a</b> (see <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro PDE Selectivity Profile of <b>38a</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PDE subtypes</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">selectivity ratio<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE1A</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>420</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE2A3</td><td class="colsep0 rowsep0" align="char" char=".">0.024</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE3A</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE4D2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>420</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE5A1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>420</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE6AB</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>420</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE7B</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>420</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE8A1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>420</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE9A2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>420</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE10A2</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char=".">310</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE11A4</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>420</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values were calculated from percent inhibition data (duplicate, <i>n</i> = 1). All values are rounded to two significant digits.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Selectivity ratio (rounded to two significant digits) = PDE“X” IC<sub>50</sub>/PDE2A IC<sub>50</sub>.</p></div></div></div><div class="NLM_p">With the potent and selective PDE2A inhibitor <b>38a</b> in hand, we conducted X-ray analysis to obtain its PDE2A cocrystal structure and unambiguously identify the binding mode. As shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A,B, <b>38a</b> binds to the PDE2A catalytic site. In agreement with the described SAR, an intramolecular hydrogen bond is observed between the amide NH and the N4 nitrogen atom of the core, most likely stabilizing the bioactive conformation. In addition, the absolute configuration at the benzylic stereocenter of <b>38a</b> was determined to be the <i>R</i> enantiomer. The X-ray crystal structure also revealed a number of key interactions with PDE2A. The C7 hydrogen of the core forms a potential C–H hydrogen bond with the carbonyl oxygen atom of Gln859, a conserved amino acid in all PDEs that plays a critical role in cyclic nucleotide binding, with a C–O separation distance of 3.2 Å.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The carbonyl oxygen atom of the amide group forms a water-mediated hydrogen-bonding network with the OH of Tyr655. This interaction may explain the considerable drop in potency observed after removal of the carbonyl group (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, <b>26</b>). The pyrazolo[1,5-<i>a</i>]pyrimidine core makes π–π and CH−π interactions with the Phe862 on the top and Ile826 on the bottom, respectively (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B). The C6 methyl group of the core points toward Leu858, thus making a favorable van der Waals contact with its side chain. The cavity that accommodates the methyl group appears to be tight, and, indeed, a loss in potency was observed when the methyl group was replaced with larger substituents (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, <b>23</b>–<b>25</b>), indicating that a methyl group may be the optimal size in this position. The branched ethyl group is accommodated in the hydrophobic pocket surrounded by Ile826, Phe830, His656, and Tyr655. The <i>para</i>-trifluoromethoxyphenyl group fits into the hydrophobic pocket that was newly created by the inhibitor binding. The relatively high selectivity observed for <b>38a</b> may be driven, in part, by the utilization of this binding-induced hydrophobic pocket, which is presumed to be unique to PDE2A among all PDEs.<a onclick="showRef(event, 'ref29 ref40'); return false;" href="javascript:void(0);" class="ref ref29 ref40">(29, 40)</a> It should also be noted that the trifluoromethoxy group sits in the hydrophobic cavity in an energetically favorable orthogonal orientation. This provides a reasonable explanation for the approximately 9-fold potency increase of <b>38</b> over the corresponding methoxylphenyl counterpart <b>21</b> with the energetic preference of a planar conformation.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0006.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray crystal structure of <b>38a</b> bound in the PDE2A catalytic site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XKM">5XKM</a>) viewed from the top (A) and the entrance of the catalytic site (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of its promising PDE2A inhibitory activity, compound <b>38a</b> was characterized in terms of its in vitro profile (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>) and PK properties (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>) to probe its suitability as a lead for further optimization and in vivo pharmacological study. Compound <b>38a</b> possessed favorable physicochemical properties, namely MW, LE, and LipE. In addition, the compound demonstrated acceptable human, rat, and mouse microsomal stability, and there was no indication of P-glycoprotein (P-gp)-mediated efflux, which suggested that there would be good brain penetration. Pharmacokinetic evaluation of <b>38a</b> in rats and mice revealed suboptimal PK parameters, as indicated by moderate to high clearance and volume of distribution; however, the compound exhibited moderate oral bioavailability and excellent CNS penetration, as reflected in <i>K</i><sub>p</sub> values of 2.9 in rats and 2.6 in mice, implying no barriers to brain uptake.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Calculated Physicochemical Properties and in Vitro Profiles for Representative Lead <b>38a</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0018.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE2A IC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">0.024 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MW</td><td class="colsep0 rowsep0" align="left">378</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Log <i>D</i><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">3.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TPSA</td><td class="colsep0 rowsep0" align="left">69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LE<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LipE<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">4.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE selectivity</td><td class="colsep0 rowsep0" align="left">180-fold (vs PDE3A)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLM<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (μL/min/mg)</td><td class="colsep0 rowsep0" align="left"><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RLM<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a> (μL/min/mg)</td><td class="colsep0 rowsep0" align="left">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MLM<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a> (μL/min/mg)</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDR1 ratio<a class="ref internalNav" href="#t5fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">0.43</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Log <i>D</i> value at pH 7.4.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">LE (ligand efficiency) = −1.37 Log IC<sub>50</sub>/number of heavy atoms.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">LipE (lipophilic efficiency) = pIC<sub>50</sub> – Log <i>D</i>.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Metabolic stability in human liver microsomes.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">Metabolic stability in rat liver microsomes.</p></div><div class="footnote" id="t5fn6"><sup>f</sup><p class="last">Metabolic stability in mouse liver microsomes.</p></div><div class="footnote" id="t5fn7"><sup>g</sup><p class="last">Multidrug resistance protein 1 EMDR1) efflux ratio in P-glycoprotein (P-gp)-overexpressing cells.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Properties and <i>K</i><sub>p</sub> Values of <b>38a</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">iv (0.1 mg/kg)</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">po (1 mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>total</sub><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vd<sub>ss</sub><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (mL/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub><a class="ref internalNav" href="#t6fn5" aria-label="e">e</a> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–8h</sub><a class="ref internalNav" href="#t6fn6" aria-label="f">f</a> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>p</sub><a class="ref internalNav" href="#t6fn8" aria-label="h">h</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">43.9</td><td class="colsep0 rowsep0" align="char" char=".">3953</td><td class="colsep0 rowsep0" align="char" char=".">15.9</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">58.7</td><td class="colsep0 rowsep0" align="char" char=".">15.4</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">43.2</td><td class="colsep0 rowsep0" align="char" char=".">4363</td><td class="colsep0 rowsep0" align="char" char=".">44.8</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">132.6</td><td class="colsep0 rowsep0" align="char" char=".">33.9</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Rat or mouse cassette dosing at 0.1 mg/kg, iv, and 1 mg/kg, po (nonfasted). Average of three rats.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Total clearance.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Volume of distribution at steady state.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">Maximum plasma concentration.</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">Time of maximum concentration.</p></div><div class="footnote" id="t6fn6"><sup>f</sup><p class="last">Area under the plasma concentration vs time curve (0–8 h).</p></div><div class="footnote" id="t6fn7"><sup>g</sup><p class="last">Oral bioavailability.</p></div><div class="footnote" id="t6fn8"><sup>h</sup><p class="last">Brain-to-plasma ratio at 2 h in rat and 1 h in mouse.</p></div></div></div><div class="NLM_p">Given the excellent PDE selectivity and brain penetration after oral dosing, compound <b>38a</b> was considered suitable for in vivo evaluation. To confirm pharmacodynamic (PD) responses resulting from PDE2A inhibition, the effects of compound <b>38a</b> on the levels of cyclic nucleotides in several brain regions of mice were determined (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A,B). The three brain regions (i.e., prefrontal cortex, striatum, and hippocampus) were selected as tissues for evaluation based on the spatial expression of the PDE2A enzyme.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> Oral administration of compound <b>38a</b> increased cGMP levels in a dose-responsive manner in all brain regions. However, only a slight elevation in cAMP levels was observed in the prefrontal cortex at the highest dose of 100 mg/kg. The limited impact of <b>38a</b> on cAMP concentrations may be attributed to cAMP degradation by other coexpressed PDE family members with greater affinities for cAMP, such as PDE1, 4, 7, 8, and 10.<a onclick="showRef(event, 'ref3 ref20'); return false;" href="javascript:void(0);" class="ref ref3 ref20">(3, 20)</a> In addition, the PDE2A enzyme has a higher <i>K</i><sub>m</sub> value for cAMP than for cGMP.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> Similar trends have been seen with other PDE2A inhibitors, such as <b>17</b>,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a><i>erythro</i>-9-(2-hydroxy-3-nonyl)adenine (EHNA),<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and <b>14</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> providing further support that PDE2A inhibitors contribute predominantly to elevation of cGMP under physiological conditions. Collectively, this encouraging in vivo efficacy toward neurochemical increases in cGMP, coupled with excellent physicochemical properties, PDE selectivity, and brain penetration, validated compound <b>38a</b> as a useful pharmacological tool and an attractive lead for further optimization.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0007.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Increase in mouse brain cGMP (A) and cAMP (B) levels 30 min after oral administration of compound <b>38a</b> at 10, 30, and 100 mg/kg to ICR mice. The prefrontal cortex (PFC), striatum (STR), and hippocampus (HIP) were isolated after microwave irradiation. Data are presented as mean + SEM (<i>n</i> = 7–8); #<i>p</i> < 0.025, ## <i>p</i> < 0.005, ### <i>p</i> < 0.0005 vs vehicle by Williams’ test or Shirley–Williams’ test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Substituted pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acids <b>44</b> were generally synthesized in a two-step sequence of reactions, involving preparation of the pyrazolo[1,5-<i>a</i>]pyrimidine core and hydrolysis of the ester moiety as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Pyrazolo[1,5-<i>a</i>]pyrimidine cores <b>42a</b>–<b>c</b> were assembled by the condensation of 5-amino-1<i>H</i>-pyrazoles <b>40</b> with a series of 1,3-dicarbonyl related electrophiles <b>41a</b>–<b>c</b> under acidic or neutral conditions. The resulting ethyl esters <b>42a</b>–<b>c</b> were then subjected to alkaline hydrolysis to afford the corresponding carboxylic acids <b>44a</b>–<b>c</b>. Alternatively, for the synthesis of <b>44e</b>, saponification of the ethyl ester of <b>40</b> was performed prior to condensation of the sodium salt of the carboxylic acid <b>43a</b> with the 1,3-dicarbonyl component <b>41e</b>. Pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic acids <b>44d</b> and <b>44f</b> were prepared by condensation of the commercially available carboxylic acid <b>43b</b> with <b>41d</b> and <b>41f</b>, respectively.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Substituted Pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic Acids <b>44a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>41a</b> or <b>41b</b>, AcOH, 70–90 °C, 0.5–16 h, 69–87% (for <b>42a</b> and <b>42b</b>); <b>41c</b>, toluene, 100 °C, 16 h, 68% (for <b>42c</b>). (b) 1 or 2 M NaOH aq, MeOH, THF, 50–60 °C, 3 h–overnight, 80–87% (for <b>44a</b>–<b>c</b>). (c) 2 M NaOH aq, EtOH, reflux, 20 h, (taken on crude) (for <b>43a</b>). (d) <b>41d</b> or <b>41e</b> or <b>41f</b>, EtOH, AcOH, 80–100 °C, 1.5–2 h, 68% (for <b>44d</b>), 64% (2 steps from <b>40</b>) (for <b>44e</b>), 75% (for <b>44f</b>).</p></p></figure><div class="NLM_p">RHS benzylamine moieties <b>48</b>, <b>50a</b>, <b>50b</b>, <b>51a</b>, and <b>51b</b> were prepared following the route illustrated in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Carboxylic acid <b>45</b> was converted into Weinreb amide <b>46</b>, which was then exposed to ethyl magnesium bromide to give ketone <b>47b</b>. Commercially available <b>47a</b> was transformed into <i>N</i>-methyl benzylamine <b>48</b> via reductive amination involving imine formation with methylamine in the presence of titanium tetraisopropoxide (Ti(O<i>i</i>-Pr)<sub>4</sub>) followed by reduction with sodium borohydride (NaBH<sub>4</sub>). Compounds <b>47a</b> and <b>47b</b> were condensed with hydroxylammonium chloride to furnish hydroxyimines <b>49a</b> and <b>49b</b>, respectively. Without purification, the resulting imines <b>49a</b> and <b>49b</b> were directly hydrogenated using a catalytic amount of palladium on carbon to produce benzylamines <b>50a</b> and <b>50b</b>, respectively, which were ultimately transformed into their hydrochloride salts <b>51a</b> and <b>51b</b> for crystallization.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of RHS Benzylamine Moieties <b>48</b>, <b>50a</b>, <b>50b</b>, <b>51a</b>, and <b>51b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) oxalyl chloride, cat. DMF, THF, rt, 4 h, then <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride, Et<sub>3</sub>N, DMA, rt, 16 h, 30%. (b) EtMgBr, THF, 0 °C, 2 h, 86%. (c) MeNH<sub>2</sub>, Ti(O<i>i</i>-Pr)<sub>4</sub>, MeOH, rt, 5 h, then NaBH<sub>4</sub>, rt, overnight, 25%. (d) hydroxylammonium chloride, Et<sub>3</sub>N, EtOH, 80 °C, 3–4 h, (taken on crude). (e) H<sub>2</sub>, 10% Pd/C, MeOH or EtOH, rt, overnight, 66–95%. (f) HCl, Et<sub>2</sub>O, EtOAc, rt, 67–91% (2 steps from <b>49a</b>,<b>b</b>).</p></p></figure><div class="NLM_p">To deliver the final target compounds, <b>18</b>–<b>23</b>, <b>27</b>, <b>29</b>, and <b>31</b>–<b>39</b>, the substituted pyrazolo[1,5-<i>a</i>]pyrimidine(or pyridine)-3-carboxylic acids <b>44</b>, which were commercially available or obtained according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, were coupled with commercially available or self-prepared RHS amine moieties as depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Enantiomers <b>38a</b> and <b>38b</b> were obtained by a preparative chiral HPLC separation of racemic compound <b>38</b> using a Chiralpak AD column. In addition, 6-bromo-pyrazolo[1,5-<i>a</i>]pyrimidine <b>39</b> was further derivatized into 6-substituted-pyrazolo[1,5-<i>a</i>]pyrimidines <b>24</b> and <b>25</b> through palladium-catalyzed Suzuki–Miyaura cross-coupling reactions with the corresponding boronic acids as illustrated in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>.</div><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives <b>18</b>–<b>23</b>, <b>27</b>, <b>29</b>, and <b>31</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) EDCI·HCl, HOBt·H<sub>2</sub>O, Et<sub>3</sub>N or none, DMF, rt, 2 h–4 days, 44–98%. (b) EDCI, HOBt, DIEA, DMF, rt, overnight, 28–84%. (c) HATU, DIEA, DMF, rt, overnight, 52%. (d) Chiralpak AD, 100% EtOH.</p></p></figure><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives <b>24</b> and <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) cyclopropylboronic acid, Pd(OAc)<sub>2</sub>, Cy<sub>3</sub>P, KO<i>t</i>-Bu, toluene, 100 °C, 16 h, 10% (for <b>24</b>); phenylboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, water, 150 °C (microwave), 20 min, 77% (for <b>25</b>).</p></p></figure><div class="NLM_p">The synthesis of compounds <b>26</b> and <b>28</b>, in which the amide carbonyl group in <b>21</b> was replaced with a methylene and a sulfone, respectively, began with electrophilic substitutions into 6-methyl-pyrazolo[1,5-<i>a</i>]pyrimidine (<b>52</b>) as shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. These substitutions, i.e., formylation and chlorosulfonylation, occurred regioselectively at the 3-position of <b>52</b>, generating <b>53</b> and <b>54</b>, which were then converted to the final compounds <b>26</b> and <b>28</b>, respectively, by reductive amination and sulfonamidation with amine <b>51a</b>.</div><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0012.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives <b>26</b> and <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) POCl<sub>3</sub>, DMF, 0 °C to rt, 3 h, 82%. (b) <b>51a</b>, NaBH(OAc)<sub>3</sub>, AcOH, Et<sub>3</sub>N, CH<sub>3</sub>CN, rt, overnight, 88%. (c) chlorosulfonic acid, 80 °C, 2 h, 26%. (d) <b>51a</b>, DIEA, CH<sub>3</sub>CN, rt, overnight, 97%.</p></p></figure><div class="NLM_p">The preparation of compound <b>30</b> is outlined in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. An <i>N</i>-amination of pyridine <b>55</b> with hydroxylamine-<i>O</i>-sulfonic acid, followed by a 1,3-dipolar cycloaddition with methyl propiolate, generated a mixture of methyl 4-hydroxymethyl- (<b>56a</b>) and 6-hydroxymethylpyrazolo[1,5-<i>a</i>]pyridine-3-carboxylate (<b>56b</b>) in 29% and 16% yield, respectively. Subsequent oxidation of the primary alcohol of <b>56a</b> with Dess–Martin reagent afforded aldehyde <b>57</b>, which was then subjected to reductive amination with amine <b>50a</b> prepared according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, followed by saponification to furnish carboxylic acid <b>59</b>. Final ring formation was accomplished with an intramolecular amidation, mediated by EDCI and HOBt, providing the desired compound <b>30</b>.</div><figure id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0013.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of 4,5-Dihydro-3<i>H</i>-pyrazolo[4,5,1-<i>ij</i>][1,6]naphthyridin-3-one Derivative <b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) hydroxylamine-<i>O</i>-sulfonic acid, NaHCO<sub>3</sub>, water, MeOH, 0–50 °C, 16 h, then methyl propiolate, K<sub>2</sub>CO<sub>3</sub>, 0 °C to rt, 2 h, 29%. (b) 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1<i>H</i>)-one (Dess–Martin periodinane), CH<sub>3</sub>CN, 0 °C to rt, 2.5 h, (taken on crude). (c) <b>50a</b>, NaBH(OAc)<sub>3</sub>, AcOH, CH<sub>3</sub>CN, 0 °C to rt, 16 h, 79%. (d) 1 M NaOH aq, MeOH, THF, 70 °C, 2 h, 94%. (e) EDCI·HCl, HOBt·H<sub>2</sub>O, DMF, rt, 16 h, 85%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">To identify high quality lead(s) suitable for optimization and in vivo validation of the physiological functions of PDE2A, structural modifications of high-throughput screening hit <b>18</b> were undertaken. Our lead generation efforts revealed three key potency-enhancing functionalities with minimal increases in MW and essentially no change in TPSA values. Combining these structural elements led to the rapid identification of 6-methyl-<i>N</i>-((1<i>R</i>)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>38a</b>), a potent, orally bioavailable, and selective molecule that possesses CNS drug-like characteristics (including minimal MW, low TPSA, and a limited number of hydrogen bond donors), which translated into excellent brain penetration with no P-gp efflux liability. Further characterization by cocrystal structure analysis of compound <b>38a</b> bound to PDE2A uncovered not only an intriguing binding pose, in which the molecule induced a conformational change in the enzyme to create a hydrophobic pocket, but also a key role of the intramolecular hydrogen bond in enforcing a favorable conformation through rigidification. Compound <b>38a</b> produced a significant in vivo elevation of cGMP levels in the brain, following oral administration, thus achieving our initial goal of identifying a promising lead and a valuable in vivo tool. The discovery of an attractive lead compound and the acquired insights into its binding mode helped us design more potent and selective PDE2A inhibitors. The subsequent publication will detail further optimization of this lead series, leading to a clinical candidate.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53660" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53660" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Chemistry Information</h3><div class="NLM_p">All solvents and reagents were obtained from commercial sources and were used as received. Microwave-assisted reactions were carried out in a single-mode reactor, Biotage Initiator 2.0 or 2.5 microwave synthesizer. Yields were not optimized. All reactions were monitored by thin layer chromatography (TLC) analysis on Merck Kieselgel 60 F254 plates or Fuji Silysia NH plates, or LC–MS (liquid chromatography–mass spectrometry) analysis. LC–MS analysis was performed on a Shimadzu liquid chromatography–mass spectrometer system operating in APCI (+ or – ) or ESI (+ or – ) ionization mode. Analytes were eluted using a linear gradient with a mobile phase of water/acetonitrile containing 0.05% TFA or 5 mM ammonium acetate and detected at 220 nm. Column chromatography was carried out on silica gel ((Merck Kieselgel 60, 70–230 mesh, Merck) or (Chromatorex NH-DM 1020, 100–200 mesh, Fuji Silysia Chemical, Ltd.)) or on prepacked Purif-Pack columns (SI or NH, particle size: 60 μm, Fuji Silysia Chemical, Ltd.). Analytical HPLC was performed using a Corona charged aerosol detector or photodiode array detector with a Capcell Pak C18AQ (3.0 mm ID × 50 mm L, Shiseido, Japan) or L-column2 ODS (2.0 mm ID × 30 mm L, CERI, Japan) column at a temperature of 50 °C and a flow rate of 0.5 mL/min. Mobile phases A and B under neutral conditions were a mixture of 50 mmol/L ammonium acetate, water, and acetonitrile (1:8:1, v/v/v) and a mixture of 50 mmol/L ammonium acetate and acetonitrile (1:9, v/v), respectively. The ratio of mobile phase B was increased linearly from 5% to 95% over 3 min, and then maintained at 95% over the next 1 min. Mobile phases A and B under acidic conditions were a mixture of 0.2% formic acid in 10 mmol/L ammonium formate and 0.2% formic acid in acetonitrile, respectively. The ratio of mobile phase B was increased linearly from 14% to 86% over 3 min, and then maintained at 86% over the next 1 min. All final test compounds were purified to >95% chemical purity as measured by analytical HPLC. Elemental analyses were carried out by Takeda Analytical Laboratories, and all results were within ±0.4% of the theoretical values. Melting points were determined on a Büchi B-545 melting point apparatus or a DSC1 system (Mettler-Toledo International Inc., Greifensee, Switzerland). Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Varian Mercury-300 (300 MHz) or Bruker DPX300 (300 MHz) instrument. All <sup>1</sup>H NMR spectra were consistent with the proposed structures. All proton shifts are given in parts per million (ppm) downfield from tetramethysilane (δ) as the internal standard in deuterated solvent, and coupling constants (<i>J</i>) are in hertz (Hz). NMR data are reported as follows: chemical shift, integration, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; m, multiplet; dd, doublet of doublets; td, triplet of doublets; ddd, doublet of doublet of doublets; and brs, broad singlet), and coupling constants. Very broad peaks for protons of, for example, hydroxyl and amino groups are not always indicated.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>N</i>-(1-(4-Methoxyphenyl)propyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>18</b>)</h4><div class="NLM_p last">To a solution of <b>44</b> (50 mg, 0.31 mmol) in DMF (2 mL) were added EDCI (71 mg, 0.37 mmol), HOBt (49 mg, 0.37 mmol), and DIEA (79 mg, 0.61 mmol). Then <b>50a</b> (55 mg, 0.34 mmol) was added. After stirring at rt overnight, the reaction mixture was diluted with EtOAc and washed with saturated aqueous NaHCO<sub>3</sub> and saturated aqueous NaCl. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by preparative TLC (petroleum ether/ethyl acetate, 1:1) to give <b>18</b> (50 mg, 0.16 mmol, 52%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.97 (3H, t, <i>J</i> = 7.6 Hz), 1.92–2.00 (2H, m), 3.78 (3H, s), 5.12–5.14 (1H, m), 6.87 (2H, d, <i>J</i> = 8.8 Hz), 6.97–6.99 (1H, m), 7.33 (2H, d, <i>J</i> = 8.8 Hz), 8.19–8.21 (1H, m), 8.63–8.66 (2H, m), 8.76–8.78 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>17</sub>H<sub>19</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 311.14, found <i>m</i>/<i>z</i> 311.1. HPLC purity 99.3%.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-(1-(4-Methoxyphenyl)propyl)-2-methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>19</b>)</h4><div class="NLM_p last">To a mixture of <b>44a</b> (128 mg, 0.720 mmol), <b>51a</b> (160 mg, 0.793 mmol), and Et<sub>3</sub>N (0.151 mL, 1.08 mmol) in DMF (5 mL) were added HOBt·H<sub>2</sub>O (133 mg, 0.868 mmol) and EDCI·HCl (166 mg, 0.866 mmol). The mixture was stirred at rt for 5 h and then poured into NaHCO<sub>3</sub> aqueous solution, extracted with EtOAc, washed with water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 2:3 to 0:100) to afford <b>19</b> (171 mg, 0.528 mmol, 73%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.89 (3H, t, <i>J</i> = 7.4 Hz), 1.75–1.91 (2H, m), 2.62 (3H, s), 3.73 (3H, s), 4.88–5.03 (1H, m), 6.85–6.95 (2H, m), 7.21 (1H, dd, <i>J</i> = 6.8, 4.2 Hz), 7.25–7.34 (2H, m), 8.43 (1H, d, <i>J</i> = 8.3 Hz), 8.78 (1H, dd, <i>J</i> = 4.2, 1.5 Hz), 9.20 (1H, dd, <i>J</i> = 7.0, 1.7 Hz). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 325.2, found <i>m</i>/<i>z</i> 325.3. HPLC purity 100%.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(1-(4-Methoxyphenyl)propyl)-5-methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>20</b>)</h4><div class="NLM_p last">To a mixture of <b>44c</b> (98.1 mg, 0.554 mmol), <b>51a</b> (123 mg, 0.610 mmol), and Et<sub>3</sub>N (0.116 mL, 0.832 mmol) in DMF (5 mL) were added HOBt·H<sub>2</sub>O (102 mg, 0.666 mmol) and EDCI·HCl (127 mg, 0.662 mmol). The mixture was stirred at rt for 5 h and then poured into NaHCO<sub>3</sub> aqueous solution, extracted with EtOAc, washed with water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 1:1 to 0:100). The product was crystallized from hexane/ethyl acetate (5:1) to afford <b>20</b> (109 mg, 0.335 mmol, 61%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.88 (3H, t, <i>J</i> = 7.4 Hz), 1.73–1.96 (2H, m), 2.67 (3H, s), 3.73 (3H, s), 4.95 (1H, q, <i>J</i> = 7.2 Hz), 6.87–6.96 (2H, m), 7.16 (1H, d, <i>J</i> = 6.8 Hz), 7.26–7.34 (2H, m), 8.40 (1H, d, <i>J</i> = 8.3 Hz), 8.46 (1H, s), 9.15 (1H, d, <i>J</i> = 7.2 Hz). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 325.2, found <i>m</i>/<i>z</i> 325.3. HPLC purity 100%; mp 89 °C.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-(1-(4-Methoxyphenyl)propyl)-6-methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>21</b>)</h4><div class="NLM_p last">The title compound was prepared in 84% yield as a yellow oil from <b>44b</b> and <b>50a</b> using the procedure analogous to that described for the synthesis of <b>18</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.97 (3H, t, <i>J</i> = 7.6 Hz), 1.92–1.97 (2H, m), 2.44 (3H, s), 3.78 (3H, s), 5.11–5.13 (1H, m), 6.87 (2H, d, <i>J</i> = 8.8 Hz), 7.32 (2H, d, <i>J</i> = 8.8 Hz), 8.16 (1H, d, <i>J</i> = 8.0 Hz), 8.51 (1H, d, <i>J</i> = 2.0 Hz), 8.55 (1H, d, <i>J</i> = 1.2 Hz), 8.58 (1H, s). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 325.2, found <i>m</i>/<i>z</i> 325.2. HPLC purity 99.9%.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(1-(4-Methoxyphenyl)propyl)-5,7-dimethylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>22</b>)</h4><div class="NLM_p last">The title compound was prepared in 53% yield as a white solid from <b>44d</b> and <b>51a</b> using the procedure analogous to that described for the synthesis of <b>20</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.82–0.94 (3H, m), 1.75–1.94 (2H, m), 2.63 (3H, s), 2.74 (3H, d, <i>J</i> = 0.8 Hz), 3.73 (3H, s), 4.88–5.03 (1H, m), 6.87–6.96 (2H, m), 7.13 (1H, d, <i>J</i> = 0.8 Hz), 7.24–7.36 (2H, m), 8.42–8.56 (2H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 339.2, found <i>m</i>/<i>z</i> 339.2. HPLC purity 100%; mp 129 °C.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 6-Chloro-<i>N</i>-(1-(4-methoxyphenyl)propyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>23</b>)</h4><div class="NLM_p last">To a mixture of <b>44e</b> (200 mg, 1.01 mmol) and <b>50a</b> (176 mg, 1.06 mmol) in DMF (8 mL) were added HOBt·H<sub>2</sub>O (186 mg, 1.21 mmol) and EDCI·HCl (233 mg, 1.21 mmol). The mixture was stirred for 2 h and then poured into NaHCO<sub>3</sub> aqueous solution. The mixture was extracted with EtOAc, washed with water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (basic silica gel, hexane/ethyl acetate, 19:1 to 2:3) to afford <b>23</b> (234 mg, 0.678 mmol, 67%) as a white solid after crystallization from hexane/ethyl acetate (5:1). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.89 (3H, t, <i>J</i> = 7.3 Hz), 1.73–1.93 (2H, m), 3.73 (3H, s), 4.96 (1H, q, <i>J</i> = 7.3 Hz), 6.82–6.95 (2H, m), 7.23–7.34 (2H, m), 8.08 (1H, d, <i>J</i> = 8.7 Hz), 8.59 (1H, s), 8.91 (1H, d, <i>J</i> = 2.3 Hz), 9.75 (1H, d, <i>J</i> = 2.3 Hz). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>17</sub>H<sub>18</sub>ClN<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 345.1, found <i>m</i>/<i>z</i> 345.2. HPLC purity 100%; mp 102 °C. Anal. Calcd for C<sub>17</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>2</sub>: C, 59.22; H, 4.97; N, 16.25. Found: C, 59.26; H, 4.98; N, 16.10.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 6-Cyclopropyl-<i>N</i>-(1-(4-methoxyphenyl)propyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>24</b>)</h4><div class="NLM_p last">To a mixture of <b>39</b> (150 mg, 0.385 mmol), cyclopropylboronic acid (49.7 mg, 0.579 mmol), and potassium <i>tert</i>-butoxide (143 mg, 1.27 mmol) in toluene (5 mL) were added Pd(OAc)<sub>2</sub> (4.3 mg, 0.02 mmol) and tricyclohexylphosphine (10.8 mg, 0.04 mmol). The mixture was stirred at 100 °C for 16 h under Ar and then poured into water. The mixture was extracted with EtOAc, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 1:4) to afford <b>24</b> (13.9 mg, 0.040 mmol, 10%) as a pale-yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.74–0.84 (2H, m), 0.97 (3H, t, <i>J</i> = 7.4 Hz), 1.07–1.18 (2H, m), 1.84–2.07 (3H, m), 3.78 (3H, s), 5.12 (1H, q, <i>J</i> = 7.6 Hz), 6.81–6.92 (2H, m), 7.28–7.37 (2H, m), 8.17 (1H, d, <i>J</i> = 8.3 Hz), 8.47 (1H, d, <i>J</i> = 1.9 Hz), 8.52 (1H, d, <i>J</i> = 1.9 Hz), 8.58 (1H, s). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 351.2, found <i>m</i>/<i>z</i> 351.2. HPLC purity 95.6%.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(1-(4-Methoxyphenyl)propyl)-6-phenylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>25</b>)</h4><div class="NLM_p last">Into a microwave vial equipped with a magnetic stirrer were added <b>39</b> (120 mg, 0.308 mmol), phenylboronic acid (41.3 mg, 0.339 mmol), DME (3 mL), and water (1.5 mL), followed by Pd(Ph<sub>3</sub>P)<sub>4</sub> (17.8 mg, 0.02 mmol). The reaction vial was flushed with nitrogen, sealed, and heated by microwave irradiation at 150 °C for 20 min. The mixture was poured into water and extracted with EtOAc. The combined organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 2:3) to afford <b>25</b> (92 mg, 0.239 mmol, 77%) as a pale-yellow solid after crystallization from hexane/ethyl acetate (5:1). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.91 (3H, t, <i>J</i> = 7.2 Hz), 1.77–1.96 (2H, m), 3.73 (3H, s), 4.99 (1H, q, <i>J</i> = 7.3 Hz), 6.84–6.98 (2H, m), 7.24–7.38 (2H, m), 7.41–7.62 (3H, m), 7.84–7.97 (2H, m), 8.22 (1H, d, <i>J</i> = 8.3 Hz), 8.60 (1H, s), 9.24 (1H, d, <i>J</i> = 1.9 Hz), 9.68 (1H, d, <i>J</i> = 2.3 Hz). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>23</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 387.2, found <i>m</i>/<i>z</i> 387.1. HPLC purity: 100%. mp 145 °C. Anal. Calcd for C<sub>23</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>·0.1H<sub>2</sub>O: C, 71.15; H, 5.76; N, 14.43. Found: C, 71.15; H, 5.84; N, 14.15.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 1-(4-Methoxyphenyl)-<i>N</i>-((6-methylpyrazolo[1,5-<i>a</i>]pyrimidin-3-yl)methyl)propan-1-amine (<b>26</b>)</h4><div class="NLM_p last">To a mixture of <b>53</b> (100 mg, 0.621 mmol), <b>51a</b> (188 mg, 0.932 mmol), acetic acid (0.107 mL, 1.86 mmol), and Et<sub>3</sub>N (0.104 mL, 0.746 mmol) in CH<sub>3</sub>CN (5 mL) at rt was added sodium triacetoxyborohydride (263 mg, 1.24 mmol). The mixture was stirred at rt overnight. The mixture was quenched with saturated aqueous NaHCO<sub>3</sub> at rt and extracted with EtOAc. The organic layer was washed with water and saturated aqueous NaCl, dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (basic silica gel, hexane/ethyl acetate, 9:1 to 1:1) to give <b>26</b> (169 mg, 0.544 mmol, 88%) as a pale-yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.77 (3H, t, <i>J</i> = 7.6 Hz), 1.52–1.79 (2H, m), 2.36 (3H, d, <i>J</i> = 0.8 Hz), 3.52 (1H, dd, <i>J</i> = 7.9, 5.7 Hz), 3.73–3.96 (5H, m), 6.89 (2H, d, <i>J</i> = 8.7 Hz), 7.19–7.31 (2H, m), 7.91 (1H, s), 8.31 (1H, d, <i>J</i> = 2.3 Hz), 8.41 (1H, dd, <i>J</i> = 2.3, 1.1 Hz). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 311.2, found <i>m</i>/<i>z</i> 311.2 [M + H]<sup>+</sup>. HPLC purity 100%.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(1-(4-Methoxyphenyl)propyl)-<i>N</i>,6-dimethylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>27</b>)</h4><div class="NLM_p last">To a mixture of <b>44b</b> (70 mg, 0.40 mmol) and <b>48</b> (78 mg, 0.44 mmol) in DMF (5 mL) was added HATU (225 mg, 0.592 mmol), followed by DIEA (102 mg, 0.791 mmol). The mixture was stirred at rt overnight and then diluted with EtOAc and washed with saturated aqueous NaHCO<sub>3</sub> and saturated aqueous NaCl. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by preparative TLC (petroleum ether/ethyl acetate, 1:1) to give <b>27</b> (70 mg, yield 52%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.91–0.94 (3H, m), 1.92–2.02 (2H, m), 2.34 (3H, s), 2.67–2.72 (3H, m), 3.74 (3H, s), 6.92 (2H, d, <i>J</i> = 8.4 Hz), 7.28–7.32 (2H, brs), 8.32 (1H, s), 8.60 (1H, d, <i>J</i> = 2.0 Hz), 9.04–9.05 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 339.2, found <i>m</i>/<i>z</i> 339.2 [M + H]<sup>+</sup>. HPLC purity 100%.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(1-(4-Methoxyphenyl)propyl)-6-methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-sulfonamide (<b>28</b>)</h4><div class="NLM_p last">To a mixture of <b>54</b> (70.2 mg, 0.303 mmol) and <b>51a</b> (67.0 mg, 0.33 mmol) in CH<sub>3</sub>CN (5 mL) at rt was added DIEA (0.127 mL, 0.741 mmol). The mixture was stirred at rt overnight. The mixture was quenched with water and extracted with EtOAc. The organic layer was washed with water and saturated aqueous NaCl, dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 9:1 to 1:3) to give <b>28</b> (106 mg, 0.294 mmol, 97%) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.82 (3H, t, <i>J</i> = 7.4 Hz), 1.52–2.00 (2H, m), 2.40 (3H, d, <i>J</i> = 0.8 Hz), 3.67 (3H, s), 4.15 (1H, q, <i>J</i> = 7.9 Hz), 5.25 (1H, d, <i>J</i> = 8.3 Hz), 6.32–6.55 (2H, m), 6.66–6.88 (2H, m), 8.18 (1H, s), 8.30–8.57 (2H, m). MS (ESI/APCI) mass calculated for [M – H]<sup>−</sup> (C<sub>17</sub>H<sub>19</sub>N<sub>4</sub>O<sub>3</sub>S) requires <i>m</i>/<i>z</i> 359.1, found <i>m</i>/<i>z</i> 359.0. HPLC purity 100%; mp 136 °C. Anal. Calcd for C<sub>17</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S: C, 56.65; H, 5.59; N, 15.54. Found: C, 56.71; H, 5.70; N, 15.28.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(1-(4-Methoxyphenyl)propyl)pyrazolo[1,5-<i>a</i>]pyridine-3-carboxamide (<b>29</b>)</h4><div class="NLM_p last">The title compound was prepared in 44% yield as a white solid from <b>44</b> and <b>50a</b> using the procedure analogous to that described for the synthesis of <b>23</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.96 (3H, t, <i>J</i> = 7.4 Hz), 1.79–2.14 (2H, m), 3.80 (3H, s), 5.07 (1H, q, <i>J</i> = 7.6 Hz), 5.97 (1H, d, <i>J</i> = 7.9 Hz), 6.80–6.99 (3H, m), 7.28–7.40 (3H, m), 8.12 (1H, s), 8.30 (1H, d, <i>J</i> = 9.1 Hz), 8.47 (1H, d, <i>J</i> = 6.8 Hz). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 310.2, found <i>m</i>/<i>z</i> 310.1 [M + H]<sup>+</sup>. HPLC purity 99.2%; mp 105 °C. Anal. Calcd for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>: C, 69.88; H, 6.19; N, 13.58. Found: C, 69.77; H, 6.18; N, 13.50.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-(1-(4-Methoxyphenyl)propyl)-4,5-dihydro-3<i>H</i>-pyrazolo[4,5,1-<i>ij</i>][1,6]naphthyridin-3-one (<b>30</b>)</h4><div class="NLM_p last">To a solution of <b>59</b> (664 mg, 1.96 mmol) in DMF (20 mL) was added EDCI·HCl (413 mg, 2.15 mmol), followed by HOBt·H<sub>2</sub>O (330 mg, 2.15 mmol). The mixture was stirred at rt for 16 h and then poured into water. The mixture was extracted with EtOAc, washed with water and saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 0:100) to afford <b>30</b> (535 mg, 1.67 mmol, 85%) as a white solid after crystallization from hexane/ethyl acetate (4:1). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.90 (3H, t, <i>J</i> = 7.4 Hz), 1.91–2.16 (2H, m), 3.73 (3H, s), 4.33 (1H, d, <i>J</i> = 18.6 Hz), 4.83 (1H, d, <i>J</i> = 18.6 Hz), 5.84–5.96 (1H, m), 6.86–6.96 (2H, m), 6.96–7.05 (1H, m), 7.13–7.21 (1H, m), 7.24–7.32 (2H, m), 8.27 (1H, s), 8.63 (1H, d, <i>J</i> = 6.8 Hz). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 322.2, found <i>m</i>/<i>z</i> 322.1. HPLC purity 100%; mp 137 °C. Anal. Calcd for C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>: C, 71.01; H, 5.96; N, 13.08. Found: C, 70.89; H, 6.01; N, 12.88.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 6-Methyl-<i>N</i>-(1-phenylpropyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>31</b>)</h4><div class="NLM_p last">The title compound was prepared in 28% yield as a white solid from <b>44b</b> and 1-phenylpropan-1-amine using the procedure analogous to that described for the synthesis of <b>18</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.99 (3H, t, <i>J</i> = 7.6 Hz), 1.93–2.00 (2H, m), 2.44 (3H, s), 5.16–5.22 (1H, m), 7.21–7.25 (1H, m), 7.31–7.35 (2H, m), 7.39–7.40 (2H, m), 8.23 (1H, d, <i>J</i> = 8.0 Hz), 8.53 (1H, d, <i>J</i> = 2.0 Hz), 8.56 (1H, s), 8.58 (1H, s). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>17</sub>H<sub>19</sub>N<sub>4</sub>O) requires <i>m</i>/<i>z</i> 295.2, found <i>m</i>/<i>z</i> 295.1. HPLC purity 100%; mp 116 °C.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 6-Methyl-<i>N</i>-(1-phenylethyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>32</b>)</h4><div class="NLM_p last">The title compound was prepared in 84% yield as a white solid from <b>44b</b> and 1-phenylethanamine using the procedure analogous to that described for the synthesis of <b>23</b>, except that silica gel was employed in place of basic silica gel in a column chromatographic separation. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.52 (3H, d, <i>J</i> = 7.2 Hz), 2.38 (3H, d, <i>J</i> = 0.8 Hz), 5.15–5.28 (1H, m), 7.21–7.45 (5H, m), 8.21 (1H, d, <i>J</i> = 8.0 Hz), 8.49 (1H, s), 8.75 (1H, d, <i>J</i> = 2.3 Hz), 9.15–9.21 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>16</sub>H<sub>17</sub>N<sub>4</sub>O) requires <i>m</i>/<i>z</i> 281.1, found <i>m</i>/<i>z</i> 281.2. HPLC purity 99.6%; mp 112 °C.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(2,3-Dihydro-1<i>H</i>-inden-1-yl)-6-methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>33</b>)</h4><div class="NLM_p last">The title compound was prepared in 69% yield as a white solid from <b>44b</b> and 2,3-dihydro-1<i>H</i>-inden-1-amine using the procedure analogous to that described for the synthesis of <b>23</b>, except that silica gel was employed in place of basic silica gel in a column chromatographic separation. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.80–1.97 (1H, m), 2.35 (3H, d, <i>J</i> = 0.8 Hz), 2.51–2.64 (1H, m), 2.79–3.07 (2H, m), 5.57 (1H, q, <i>J</i> = 8.2 Hz), 7.16–7.34 (4H, m), 8.12 (1H, d, <i>J</i> = 8.3 Hz), 8.56 (1H, s), 8.65 (1H, d, <i>J</i> = 1.9 Hz), 9.15–9.20 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>17</sub>H<sub>17</sub>N<sub>4</sub>O) requires <i>m</i>/<i>z</i> 293.1, found <i>m</i>/<i>z</i> 292.7. HPLC purity 100%; mp 160 °C.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(4-Methoxybenzyl)-6-methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>34</b>)</h4><div class="NLM_p last">The title compound was prepared in 84% yield as a yellow oil from <b>44b</b> and 1-(4-methoxyphenyl)methanamine using the procedure analogous to that described for the synthesis of <b>18</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.42 (3H, s), 3.79 (3H, s), 4.65 (2H, d, <i>J</i> = 5.6 Hz), 6.88 (2H, d, <i>J</i> = 8.8 Hz), 7.33 (2H, d, <i>J</i> = 8.8 Hz), 8.12 (1H, s), 8.43 (1H, d, <i>J</i> = 2.0 Hz), 8.55 (1H, s), 8.63 (1H, s). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>16</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 297.1, found <i>m</i>/<i>z</i> 297.2. HPLC purity 98.0%.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(3-Methoxybenzyl)-6-methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>35</b>)</h4><div class="NLM_p last">The title compound was prepared in 90% yield as a colorless oil from <b>44b</b> and 2,3-dihydro-1<i>H</i>-inden-1-amine using the procedure analogous to that described for the synthesis of <b>23</b>, except that silica gel was employed in place of basic silica gel in a column chromatographic separation. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.38 (3H, d, <i>J</i> = 0.8 Hz), 3.73 (3H, s), 4.56 (2H, d, <i>J</i> = 6.1 Hz), 6.78–6.86 (1H, m), 6.88–6.97 (2H, m), 7.19–7.30 (1H, m), 8.31 (1H, t, <i>J</i> = 5.9 Hz), 8.52 (1H, s), 8.71 (1H, d, <i>J</i> = 1.9 Hz), 9.14–9.21 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>16</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 297.1, found <i>m</i>/<i>z</i> 297.2. HPLC purity 100%.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(2-Methoxybenzyl)-6-methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>36</b>)</h4><div class="NLM_p last">The title compound was prepared in 69% yield as a white solid from <b>44b</b> and (2-methoxyphenyl)methanamine using the procedure analogous to that described for the synthesis of <b>21</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.38 (3H, d, <i>J</i> = 0.8 Hz), 3.88 (3H, s), 4.53 (2H, d, <i>J</i> = 6.1 Hz), 6.85–6.94 (1H, m), 7.02 (1H, d, <i>J</i> = 8.0 Hz), 7.20–7.31 (2H, m), 8.40 (1H, t, <i>J</i> = 5.9 Hz), 8.49 (1H, s), 8.74 (1H, d, <i>J</i> = 1.9 Hz), 9.14–9.20 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>16</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 297.1, found <i>m</i>/<i>z</i> 297.1. HPLC purity 100%; mp 171 °C.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 6-Methyl-<i>N</i>-(4-(trifluoromethoxy)benzyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>37</b>)</h4><div class="NLM_p last">The title compound was prepared in 69% yield as a white solid from <b>44b</b> and 1-(4-(trifluoromethoxy)phenyl)methanamine using the procedure analogous to that described for the synthesis of <b>23</b>, except that silica gel was employed in place of basic silica gel in a column chromatographic separation. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.38 (3H, d, <i>J</i> = 0.8 Hz), 4.61 (2H, d, <i>J</i> = 6.1 Hz), 7.28–7.37 (2H, m), 7.43–7.51 (2H, m), 8.42 (1H, t, <i>J</i> = 6.1 Hz), 8.52 (1H, s), 8.71 (1H, d, <i>J</i> = 1.9 Hz), 9.15–9.21 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>16</sub>H<sub>14</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 251.1, found <i>m</i>/<i>z</i> 351.1. HPLC purity 100%; mp 111 °C.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 6-Methyl-<i>N</i>-(1-(4-(trifluoromethoxy)phenyl]propyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>38</b>)</h4><div class="NLM_p last">The title compound was prepared in 98% yield as a colorless oil from <b>44b</b> and 1-(4-(trifluoromethoxy)phenyl)propan-1-amine using the procedure analogous to that described for the synthesis of <b>23</b>, except that silica gel was employed in place of basic silica gel in a column chromatographic separation. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.92 (3H, t, <i>J</i> = 7.4 Hz), 1.78–1.96 (2H, m), 2.39 (3H, s), 5.04 (1H, q, <i>J</i> = 7.2 Hz), 7.27–7.39 (2H, m), 7.44–7.57 (2H, m), 8.28 (1H, d, <i>J</i> = 7.9 Hz), 8.47 (1H, s), 8.77 (1H, d, <i>J</i> = 2.3 Hz), 9.14–9.23 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 379.1, found <i>m</i>/<i>z</i> 379.1. HPLC purity 99.0%.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 6-Methyl-<i>N</i>-((1<i>R</i>)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>38a</b>)</h4><div class="NLM_p last"><b>38</b> (1.07 g, 2.78 mmol) was chirally separated utilizing chiral chromatography with a Chiralpak AD 50 mm ID × 500 mm L column, mobile phase 100% EtOH, and flow rate 60 mL/min, to afford <b>38a</b> (475 mg, tR1), which was recrystallized from hexane/ethyl acetate (5:1) to afford <b>38a</b> (339 mg, 0.896 mmol, 32%, 64% theoretical) as a white solid. Analytical HPLC analysis carried out on a 4.6 mm ID × 250 mm L Chiralpak AD column with the same eluent as above at a flow rate of 0.5 mL/min indicated that <b>38a</b> was of >99.9% ee. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.93 (3H, t, <i>J</i> = 7.3 Hz), 1.79–1.97 (2H, m), 2.39 (3H, s), 5.04 (1H, q, <i>J</i> = 7.3 Hz), 7.27–7.40 (2H, m), 7.45–7.57 (2H, m), 8.29 (1H, d, <i>J</i> = 7.9 Hz), 8.48 (1H, s), 8.77 (1H, d, <i>J</i> = 1.9 Hz), 9.14–9.23 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 379.1, found <i>m</i>/<i>z</i> 379.1. HPLC purity: 99.7%. Anal. Calcd for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>: C, 57.14; H, 4.53; N, 14.81. Found: C, 57.07; H, 4.53; N, 14.74; mp 106 °C.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 6-Methyl-<i>N</i>-((1<i>S</i>)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>38b</b>)</h4><div class="NLM_p last"><b>38</b> (1.07 g, 2.78 mmol) was chirally separated utilizing chiral chromatography with a Chiralpak AD 50 mm ID × 500 mm L column, mobile phase 100% EtOH, and flow rate 60 mL/min, to afford <b>38b</b> (452 mg, tR2), which was recrystallized from hexane/ethyl acetate (5:1) to afford <b>38b</b> (230 mg, 0.609 mmol, 22%, 44% theoretical) as a white solid. Analytical HPLC analysis carried out on a 4.6 mm ID × 250 mm L Chiralpak AD column with the same eluent as above at a flow rate of 0.5 mL/min indicated that <b>38b</b> was of 99.7% ee. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.93 (3H, t, <i>J</i> = 7.3 Hz), 1.78–1.98 (2H, m), 2.39 (3H, s), 5.04 (1H, q, <i>J</i> = 7.3 Hz), 7.27–7.39 (2H, m), 7.44–7.57 (2H, m), 8.29 (1H, d, <i>J</i> = 7.9 Hz), 8.48 (1H, s), 8.77 (1H, d, <i>J</i> = 1.9 Hz), 9.16–9.23 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 379.1, found <i>m</i>/<i>z</i> 379.1. HPLC purity 100%; mp 106 °C. Anal. Calcd for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>: C, 57.14; H, 4.53; N, 14.81. Found: C, 57.03; H, 4.55; N, 14.72.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 6-Bromo-<i>N</i>-(1-(4-methoxyphenyl)propyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>39</b>)</h4><div class="NLM_p last">The title compound was prepared in 83% yield as an off-white solid from <b>44f</b> and <b>50a</b> using the procedure analogous to that described for the synthesis of <b>23</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.88 (3H, t, <i>J</i> = 7.4 Hz), 1.75–1.92 (2H, m), 3.73 (3H, s), 4.89–5.02 (1H, m), 6.83–6.96 (2H, m), 7.22–7.36 (2H, m), 8.07 (1H, d, <i>J</i> = 8.3 Hz), 8.56 (1H, s), 8.93 (1H, d, <i>J</i> = 2.3 Hz), 9.79 (1H, d, <i>J</i> = 2.3 Hz). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>17</sub>H<sub>18</sub>BrN<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 389.1, found <i>m</i>/<i>z</i> 389.0.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Ethyl 2-Methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylate (<b>42a</b>)</h4><div class="NLM_p last">The mixture of <b>40</b> (1.04 g, 6.16 mmol) and <b>41a</b> (1.21 g, 7.39 mmol) in AcOH (20 mL) was stirred at 70 °C for 16 h. The mixture was concentrated in vacuo and then partitioned between EtOAc and NaHCO<sub>3</sub> aqueous solution. The phases were separated, and the aqueous phase was extracted with EtOAc. The combined organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by column chromatography (basic silica gel, hexane/ethyl acetate, 1:1 to 0:100) to afford <b>42a</b> (0.870 g, 4.24 mmol, 69%) as a white solid after trituration with hexane/ethyl acetate (5:1). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.32 (3H, t, <i>J</i> = 7.2 Hz), 2.61 (3H, s), 4.30 (2H, q, <i>J</i> = 7.1 Hz), 7.22 (1H, dd, <i>J</i> = 6.8, 4.2 Hz), 8.77 (1H, dd, <i>J</i> = 4.2, 1.9 Hz), 9.15 (1H, dd, <i>J</i> = 7.0, 1.7 Hz).</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Ethyl 6-Methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylate (<b>42b</b>)</h4><div class="NLM_p last">The title compound was prepared in 87% yield as a white solid from <b>40</b> and <b>41b</b> using the procedure analogous to that described for the synthesis of <b>42a</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.42 (3H, t, <i>J</i> = 7.0 Hz), 2.44 (3H, s), 4.44 (2H, q, <i>J</i> = 6.9 Hz), 8.51 (1H, s), 8.55 (1H, s), 8.66 (1H, d, <i>J</i> = 1.9 Hz).</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Ethyl 5-Methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylate (<b>42c</b>)</h4><div class="NLM_p last">A mixture of <b>40</b> (1.05 g, 6.45 mmol) and <b>41c</b> (1.71 g, 12.9 mmol) in toluene (10 mL) was stirred at 100 °C for 16 h and then concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 0:100) to afford <b>42c</b> (0.898 g, 4.37 mmol, 68%) as a beige solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.31 (3H, t, <i>J</i> = 7.0 Hz), 2.62 (3H, s), 4.28 (2H, q, <i>J</i> = 7.2 Hz), 7.17 (1H, d, <i>J</i> = 7.2 Hz), 8.53 (1H, s), 9.11 (1H, d, <i>J</i> = 7.2 Hz).</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-Methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic Acid (<b>44a</b>)</h4><div class="NLM_p last">To a solution of <b>42a</b> (866 mg, 4.22 mmol) in THF (20 mL) and MeOH (10 mL) was added 1 M NaOH aqueous solution (12.7 mL, 12.7 mmol). The mixture was stirred at 50 °C for 16 h and then concentrated in vacuo. The residue was suspended in water, and 1 M HCl aqueous solution (12.7 mL, 12.7 mmol) was added. The resulting solid was collected by filtration, rinsed with water, and dried to afford <b>44a</b> (649 mg, 3.66 mmol, 87%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.60 (3H, s), 7.19 (1H, dd, <i>J</i> = 7.2, 4.2 Hz), 8.73 (1H, dd, <i>J</i> = 4.2, 1.5 Hz), 9.14 (1H, dd, <i>J</i> = 6.8, 1.9 Hz), 12.26 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>8</sub>H<sub>8</sub>N<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 178.1, found <i>m</i>/<i>z</i> 178.1.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 6-Methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic Acid (<b>44b</b>)</h4><div class="NLM_p last">A mixture of <b>42b</b> (6.44 g, 31.38 mmol), 2 M NaOH aqueous solution (23.5 mL, 47.1 mmol), THF (20 mL), and MeOH (20 mL) was stirred at 60 °C overnight. The mixture was acidified with 10% citric acid aqueous solution. The resulting precipitate was collected by filtration, washed with water, and dried to give <b>44b</b> (3.91 g, 22.1 mmol, 70%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.37 (3H, s), 8.50 (1H, s), 8.71 (1H, d, <i>J</i> = 1.9 Hz), 9.09–9.15 (1H, m), 12.33 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>8</sub>H<sub>8</sub>N<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 178.1, found <i>m</i>/<i>z</i> 178.0.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 5-Methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic Acid (<b>44c</b>)</h4><div class="NLM_p last">The title compound was prepared in 84% yield as a beige solid from <b>42c</b> using the procedure analogous to that described for the synthesis of <b>44a</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.62 (3H, s), 7.15 (1H, d, <i>J</i> = 7.2 Hz), 8.49 (1H, s), 9.10 (1H, d, <i>J</i> = 7.2 Hz), 12.27 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>8</sub>H<sub>8</sub>N<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 178.1, found <i>m</i>/<i>z</i> 178.1.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 5,7-Dimethylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic Acid (<b>44d</b>)</h4><div class="NLM_p last">A mixture of <b>43b</b> (502 mg, 3.75 mmol) and <b>41d</b> (394 mg, 3.94 mmol) in EtOH (8 mL) and AcOH (8 mL) was stirred at 100 °C for 1.5 h and then concentrated in vacuo. To the residue were added EtOH (4 mL). The resulting solid was collected by filtration, rinsed with EtOH (2 mL), and dried to afford <b>44d</b> (487 mg, 2.54 mmol, 68%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.58 (3H, s), 2.72 (3H, d, <i>J</i> = 0.8 Hz), 7.10 (1H, d, <i>J</i> = 0.8 Hz), 8.51 (1H, s), 12.20 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>9</sub>H<sub>10</sub>N<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 192.1, found <i>m</i>/<i>z</i> 192.1.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 6-Chloropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic Acid (<b>44e</b>)</h4><div class="NLM_p last">To a solution of <b>40</b> (1.00 g, 6.45 mmol) in EtOH (15 mL) was added 2 M NaOH aqueous solution (9.67 mL, 19.3 mmol). The mixture was stirred at reflux for 20 h. The mixture was concentrated in vacuo (azeotroped with toluene) to give the crude product <b>43a</b>. The residue was suspended in EtOH (2 mL) and AcOH (7 mL), and then <b>41e</b> (0.721 g, 6.77 mmol) was added. The mixture was stirred at 80 °C for 2 h and then cooled to rt. Water was then added and the precipitate was filtered by filtration, rinsed with water and EtOH, and dried to afford <b>44e</b> (0.809 g, 4.10 mmol, 64%) as a beige solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.61 (1H, s), 8.86 (1H, d, <i>J</i> = 2.3 Hz), 9.71 (1H, d, <i>J</i> = 2.3 Hz), 12.54 (1H, brs). MS (ESI/APCI) mass calculated for [M – H]<sup>−</sup> (C<sub>7</sub>H<sub>3</sub>ClN<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 196.0, found <i>m</i>/<i>z</i> 196.0.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 6-Bromopyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic Acid (<b>44f</b>)</h4><div class="NLM_p last">To a solution of <b>43b</b> (2.63 g, 19.64 mmol) in EtOH (30 mL) and AcOH (30.0 mL) was added <b>41f</b> (3.11 g, 20.6 mmol). The mixture was stirred at 80 °C for 1.5 h and then cooled to rt. The resulting solid was collected by filtration, rinsed with water, and dried to afford <b>44f</b> (3.58 g, 14.8 mmol, 75%) as a beige solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (1H, s), 8.88 (1H, d, <i>J</i> = 2.3 Hz), 9.76 (1H, d, <i>J</i> = 2.3 Hz), 12.54 (1H, brs).</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-Methoxy-<i>N</i>-methyl-4-(trifluoromethoxy)benzamide (<b>46</b>)</h4><div class="NLM_p last">To a solution of <b>45</b> (9.96 g, 48.3 mmol) in THF (200 mL) was added oxalyl chloride (5.97 mL, 62.8 mmol), followed by a drop of DMF. The mixture was stirred at rt for 4 h and then concentrated in vacuo (azeotroped with toluene) to afford the corresponding acyl chloride as a pale-yellow oil. This was dissolved in DMA (150 mL), and then Et<sub>3</sub>N (10.1 mL, 72.5 mmol) and <i>O</i>,<i>N</i>-dimethylhydroxylamine hydrochloride (6.13 g, 62.8 mmol) were sequentially added. The mixture was stirred for 16 h and poured into water. The mixture was extracted with EtOAc, washed with water, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 100:0 to 1:1) to afford <b>46</b> (3.64 g, 14.6 mmol, 30%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.27 (3H, s), 3.55 (3H, s), 7.44 (2H, dd, <i>J</i> = 8.9, 0.9 Hz), 7.69–7.78 (2H, m).</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-(4-(Trifluoromethoxy)phenyl)propan-1-one (<b>47b</b>)</h4><div class="NLM_p last">To a solution of <b>46</b> (3.64 g, 14.6 mmol) in THF (40 mL) at 0 °C was added dropwise EtMgBr (1 M in THF, 21.9 mL, 21.9 mmol). The mixture was stirred at rt for 2 h. LC–MS analysis indicated that the starting material still remained. Therefore, further EtMgBr (1 M in THF, 10.0 mL, 10.0 mmol) was added. The mixture was stirred for another 30 min and then poured into 0.5 M HCl aqueous solution, extracted with EtOAc, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 100:0 to 3:1) to afford <b>47b</b> (2.73 g, 12.5 mmol, 86%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.09 (3H, t, <i>J</i> = 7.2 Hz), 3.07 (2H, q, <i>J</i> = 7.2 Hz), 7.44–7.56 (2H, m), 8.02–8.16 (2H, m).</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(4-Methoxyphenyl)-<i>N</i>-methylpropan-1-amine (<b>48</b>)</h4><div class="NLM_p last">To a mixture of <b>47a</b> (1.50 g, 9.14 mmol) and methylamine (27 wt % in methanol, 2.10 g, 18.3 mmol) in MeOH (20 mL) was added titanium tetraisopropoxide (3.11 g, 11.0 mmol), and the mixture was stirred at rt for 5 h. Then sodium borohydride (0.680 g, 18.3 mmol) was added. After the mixture was stirred overnight, it was diluted with NaOH aqueous solution and filtered. The filtrate was extracted with dichloromethane, and the organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 0:100) to give <b>48</b> (0.400 g, 2.23 mmol, 25%) as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 0.79 (3H, t, <i>J</i> = 7.6 Hz), 1.55–1.62 (1H, m), 1.71–1.78 (1H, m), 2.27 (3H, s), 3.29–3.33 (1H, m), 3.81 (3H, s), 6.85–6.88 (2H, m), 7.16–7.19 (2H, m).</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 1-(4-Methoxyphenyl)propan-1-amine (<b>50a</b>)</h4><div class="NLM_p last">To a solution of <b>47a</b> (23.5 g, 143 mmol) and hydroxylammonium chloride (10.9 g, 157 mmol) in EtOH (300 mL) was added Et<sub>3</sub>N (21.9 mL, 157 mmol) at rt. The mixture was refluxed for 3 h and then evaporated under reduced pressure to remove EtOH. The residue was partitioned between EtOAc and water, and the organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to give the crude product <b>49a</b> (26.7 g, 149 mmol, ∼quant) as a white solid, which was subjected to the next reaction without further purification. A mixture of <b>49a</b> (12.4 g, 69.2 mmol) and 10% Pd/C (containing 50% water, 8.19 g) in EtOH (300 mL) was hydrogenated under balloon pressure at rt overnight. The catalyst was removed by filtration, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (basic silica gel, 200 g, hexane/ethyl acetate, 9:1 to 1:9) to give <b>50a</b> (7.56 g, 45.8 mmol, 66%) as a pale-yellow oil. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.76 (3H, t, <i>J</i> = 7.4 Hz), 1.30–1.64 (2H, m), 1.87 (2H, brs), 3.63 (1H, t, <i>J</i> = 6.7 Hz), 3.72 (3H, s), 6.74–6.91 (2H, m), 7.15–7.29 (2H, m). MS (ESI/APCI) mass calculated for [M – NH<sub>2</sub>]<sup>+</sup> (C<sub>10</sub>H<sub>13</sub>O) requires <i>m</i>/<i>z</i> 149.1, found <i>m</i>/<i>z</i> 149.2.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 1-(4-(Trifluoromethoxy)phenyl)propan-1-amine (<b>50b</b>)</h4><div class="NLM_p last">The crude product <b>49b</b> was prepared in 99% yield as a colorless oil from <b>47b</b> using the procedure analogous to that described for the synthesis of <b>49a</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.04 (3H, t, <i>J</i> = 7.6 Hz), 2.72 (2H, q, <i>J</i> = 7.6 Hz), 7.31–7.44 (2H, m), 7.70–7.82 (2H, m), 11.29 (1H, s). A mixture of <b>49b</b> (2.89 g, 12.4 mmol) and 10% Pd/C (containing 50% water, 800 mg) in MeOH (30 mL) was hydrogenated under balloon pressure at rt overnight. The catalyst was removed by filtration, and the filtrate was concentrated in vacuo to give the crude product <b>50b</b> (2.58 g, 11.8 mmol, 95%) as a colorless oil. This material was taken on to the next reaction without further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.77 (3H, t, <i>J</i> = 7.4 Hz), 1.41–1.68 (2H, m), 2.21 (2H, brs), 3.74 (1H, t, <i>J</i> = 6.6 Hz), 7.21–7.34 (2H, m), 7.41–7.52 (2H, m).</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 1-(4-Methoxyphenyl)propan-1-amine Hydrochloride (<b>51a</b>)</h4><div class="NLM_p last">A mixture of <b>49a</b> (26.7 g, 149 mmol) and 10% Pd/C (containing 50% water, 15.8 g) in MeOH (200 mL) was hydrogenated under balloon pressure at rt overnight. The catalyst was removed by filtration, and the filtrate was concentrated in vacuo to give the crude product <b>50a</b>. The crude material <b>50a</b> was diluted with EtOAc (100 mL) and 1 M HCl solution in diethyl ether (150 mL) added. The resulting solid was collected and washed with EtOAc to give <b>51a</b> (27.4 g, 136 mmol, 91%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.74 (3H, t, <i>J</i> = 7.4 Hz), 1.58–2.13 (2H, m), 3.76 (3H, s), 4.04 (1H, dd, <i>J</i> = 9.5, 5.3 Hz), 6.84–7.12 (2H, m), 7.29–7.61 (2H, m), 8.44 (3H, brs).</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1-(4-(Trifluoromethoxy)phenyl)propan-1-amine Hydrochloride (<b>51b</b>)</h4><div class="NLM_p last">The crude product <b>50b</b> (11.3 g, 51.4 mmol) was dissolved in EtOAc (70 mL) and MeOH (10 mL), and then 4 M HCl solution in EtOAc (40 mL) was added. After 20 min of stirring (no precipitate occurred), the solvent was removed under reduced pressure. To the residual white solid was added Et<sub>2</sub>O, and the resulting solid was collected by filtration, rinsed with Et<sub>2</sub>O, and dried to afford <b>51b</b> (10.1 g, 39.6 mmol, 67%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.76 (3H, t, <i>J</i> = 7.4 Hz), 1.70–2.11 (2H, m), 4.20 (1H, dd, <i>J</i> = 9.1, 5.7 Hz), 7.39–7.53 (2H, m), 7.61–7.71 (2H, m), 8.63 (3H, brs).</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 6-Methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-carbaldehyde (<b>53</b>)</h4><div class="NLM_p last">To a solution of <b>52</b> (5.91 g, 44.4 mmol) in DMF (50 mL) was added phosphorus oxychloride (12.4 mL, 133 mmol) at 0 °C. The mixture was stirred at rt for 3 h. The mixture was neutralized with 8 M NaOH aqueous solution and extracted with EtOAc/THF (2:1). The organic layer was dried over anhydrous MgSO<sub>4</sub> and was passed through a silica gel pad (eluted with THF). The appropriate fraction was concentrated in vacuo, and the obtained solid was collected by filtration, washed with cold EtOAc, and dried to give <b>53</b> (5.86 g, 36.4 mmol, 82%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.48 (3H, s), 8.54 (1H, s), 8.60 (1H, s), 8.66 (1H, d, <i>J</i> = 1.9 Hz), 10.27 (1H, s). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>8</sub>H<sub>8</sub>N<sub>3</sub>O) requires <i>m</i>/<i>z</i> 162.1, found <i>m</i>/<i>z</i> 162.2.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 6-Methylpyrazolo[1,5-<i>a</i>]pyrimidine-3-sulfonyl Chloride (<b>54</b>)</h4><div class="NLM_p last">6-Methylpyrazolo[1,5-<i>a</i>]pyrimidine (<b>52</b>) (300 mg, 2.25 mmol) was added to chlorosulfonic acid (1.50 mL, 22.5 mmol). The mixture was stirred at 80 °C for 2 h and then poured into iced water. The precipitate was collected, washed with water, and dried to give <b>54</b> (135 mg, 0.583 mmol, 26%) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.53 (3H, d, <i>J</i> = 1.1 Hz), 8.52 (1H, s), 8.66 (1H, dd, <i>J</i> = 2.3, 1.1 Hz), 8.82 (1H, d, <i>J</i> = 1.9 Hz).</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Methyl 4-(Hydroxymethyl)pyrazolo[1,5-<i>a</i>]pyridine-3-carboxylate (<b>56a</b>)</h4><div class="NLM_p last">A solution of hydroxylamine-<i>O</i>-sulfonic acid (2.07 g, 18.3 mmol) in water (10 mL) was basified with saturated aqueous NaHCO<sub>3</sub> at 0 °C. To this mixture was added a solution of <b>55</b> (1.00 g, 9.16 mmol) in MeOH (10 mL) at the same temperature, and the mixture was heated at 50 °C for 16 h. The mixture was diluted with toluene and concentrated in vacuo (this protocol was repeated 3 times). The residual solid was suspended in DMF (23 mL), to which methyl propiolate (0.897 mL, 10.1 mmol) and potassium carbonate (3.80 g, 27.5 mmol) were successively added at 0 °C. After vigorous stirring at rt for 2 h, the mixture was filtered by filtration. The filtrate was partitioned between EtOAc and water. The phases were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 1:4) to afford <b>56a</b> (0.556 g, 2.70 mmol, 29%) and methyl 6-(hydroxymethyl)pyrazolo[1,5-<i>a</i>]pyridine-3-carboxylate (<b>56b</b>) (0.311 g, 1.51 mmol, 16%) as white solids. Data for <b>56a</b>: <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.80 (3H, s), 5.04 (2H, d, <i>J</i> = 5.7 Hz), 5.37 (1H, t, <i>J</i> = 5.7 Hz), 7.10–7.21 (1H, m), 7.65 (1H, dd, <i>J</i> = 7.2, 1.1 Hz), 8.44 (1H, s), 8.70–8.78 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>10</sub>H<sub>11</sub>N<sub>2</sub>O<sub>3</sub>) requires <i>m</i>/<i>z</i> 207.1, found <i>m</i>/<i>z</i> 207.1. Data for <b>56b</b>: <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.83 (3H, s), 4.58 (2H, d, <i>J</i> = 4.9 Hz), 5.46 (1H, t, <i>J</i> = 5.7 Hz), 7.58 (1H, dd, <i>J</i> = 9.1, 1.5 Hz), 8.05 (1H, dd, <i>J</i> = 9.1, 0.8 Hz), 8.43 (1H, s), 8.67–8.79 (1H, m). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>10</sub>H<sub>11</sub>N<sub>2</sub>O<sub>3</sub>) requires <i>m</i>/<i>z</i> 207.1, found <i>m</i>/<i>z</i> 207.1.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Methyl 4-Formylpyrazolo[1,5-<i>a</i>]pyridine-3-carboxylate (<b>57</b>)</h4><div class="NLM_p last">To a suspension of <b>56</b> (550 mg, 2.67 mmol) in CH<sub>3</sub>CN (70 mL) at 0 °C was added portionwise Dess–Martin periodinane (1.36 g, 3.20 mmol). The mixture was stirred at rt for 1.5 h. Further Dess–Martin periodinane (500 mg) was added at rt. Stirring was continued for another 1 h, and then NaHCO<sub>3</sub> aqueous solution and solid Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> were successively added. After stirring for 20 min, the mixture was extracted with EtOAc, washed with saturated aqueous NaHCO<sub>3</sub> and saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to afford <b>57</b> (545 mg, 2.67 mmol, 100%) as a reddish solid. This was used in the next reaction without further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.85 (3H, s), 7.29–7.38 (1H, m), 8.06 (1H, dd, <i>J</i> = 7.6, 1.1 Hz), 8.64 (1H, s), 9.17 (1H, dd, <i>J</i> = 6.8, 1.1 Hz), 10.96 (1H, d, <i>J</i> = 0.8 Hz).</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Methyl 4-(((1-(4-Methoxyphenyl)propyl)amino)methyl)pyrazolo[1,5-<i>a</i>]pyridine-3-carboxylate (<b>58</b>)</h4><div class="NLM_p last">To a mixture of <b>57</b> (540 mg, 2.64 mmol), <b>50a</b> (612 mg, 3.70 mmol), and acetic acid (0.454 mL, 7.93 mmol) in CH<sub>3</sub>CN (25 mL) at 0 °C was added portionwise sodium triacetoxyborohydride (1.18 g, 5.29 mmol). The mixture was stirred at rt for 16 h and then poured into saturated aqueous NaHCO<sub>3</sub>. The mixture was extracted with EtOAc, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by column chromatography (basic silica gel, hexane/ethyl acetate, 19:1 to 1:1) to afford <b>58</b> (739 mg, 2.09 mmol, 79%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.68 (3H, t, <i>J</i> = 7.4 Hz), 1.36–1.73 (2H, m), 3.31–3.43 (1H, m), 3.73 (3H, s), 3.75 (3H, s), 3.90–4.16 (2H, m), 6.78–6.95 (2H, m), 7.09 (1H, t, <i>J</i> = 7.0 Hz), 7.14–7.26 (2H, m), 7.34–7.45 (1H, m), 8.42 (1H, s), 8.65–8.79 (1H, m) (one proton was not observed). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub>) requires <i>m</i>/<i>z</i> 354.2, found <i>m</i>/<i>z</i> 354.2.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4-(((1-(4-Methoxyphenyl)propyl)amino)methyl)pyrazolo[1,5-<i>a</i>]pyridine-3-carboxylic Acid (<b>59</b>)</h4><div class="NLM_p last">To a solution of <b>58</b> (743 mg, 2.10 mmol) in THF (15 mL) and MeOH (7.5 mL) was added 1 M NaOH aqueous solution (6.31 mL, 6.31 mmol). The mixture was stirred at 50 °C for 30 min and then at 70 °C for 1.5 h. The mixture was acidified with 1 M HCl aqueous solution (12.6 mL, 12.6 mmol) and then evaporated under reduced pressure to remove the organic solvents. The residual aqueous solution was passed through HP20 (DIAION, Mitsubishi Chemical) (eluted with water and then CH<sub>3</sub>CN). The acetonitrile fractions containing the desired product was concentrated in vacuo to afford <b>59</b> (674 mg, 1.99 mmol, 94%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.61–0.77 (3H, m), 1.58–2.05 (2H, m), 3.62–3.93 (5H, m), 3.94–4.09 (1H, m), 6.83–7.03 (3H, m), 7.12 (1H, d, <i>J</i> = 6.8 Hz), 7.26–7.43 (2H, m), 8.32 (1H, s), 8.72 (1H, d, <i>J</i> = 6.8 Hz), 11.33 (1H, brs) (one proton was not observed). MS (ESI/APCI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub>) requires <i>m</i>/<i>z</i> 340.2, found <i>m</i>/<i>z</i> 340.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Enzyme Assay Protocol</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Preparation of Human PDE</h4><div class="NLM_p last">Human PDE1A, 3A, 4D2, 5A1, 7B, 8A1, 9A2, and 11A4 enzymes were purchased from BPS Bioscience. Human PDE6AB enzyme was purchased from SB Drug Discovery. Human PDE2A3 full-length gene was transduced into Sf9 cells, and the enzyme was purified by His-tag affinity column and gel filtration. Human PDE10A2 was generated from COS-7 cells that had been transfected with the full-length gene. The enzymes were stored at −70 °C until use.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> PDE2A3 Enzyme Inhibitory Assay</h4><div class="NLM_p last">PDE activity was measured using an scintillation proximity assay (SPA) (GE Healthcare). To evaluate the inhibitory activity of a compound, 10 μL of serially diluted compounds were incubated with 20 μL of PDE enzyme (final concentration 0.023 nM) in assay buffer (50 mM HEPES–NaOH, 8.3 mM MgCl<sub>2</sub>, 1.7 mM EGTA, and 0.1% bovine serum albumin (BSA) (pH 7.4)) for 30 min at rt. The final concentration of DMSO in the reaction solution was 1%. Compounds were tested in duplicate in 96-well half area plates (Corning) or a 384-well OptiPlates (PerkinElmer). We used an 8 concentration serial dilution dose response ranging from 100 μM to 10 pM compound concentrations. To start the reaction, 10 μL of substrate [<sup>3</sup>H] cGMP (final concentration 77 nM, PerkinElmer) were added to a total volume of 40 μL. After 60 min at rt, 20 μL of 20 mg/mL yttrium silicate SPA beads containing zinc sulfate were added to terminate the PDE reaction. After allowing to settle for an additional 60 min, the assay plates were counted in a scintillation counter (PerkinElmer) to allow calculation of the inhibition rate. The inhibition rate was calculated based on the 0% control wells with enzyme and DMSO, and the 100% control wells without enzyme. All IC<sub>50</sub> values were obtained by fitting the results to the following four-parameter logistic equation:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/jm-2017-007093_m001.gif" alt="" /></img></span>where <i>A</i> is the minimum <i>y</i> value, <i>B</i> is the maximum <i>y</i> value, <i>C</i> is Log(EC<sub>50</sub>) value, and <i>D</i> is the slope factor.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Human PDE Enzyme Assay</h4><div class="NLM_p last">PDE activities were measured using an SPA (GE Healthcare). To evaluate the inhibitory activity, 10 μL of serially diluted compounds were incubated with 20 μL of PDE enzymes, except for PDE1A, in the following assay buffer: 50 mM HEPES-NaOH, 8.3 mM MgCl<sub>2</sub>, 1.7 mM EGTA, and 0.1% BSA (pH 7.4) for 30 min at rt. The PDE1A enzyme assay was performed in the following assay buffer: 50 mM Tris-HCl, 8.3 mM MgCl<sub>2</sub>, 0.2 mM CaCl<sub>2</sub>, 0.1% BSA, and 30 nM Calmodulin (pH 7.5). The final concentration of DMSO in the assay was 1%, and compounds were tested in duplicate in 96-well half area plates (Corning). We used a 4 concentration serial dilution dose response ranging from 10 μM to 10 nM compound concentrations. To start the reaction, 10 μL of substrate ([<sup>3</sup>H] cGMP (final concentration 77 nM, PerkinElmer) for PDE1A, 5A1, 6AB, 9A2, 10A2, and 11A4 or [<sup>3</sup>H] cAMP (final concentration 14.7 nM, PerkinElmer) for PDE3A, 4D2, 7B, and 8A1) was added for a final assay volume of 40 μL. After 60 min incubation at rt, 20 μL of 20 mg/mL yttrium silicate SPA beads containing zinc sulfate was added to terminate the PDE reaction. After allowing to settle for more than 120 min, the assay plates were counted in a scintillation counter (PerkinElmer) to allow calculation of the inhibition rate.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Estimation of Log <i>D</i> at pH 7.4</h3><div class="NLM_p last">Log <i>D</i><sub>7.4</sub>, which is the partition coefficient of the compounds between 1-octanol and aqueous buffer at pH 7.4, was measured using a chromatographic procedure based on a previously published method.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The instruments utilized were a Waters Alliance 2795 HPLC system and a 2996 UV–vis detector (Milford, MA, USA).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> In Vitro Metabolic Clearance Assay</h3><div class="NLM_p last">In vitro oxidative metabolic studies of the tested compounds were performed using hepatic microsomes obtained from humans, rats, or mice. The reaction mixture with a final volume of 0.05 mL consisted of 0.2 mg/mL hepatic microsome in 50 mM KH<sub>2</sub>PO<sub>4</sub>–K<sub>2</sub>HPO<sub>4</sub> phosphate buffer (pH 7.4) and 1 μM test compound. The reaction was initiated by the addition of an NADPH-generating system containing 25 mM MgCl<sub>2</sub>, 25 mM glucose 6-phosphate, 2.5 mM β-NADP<sup>+</sup>, and 7.5 unit/mL glucose 6-phosphate dehydrogenase at 20% of the volume of the reaction mixture. After the addition of the NADPH-generating system, the mixture was incubated at 37 °C for 0, 15, and 30 min. The reaction was terminated by adding an equivalent volume of CH<sub>3</sub>CN. After the samples were mixed and centrifuged, the supernatant fractions were analyzed using liquid chromatography tandem mass spectrometry (LC–MS/MS). For metabolic clearance determinations, chromatograms were analyzed for the disappearance rate of the parent compound from the reaction mixtures. All incubations were made in duplicate.</div></div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Transcellular Transport Study Using a Transporter-Expression System</h3><div class="NLM_p last">Human MDR1-expressing LLC-PK1 cells were cultured as reported previously with minor modifications.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The transcellular transport study was performed as reported previously.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In brief, the cells were grown for 7 days in an HTS Transwell 96-well permeable support (pore size, 0.4 μm; surface area, 0.143 cm<sup>2</sup>) with a polyethylene terephthalate membrane (Corning Life Sciences, Lowell, MA, USA) at a density of 1.125 × 10<sup>5</sup> cells/well. The cells were preincubated with M199 at 37 °C for 30 min. Subsequently, transcellular transport was initiated by the addition of M199 either to apical compartments (75 μL) or to basolateral compartments (250 μL) containing 10 μM digoxin, 200 μM lucifer yellow as a marker for the monolayer tightness, and 10 μM test compounds, and then terminated by the removal of each assay plate after 2 h. Aliquots (25 μL) from the opposite compartments were mixed with acetonitrile containing alprenolol and diclofenac as internal standards, and then centrifuged. The compound concentrations in the supernatant were measured by LC–MS/MS. The apparent permeability (<i>P</i><sub>app</sub>) of test compounds in the receiver wells was determined and the efflux ratio (ER) for the MDR1 membrane permeability test was calculated using the following equation:<span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/jm-2017-007093_m002.gif" alt="" /></img></span>where <i>P</i><sub>app,AtoB</sub> is the apical-to-basal passive permeability–surface area product and <i>P</i><sub>app,BtoA</sub> is the basal-to-apical passive permeability–surface area product.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Protein Expression and Purification</h3><div class="NLM_p last">Human PDE2A catalytic domain (residues 578–919) for crystallographic study was purified from insect cells as a fusion protein with an N-terminal 6× histidine tag and adjacent tobacco etch virus (TEV) protease cleavage site. An extra His–Ala sequence was added prior to Ser578 of the PDE2A sequence based on the previously described structure.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The histidine-tagged PDE2A was expressed in Sf9 insect cells, and the harvested cell pellets were suspended in lysis buffer (50 mM Tris-HCl (pH 8.0), 1 mM DTT, 1 mM EDTA, and 10% glycerol), followed by centrifugation. The supernatant was supplemented with 300 mM NaCl and 20 mM imidazole and loaded onto an Ni-NTA Superflow cartridge (QIAGEN). The PDE2A bound resin was washed with wash buffer (50 mM Tris-HCl (pH 8.0), 10% glycerol, 300 mM NaCl, and 20 mM imidazole) and eluted with wash buffer containing 250 mM imidazole. The eluted histidine-tagged PDE2A catalytic domain was desalted using a HiPrep 26/10 desalting column (GE Healthcare) with TBS (pH 7.4), 0.5 mM DTT, 1 mM EDTA, and 10% glycerol. The histidine-tagged protein was cleaved at the TEV cleavage site by TEV protease treatment. After TEV cleavage, the digested protein was passed through the Ni-NTA Superflow cartridge to remove the unwanted histidine-tagged fragments and histidine-tagged TEV proteases, followed by ion exchange chromatography using a MonoQ 10/100 GL column (GE Healthcare) in basal buffer (50 mM Tris-HCl (pH 8.0), 1 mM DTT, and 10% glycerol) with a 0–500 mM NaCl linear gradient. Subsequently, the purified catalytic domain was further treated with HiLoad 26/60 Superdex200 column (GE Healthcare), concentrated by ultrafiltration to 9.5 mg/mL, and stored at −80 °C until use.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Crystallization and Structure Determination</h3><div class="NLM_p last">Crystals were obtained using the sitting-drop vapor-diffusion method by mixing 50 nL of protein solution (9.5 mg/mL PDE2A catalytic domain in 1 mM <b>38a</b>, TBS (pH 7.4), 0.5 mM DTT, 1 mM EDTA, and 10% glycerol) and 50 nL of reservoir solution containing 0.1 M Tris-HCl (pH 7.5), 410 mM magnesium chloride, and 29.3% PEG 3350 at 20 °C. Complex crystals were transferred into liquid nitrogen and stored until data collection. Diffraction data were collected from a single crystal at the Advanced Light Source beamline 5.0.3 (Berkeley, CA) for compounds <b>38a</b> and processed using the program HKL2000.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The structures were determined by molecular replacement using MOLREP,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> utilizing the previously reported coordinate of PDE2A with the PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XKM">5XKM</a>.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Subsequently, the structures were refined through an iterative procedure utilizing REFMAC,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> followed by model building with WinCoot.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The dictionary files for the inhibitors were prepared using AFITT (OpenEye Scientific Software).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Animal Experiments</h3><div class="NLM_p last">The care and use of animals and the experimental protocols were approved by the Experimental Animal Care and Use Committee of Takeda Pharmaceutical Company Limited.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Pharmacokinetic Analysis in Rat or Mouse Cassette Dosing</h3><div class="NLM_p last">Compound <b>38a</b> was administered intravenously (0.1 mg/kg) or orally (1 mg/kg) by cassette dosing to nonfasted male Crl:CD(SD)(IGS) rats (8W, <i>n</i> = 3) or male ICR mice (8W, <i>n</i> = 3). The combination for a cassette dosing was determined to avoid combinations of compounds with the same molecular weight. The solution of compounds in dimethylacetamide containing 50% (v/v) 1,3-butanediol at 0.1 mg/mL/kg was administered intravenously to isoflurane-anesthetized mice via femoral vein. The suspension of compounds in 0.5% methyl cellulose with water was used for vehicle (1 mg/kg) and was administered orally by gavage. After administration, blood samples were collected via tail vein by syringes with heparin at 5, 10, 15, and 30 min, and 1, 2, 4, and 8 h (iv) and 15 and 30 min, and 1, 2, 4, and 8 h (po), and centrifuged to obtain the plasma fraction. The plasma samples were deproteinized by mixing with acetonitrile followed by centrifugation. The compound concentrations in the supernatant were measured by LC–MS/MS with a standard curve. Pharmacokinetic parameters were calculated by the noncompartmental analysis. The area under the concentration–time curve (AUC) and the area under the first moment curve (AUMC) were calculated using the linear trapezoidal method. The mean residence time (MRT) was calculated as AUMC/AUC. The total clearance (CL<sub>total</sub>) was calculated as dose<sub>iv</sub>/AUC<sub>iv</sub>. The volume of distribution (Vd<sub>ss</sub>) was calculated as CL<sub>total</sub> × MRT<sub>iv</sub>. Oral bioavailability (<i>F</i>) was calculated as (AUC<sub>po</sub>/dose<sub>po</sub>)/(AUC<sub>iv</sub>/dose<sub>iv</sub>) × 100.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Brain and Plasma Concentrations in Rats and Mice</h3><div class="NLM_p last">Compound <b>38a</b> was administered orally to nonfasted rats or mice at 1 mg/kg. Blood and brain samples were collected 2 or 1 h after oral administration to rats or mice, respectively. The blood samples were centrifuged to obtain the plasma fraction. The brain samples were homogenized in 0.1 M phosphate buffer (pH 7.4) to obtain the brain homogenate. The plasma and brain homogenate samples were deproteinized with CH<sub>3</sub>CN containing an internal standard. After centrifugation, the compound concentrations in the supernatant were measured by LC–MS/MS.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Measurement of Cyclic Nucleotide Content in the Mouse Brain</h3><div id="sec5_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Animals</h4><div class="NLM_p last">Five-week-old male ICR mice were purchased from CLEA Japan, Inc. (Japan). The mice were housed in groups of five/cage in a light-controlled room (12 h light/dark cycles with lights on at 07:00). Food and water were provided ad libitum. After a one-week acclimation period, the six-week-old mice were used for experiments.</div></div><div id="sec5_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Measurements</h4><div class="NLM_p last">Compound <b>38a</b> was suspended in 0.5% (w/v) methylcellulose in distilled water and was administered at 10 mL/kg body weight for mice. Mice were administered orally either vehicle or <b>38a</b> (10, 30, or 100 mg/kg) after a habituation period of at least 30 min. A microwave fixation system (Muromachi Kikai, Tokyo, Japan) was used to sacrifice unanesthetized mice by exposure of the head to a microwave beam 30 min after administration of <b>38a</b>. Brain tissues were isolated and then homogenized in 0.5 M HCl, followed by centrifugation. Concentration of cyclic nucleotides in the supernatant were measured using cyclic AMP EIA kit or cyclic GMP EIA kit (Cayman Chemical, USA) according to the manufacturer’s instructions. Values were calculated as pmol/mg tissue weight.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00709">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76648" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76648" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00709" class="ext-link">10.1021/acs.jmedchem.7b00709</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">X-ray data collection and refinement statistics for the crystal structure of PDE2A in complex with compound <b>38a</b> and molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00709/suppl_file/jm7b00709_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00709/suppl_file/jm7b00709_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00709/suppl_file/jm7b00709_si_001.pdf">jm7b00709_si_001.pdf (129.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00709/suppl_file/jm7b00709_si_002.csv">jm7b00709_si_002.csv (1.12 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates of the crystal structure of PDE2A in complex with compound <b>38a</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XKM">5XKM</a>) have been deposited in the Protein Data Bank. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b00709" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08022" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08022" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satoshi Mikami</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3587-0343" title="Orcid link">http://orcid.org/0000-0002-3587-0343</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fa899b8e95899293d49793919b9793ba8e9b919f9e9bd4999597"><span class="__cf_email__" data-cfemail="9eedffeaf1edf6f7b0f3f7f5fff3f7deeafff5fbfaffb0fdf1f3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shigekazu Sasaki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yasutomi Asano</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Osamu Ujikawa</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shoji Fukumoto</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kosuke Nakashima</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hideyuki Oki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naomi Kamiguchi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haruka Imada</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroki Iwashita</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takahiko Taniguchi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1,
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d142e6126-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88003" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88003" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge Shinobu Sasaki for synthetic support, Katsuaki Oda for chiral separations, Hironori Kokubo for molecular modeling studies, Mitsuyo Kondo for preparation of the PDE2A protein used in the in vitro enzyme assays and crystallographic experiments, and Noriko Uchiyama for assistance in running additional in vitro enzyme assays.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i84" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i84"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i85" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i85"> Abbreviations Used</h2><tr><td class="NLM_term">AC</td><td class="NLM_def"><p class="first last">adenylyl cyclase</p></td></tr><tr><td class="NLM_term">HCO<sub>3</sub><sup>–</sup></td><td class="NLM_def"><p class="first last">bicarbonate</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-(bis(dimethylamino)methylene)-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">3′,5′-cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">cGMP</td><td class="NLM_def"><p class="first last">3′,5′-cyclic guanosine monophosphate</p></td></tr><tr><td class="NLM_term">EHNA</td><td class="NLM_def"><p class="first last"><i>erythro</i>-9-(2-hydroxy-3-nonyl)adenine</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">1,2-dimethoxyethane</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide</p></td></tr><tr><td class="NLM_term">GC</td><td class="NLM_def"><p class="first last">guanylyl cyclases</p></td></tr><tr><td class="NLM_term">HIP</td><td class="NLM_def"><p class="first last">hippocampus</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">IBMX</td><td class="NLM_def"><p class="first last">3-isobutyl-1-methylxanthine</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">LC–MS/MS</td><td class="NLM_def"><p class="first last">liquid chromatography tandem mass spectrometry</p></td></tr><tr><td class="NLM_term">LTP</td><td class="NLM_def"><p class="first last">long-term potentiation</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance protein 1</p></td></tr><tr><td class="NLM_term">NO</td><td class="NLM_def"><p class="first last">nitric oxide</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PDE</td><td class="NLM_def"><p class="first last">phosphodiesterase</p></td></tr><tr><td class="NLM_term">PFC</td><td class="NLM_def"><p class="first last">prefrontal cortex</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PKA</td><td class="NLM_def"><p class="first last">protein kinase A</p></td></tr><tr><td class="NLM_term">PKG</td><td class="NLM_def"><p class="first last">protein kinase G</p></td></tr><tr><td class="NLM_term">RHS</td><td class="NLM_def"><p class="first last">right-hand side</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">STR</td><td class="NLM_def"><p class="first last">striatum</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24243" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24243" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Tresguerres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buck, J.</span><span> </span><span class="NLM_article-title">Intracellular cAMP Signaling by Soluble Adenylyl Cyclase</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">1277</span><span class="NLM_x">–</span> <span class="NLM_lpage">1288</span><span class="refDoi"> DOI: 10.1038/ki.2011.95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1038%2Fki.2011.95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=21490586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFyjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=1277-1288&author=M.+Tresguerresauthor=L.+R.+Levinauthor=J.+Buck&title=Intracellular+cAMP+Signaling+by+Soluble+Adenylyl+Cyclase&doi=10.1038%2Fki.2011.95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular cAMP signaling by soluble adenylyl cyclase</span></div><div class="casAuthors">Tresguerres, Martin; Levin, Lonny R.; Buck, Jochen</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1277-1288</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sol. adenylyl cyclase (sAC) is a recently identified source of the ubiquitous second messenger cyclic adenosine 3',5' monophosphate (cAMP). sAC is distinct from the more widely studied source of cAMP, the transmembrane adenylyl cyclases (tmACs); its activity is uniquely regulated by bicarbonate anions, and it is distributed throughout the cytoplasm and in cellular organelles.  Due to its unique localization and regulation, sAC has various functions in a variety of physiol. systems that are distinct from tmACs.  In this review, we detail the known functions of sAC, and we reassess commonly held views of cAMP signaling inside cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyDPAutHDsDLVg90H21EOLACvtfcHk0lhHxhA1XcVJoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFyjsr0%253D&md5=a14f78b3036a5c704c9ff12209bbe92e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fki.2011.95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2011.95%26sid%3Dliteratum%253Aachs%26aulast%3DTresguerres%26aufirst%3DM.%26aulast%3DLevin%26aufirst%3DL.%2BR.%26aulast%3DBuck%26aufirst%3DJ.%26atitle%3DIntracellular%2520cAMP%2520Signaling%2520by%2520Soluble%2520Adenylyl%2520Cyclase%26jtitle%3DKidney%2520Int.%26date%3D2011%26volume%3D79%26spage%3D1277%26epage%3D1288%26doi%3D10.1038%2Fki.2011.95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lucas, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitari, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazerounian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Stewart, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chepenik, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, S. A.</span><span> </span><span class="NLM_article-title">Guanylyl Cyclases and Signaling by Cyclic GMP</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">413</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10977868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2000&pages=375-413&author=K.+A.+Lucasauthor=G.+M.+Pitariauthor=S.+Kazerounianauthor=I.+Ruiz-Stewartauthor=J.+Parkauthor=S.+Schulzauthor=K.+P.+Chepenikauthor=S.+A.+Waldman&title=Guanylyl+Cyclases+and+Signaling+by+Cyclic+GMP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Guanylyl cyclases and signaling by cyclic GMP</span></div><div class="casAuthors">Lucas, Kimberly A.; Pitari, Giovanni M.; Kazerounian, Shiva; Ruiz-Stewart, Inez; Park, Jason; Schulz, Stephanie; Chepenik, Kenneth P.; Waldman, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-413</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review with 393 refs.  Guanylyl cyclases are a family of enzymes that catalyze the conversion of GTP to cGMP.  The family comprises both membrane-bound and sol. isoforms that are expressed in nearly all cell types.  They are regulated by diverse extracellular agonists that include peptide hormones, bacterial toxins, and free radicals, as well as intracellular mols., such as Ca2+ and adenine nucleotides.  Stimulation of guanylyl cyclases and the resultant accumulation of cGMP regulates complex signaling cascades through immediate downstream effectors, including cGMP-dependent protein kinases, cGMP-regulated phosphodiesterases, and cyclic nucleotide-gated ion channels.  Guanylyl cyclases and cGMP-mediated signaling cascades play a central role in the regulation of diverse (patho)physiol. processes, including vascular smooth muscle motility, intestinal fluid and electrolyte homeostasis, and retinal phototransduction.  Topics addressed in this review include the structure and chromosomal localization of the genes for guanylyl cyclases, structure and function of the members of the guanylyl cyclase family, mol. mechanisms regulating enzymic activity, and mol. sequences coupling ligand binding to catalytic activity.  A brief overview is presented of the downstream events controlled by guanylyl cyclases, including the effectors that are regulated by cGMP and the role that guanylyl cyclases play in cell physiol. and pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHStLFSGOzzbVg90H21EOLACvtfcHk0lhHxhA1XcVJoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbg%253D&md5=0694e83a91440f3fff3c0a2312682b15</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DK.%2BA.%26aulast%3DPitari%26aufirst%3DG.%2BM.%26aulast%3DKazerounian%26aufirst%3DS.%26aulast%3DRuiz-Stewart%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DChepenik%26aufirst%3DK.%2BP.%26aulast%3DWaldman%26aufirst%3DS.%2BA.%26atitle%3DGuanylyl%2520Cyclases%2520and%2520Signaling%2520by%2520Cyclic%2520GMP%26jtitle%3DPharmacol.%2520Rev.%26date%3D2000%26volume%3D52%26spage%3D375%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Bender, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beavo, J. A.</span><span> </span><span class="NLM_article-title">Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">488</span><span class="NLM_x">–</span> <span class="NLM_lpage">520</span><span class="refDoi"> DOI: 10.1124/pr.58.3.5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1124%2Fpr.58.3.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=16968949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=488-520&author=A.+T.+Benderauthor=J.+A.+Beavo&title=Cyclic+Nucleotide+Phosphodiesterases%3A+Molecular+Regulation+to+Clinical+Use&doi=10.1124%2Fpr.58.3.5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use</span></div><div class="casAuthors">Bender, Andrew T.; Beavo, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-520</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that regulate the cellular levels of the second messengers, cAMP and cGMP, by controlling their rates of degrdn.  There are 11 different PDE families, with each family typically having several different isoforms and splice variants.  These unique PDEs differ in their three-dimensional structure, kinetic properties, modes of regulation, intracellular localization, cellular expression, and inhibitor sensitivities.  Current data suggest that individual isoenzymes modulate distinct regulatory pathways in the cell.  These properties therefore offer the opportunity for selectively targeting specific PDEs for treatment of specific disease states.  The feasibility of these enzymes as drug targets is exemplified by the com. and clin. successes of the erectile dysfunction drugs, sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra).  PDE inhibitors are also currently available or in development for treatment of a variety of other pathol. conditions.  In this review the basic biochem. properties, cellular regulation, expression patterns, and physiol. functions of the different PDE isoforms will be discussed.  How these properties relate to the current and future development of PDE inhibitors as pharmacol. agents is esp. considered.  PDEs hold great promise as drug targets and recent research advances make this an exciting time for the field of PDE research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJl4RDiZ0ugrVg90H21EOLACvtfcHk0ljK7zTzf_wXcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfI&md5=af31cf6952efe7adb428a951779f36bc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fpr.58.3.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.58.3.5%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DBeavo%26aufirst%3DJ.%2BA.%26atitle%3DCyclic%2520Nucleotide%2520Phosphodiesterases%253A%2520Molecular%2520Regulation%2520to%2520Clinical%2520Use%26jtitle%3DPharmacol.%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D488%26epage%3D520%26doi%3D10.1124%2Fpr.58.3.5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Beavo, J. A.</span><span> </span><span class="NLM_article-title">Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms</span> <span class="citation_source-journal">Physiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1995&pages=725-748&author=J.+A.+Beavo&title=Cyclic+Nucleotide+Phosphodiesterases%3A+Functional+Implications+of+Multiple+Isoforms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeavo%26aufirst%3DJ.%2BA.%26atitle%3DCyclic%2520Nucleotide%2520Phosphodiesterases%253A%2520Functional%2520Implications%2520of%2520Multiple%2520Isoforms%26jtitle%3DPhysiol.%2520Rev.%26date%3D1995%26volume%3D75%26spage%3D725%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Maurice, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manganiello, V. C.</span><span> </span><span class="NLM_article-title">Advances in Targeting Cyclic Nucleotide Phosphodiesterases</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">290</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span><span class="refDoi"> DOI: 10.1038/nrd4228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1038%2Fnrd4228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=24687066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=290-314&author=D.+H.+Mauriceauthor=H.+Keauthor=F.+Ahmadauthor=Y.+Wangauthor=J.+Chungauthor=V.+C.+Manganiello&title=Advances+in+Targeting+Cyclic+Nucleotide+Phosphodiesterases&doi=10.1038%2Fnrd4228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in targeting cyclic nucleotide phosphodiesterases</span></div><div class="casAuthors">Maurice, Donald H.; Ke, Hengming; Ahmad, Faiyaz; Wang, Yousheng; Chung, Jay; Manganiello, Vincent C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">290-314</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cyclic GMP, thereby regulating the intracellular concns. of these cyclic nucleotides, their signalling pathways and, consequently, myriad biol. responses in health and disease.  Currently, a small no. of PDE inhibitors are used clin. for treating the pathophysiol. dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease.  However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMRfUs-zUmLVg90H21EOLACvtfcHk0ljK7zTzf_wXcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D&md5=410c8d5bb5fbd7d2906e30dc1b5f2876</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd4228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4228%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DD.%2BH.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DManganiello%26aufirst%3DV.%2BC.%26atitle%3DAdvances%2520in%2520Targeting%2520Cyclic%2520Nucleotide%2520Phosphodiesterases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D290%26epage%3D314%26doi%3D10.1038%2Fnrd4228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Packer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carver, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodeheffer, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanhoe, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiBianco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeldis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrix, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bommer, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkayam, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukin, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallis, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sollano, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tandon, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMets, D. L.</span><span> </span><span class="NLM_article-title">Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">325</span><span class="NLM_x">, </span> <span class="NLM_fpage">1468</span><span class="NLM_x">–</span> <span class="NLM_lpage">1475</span><span class="refDoi"> DOI: 10.1056/NEJM199111213252103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1056%2FNEJM199111213252103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1944425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A280%3ADyaK38%252FkvFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=1991&pages=1468-1475&author=M.+Packerauthor=J.+R.+Carverauthor=R.+J.+Rodehefferauthor=R.+J.+Ivanhoeauthor=R.+DiBiancoauthor=S.+M.+Zeldisauthor=G.+H.+Hendrixauthor=W.+J.+Bommerauthor=U.+Elkayamauthor=M.+L.+Kukinauthor=G.+I.+Mallisauthor=J.+A.+Sollanoauthor=J.+Shannonauthor=P.+K.+Tandonauthor=D.+L.+DeMets&title=Effect+of+Oral+Milrinone+on+Mortality+in+Severe+Chronic+Heart+Failure&doi=10.1056%2FNEJM199111213252103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group</span></div><div class="casAuthors">Packer M; Carver J R; Rodeheffer R J; Ivanhoe R J; DiBianco R; Zeldis S M; Hendrix G H; Bommer W J; Elkayam U; Kukin M L</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1468-75</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Milrinone, a phosphodiesterase inhibitor, enhances cardiac contractility by increasing intracellular levels of cyclic AMP, but the long-term effect of this type of positive inotropic agent on the survival of patients with chronic heart failure has not been determined.  METHODS:  We randomly assigned 1,088 patients with severe chronic heart failure (New York Heart Association class III or IV) and advanced left ventricular dysfunction to double-blind treatment with (40 mg of oral milrinone daily (561 patients) or placebo (527 patients).  In addition, all patients received conventional therapy with digoxin, diuretics, and a converting-enzyme inhibitor throughout the trial.  The median period of follow-up was 6.1 months (range, 1 day to 20 months).  RESULTS:  As compared with placebo, milrinone therapy was associated with a 28 percent increase in mortality from all causes (95 percent confidence interval, 1 to 61 percent; P = 0.038) and a 34 percent increase in cardiovascular mortality (95 percent confidence interval, 6 to 69 percent; P = 0.016).  The adverse effect of milrinone was greatest in patients with the most severe symptoms (New York Heart Association class IV), who had a 53 percent increase in mortality (95 percent confidence interval, 13 to 107 percent; P = 0.006).  Milrinone did not have a beneficial effect on the survival of any subgroup.  Patients treated with milrinone had more hospitalizations (44 vs. 39 percent, P = 0.041), were withdrawn from double-blind therapy more frequently (12.7 vs. 8.7 percent, P = 0.041), and had serious adverse cardiovascular reactions, including hypotension (P = 0.006) and syncope (P = 0.002), more often than the patients given placebo.  CONCLUSIONS:  Our findings indicate that despite its beneficial hemodynamic actions, long-term therapy with oral milrinone increases the morbidity and mortality of patients with severe chronic heart failure.  The mechanism by which the drug exerts its deleterious effects is unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGSjQUFbf_0_6AExegM5LLfW6udTcc2eaQbCSWU1U6bbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252FkvFGlsQ%253D%253D&md5=e43d8fc27d240be714ba780e5efd4b28</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJM199111213252103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199111213252103%26sid%3Dliteratum%253Aachs%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DCarver%26aufirst%3DJ.%2BR.%26aulast%3DRodeheffer%26aufirst%3DR.%2BJ.%26aulast%3DIvanhoe%26aufirst%3DR.%2BJ.%26aulast%3DDiBianco%26aufirst%3DR.%26aulast%3DZeldis%26aufirst%3DS.%2BM.%26aulast%3DHendrix%26aufirst%3DG.%2BH.%26aulast%3DBommer%26aufirst%3DW.%2BJ.%26aulast%3DElkayam%26aufirst%3DU.%26aulast%3DKukin%26aufirst%3DM.%2BL.%26aulast%3DMallis%26aufirst%3DG.%2BI.%26aulast%3DSollano%26aufirst%3DJ.%2BA.%26aulast%3DShannon%26aufirst%3DJ.%26aulast%3DTandon%26aufirst%3DP.%2BK.%26aulast%3DDeMets%26aufirst%3DD.%2BL.%26atitle%3DEffect%2520of%2520Oral%2520Milrinone%2520on%2520Mortality%2520in%2520Severe%2520Chronic%2520Heart%2520Failure%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1991%26volume%3D325%26spage%3D1468%26epage%3D1475%26doi%3D10.1056%2FNEJM199111213252103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kanlop, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chattipakorn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chattipakorn, N.</span><span> </span><span class="NLM_article-title">Effects of Cilostazol in the Heart</span> <span class="citation_source-journal">J. Cardiovasc. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.2459/JCM.0b013e3283439746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.2459%2FJCM.0b013e3283439746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A280%3ADC%252BC3M7gvVKntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=88-95&author=N.+Kanlopauthor=S.+Chattipakornauthor=N.+Chattipakorn&title=Effects+of+Cilostazol+in+the+Heart&doi=10.2459%2FJCM.0b013e3283439746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of cilostazol in the heart</span></div><div class="casAuthors">Kanlop Natnicha; Chattipakorn Siriporn; Chattipakorn Nipon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cardiovascular medicine (Hagerstown, Md.)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cilostazol is a selective phosphodiesterase 3 (PDE3) inhibitor approved by the Food and Drug Administration for treatment of intermittent claudication.  It has also been used in bradyarrhythmic patients to increase heart rates.  Recently, cilostazol has been shown to prevent ventricular fibrillation in patients with Brugada syndrome.  Cilostazol is hypothesized to suppress transient outward potassium (Ito) current and increase inward calcium current, thus, maintaining the dome (phase 2) of action potential, decreasing transmural dispersion of repolarization and preventing ventricular fibrillation.  Although many PDE3 inhibitors have been shown to increase cardiac arrhythmia in heart failure, cilostazol has presented effects that are different from other PDE3 inhibitors, especially adenosine uptake inhibition.  Owing to this effect, cilostazol could be an effective cardioprotective drug, with its beneficial effects in preventing arrhythmia.  In this review, the cardiac electrophysiological effects of cilostazol are presented and its possible cardioprotective effects, particularly in preventing ventricular fibrillation, are discussed, with emphasis on the need to further verify its clinical benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxeNJlN3c-uIxhnOQkIHOxfW6udTcc2eZMC8zjtSoQ_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7gvVKntQ%253D%253D&md5=be5f8e4ae942dd783b41e716eae76f4c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2459%2FJCM.0b013e3283439746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2459%252FJCM.0b013e3283439746%26sid%3Dliteratum%253Aachs%26aulast%3DKanlop%26aufirst%3DN.%26aulast%3DChattipakorn%26aufirst%3DS.%26aulast%3DChattipakorn%26aufirst%3DN.%26atitle%3DEffects%2520of%2520Cilostazol%2520in%2520the%2520Heart%26jtitle%3DJ.%2520Cardiovasc.%2520Med.%26date%3D2011%26volume%3D12%26spage%3D88%26epage%3D95%26doi%3D10.2459%2FJCM.0b013e3283439746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Rabe, K. F.</span><span> </span><span class="NLM_article-title">Update on Roflumilast, a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1111%2Fj.1476-5381.2011.01218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=21232047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=53-67&author=K.+F.+Rabe&title=Update+on+Roflumilast%2C+a+Phosphodiesterase+4+Inhibitor+for+the+Treatment+of+Chronic+Obstructive+Pulmonary+Disease&doi=10.1111%2Fj.1476-5381.2011.01218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rabe, Klaus F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-67</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main PDE isoenzyme occurring in cells involved in inflammatory airway disease such as chronic obstructive pulmonary disease (COPD).  COPD is a preventable and treatable disease and is characterized by airflow obstruction that is not fully reversible.  Chronic progressive symptoms, particularly dyspnea, chronic bronchitis and impaired overall health are worse in those who have frequent, acute episodes of symptom exacerbation.  Although several exptl. PDE4 inhibitors are in clin. development, roflumilast, a highly selective PDE4 inhibitor, is the first in its class to be licensed, and has recently been approved in several countries for oral, once-daily treatment of severe COPD.  Clin. trials have demonstrated that roflumilast improves lung function and reduces exacerbation frequency in COPD.  Furthermore, its unique mode of action may offer the potential to target the inflammatory processes underlying COPD.  Roflumilast is effective when used concomitantly with all forms of bronchodilator and even in patients treated with inhaled corticosteroids.  Roflumilast thus represents an important addn. to current therapeutic options for COPD patients with chronic bronchitis, including those who remain symptomatic despite treatment.  This article reviews the current status of PDE4 inhibitors, focusing on the pharmacokinetics, efficacy and safety of roflumilast.  In particular, it provides an overview of the effects of roflumilast on lung function and exacerbations, glucose homoeostasis and wt. loss, and the concomitant use of long-acting beta2-adrenergic receptor agonists and short-acting muscarinic receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryBUcu0ToPGrVg90H21EOLACvtfcHk0ljqyPNkjblnjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D&md5=c6ac3310e2d9ff1c7de86aecbd1356bb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01218.x%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DUpdate%2520on%2520Roflumilast%252C%2520a%2520Phosphodiesterase%25204%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D53%26epage%3D67%26doi%3D10.1111%2Fj.1476-5381.2011.01218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Tenor, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzelmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beume, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethke, T. D.</span><span> </span><span class="NLM_article-title">Pharmacology, Clinical Efficacy, and Tolerability of Phosphodiesterase-4 Inhibitors: Impact of Human Pharmacokinetics</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span><span class="refDoi"> DOI: 10.1007/978-3-642-17969-3_3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1007%2F978-3-642-17969-3_3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2011&pages=85-119&author=H.+Tenorauthor=A.+Hatzelmannauthor=R.+Beumeauthor=G.+Lahuauthor=K.+Zechauthor=T.+D.+Bethke&title=Pharmacology%2C+Clinical+Efficacy%2C+and+Tolerability+of+Phosphodiesterase-4+Inhibitors%3A+Impact+of+Human+Pharmacokinetics&doi=10.1007%2F978-3-642-17969-3_3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitirors: impact of human pharmacokinetics</span></div><div class="casAuthors">Tenor, Hermann; Hatzelmann, Armin; Beume, Rolf; Lahu, Gezim; Zech, Karl; Bethke, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">Phosphodiesterases as Drug Targets</span>),
    <span class="NLM_cas:pages">85-119</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Since more than two decades anti-inflammatory effects of inhibitors of phosphodiesterase-4 have been described in numerous cellular and animal studies and were finally confirmed in clin. trials.  The path from an early, pioneering study with Ro20-1724 showing redn. of psoriatic plaque size in 1979 to modern PDE4 inhibitors such as oral apremilast in development for psoriasis, the inhaled PDE4 inhibitor GSK256066 in development for asthma and COPD and finally roflumilast, the first PDE4 inhibitor approved and currently marketed as an oral, once-daily remedy for severe COPD was marked by large progress in chem. optimization based on improved understanding of PDE4 biol. and drug-like properties detg. the appropriate pharmacokinetic profile.  In this chapter aspects of the pharmacol. and clin. efficacy of PDE4 inhibitors, which have been in clin. development over the years are summarized with specific emphasis on their clin. pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZJeyCYZnL-LVg90H21EOLACvtfcHk0ljqyPNkjblnjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChsLnJ&md5=f138b847bfa54d92569f2d7e2f791973</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-17969-3_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-17969-3_3%26sid%3Dliteratum%253Aachs%26aulast%3DTenor%26aufirst%3DH.%26aulast%3DHatzelmann%26aufirst%3DA.%26aulast%3DBeume%26aufirst%3DR.%26aulast%3DLahu%26aufirst%3DG.%26aulast%3DZech%26aufirst%3DK.%26aulast%3DBethke%26aufirst%3DT.%2BD.%26atitle%3DPharmacology%252C%2520Clinical%2520Efficacy%252C%2520and%2520Tolerability%2520of%2520Phosphodiesterase-4%2520Inhibitors%253A%2520Impact%2520of%2520Human%2520Pharmacokinetics%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2011%26volume%3D204%26spage%3D85%26epage%3D119%26doi%3D10.1007%2F978-3-642-17969-3_3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Fabbri, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izquierdo-Alonso, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bundschuh, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabe, K. F.</span><span> </span><span class="NLM_article-title">Roflumilast in Moderate-to-Severe Chronic Obstructive Pulmonary Disease Treated with Longacting Bronchodilators: Two Randomised Clinical Trials</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">703</span><span class="refDoi"> DOI: 10.1016/S0140-6736(09)61252-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2FS0140-6736%2809%2961252-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2009&pages=695-703&author=L.+M.+Fabbriauthor=P.+M.+Calverleyauthor=J.+L.+Izquierdo-Alonsoauthor=D.+S.+Bundschuhauthor=M.+Broseauthor=F.+J.+Martinezauthor=K.+F.+Rabe&title=Roflumilast+in+Moderate-to-Severe+Chronic+Obstructive+Pulmonary+Disease+Treated+with+Longacting+Bronchodilators%3A+Two+Randomised+Clinical+Trials&doi=10.1016%2FS0140-6736%2809%2961252-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2961252-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252961252-6%26sid%3Dliteratum%253Aachs%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26aulast%3DIzquierdo-Alonso%26aufirst%3DJ.%2BL.%26aulast%3DBundschuh%26aufirst%3DD.%2BS.%26aulast%3DBrose%26aufirst%3DM.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DRoflumilast%2520in%2520Moderate-to-Severe%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%2520Treated%2520with%2520Longacting%2520Bronchodilators%253A%2520Two%2520Randomised%2520Clinical%2520Trials%26jtitle%3DLancet%26date%3D2009%26volume%3D374%26spage%3D695%26epage%3D703%26doi%3D10.1016%2FS0140-6736%2809%2961252-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Reed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosbie, D.</span><span> </span><span class="NLM_article-title">Apremilast in the Treatment of Psoriatic Arthritis: A Perspective Review</span> <span class="citation_source-journal">Ther. Adv. Musculoskeletal Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span><span class="refDoi"> DOI: 10.1177/1759720X16673786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1177%2F1759720X16673786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=28255338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A280%3ADC%252BC1czitl2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=45-53&author=M.+Reedauthor=D.+Crosbie&title=Apremilast+in+the+Treatment+of+Psoriatic+Arthritis%3A+A+Perspective+Review&doi=10.1177%2F1759720X16673786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Apremilast in the treatment of psoriatic arthritis: a perspective review</span></div><div class="casAuthors">Reed Michael; Crosbie David</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic advances in musculoskeletal disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">45-53</span>
        ISSN:<span class="NLM_cas:issn">1759-720X</span>.
    </div><div class="casAbstract">Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4).  Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis.  Established therapeutic options have variable effectiveness across the different domains of psoriatic disease.  Whilst biologic therapies have proven to be of significant benefit to many patients, not all patients respond, and others are not eligible or do not tolerate biologic therapy.  We review the mechanism of action, pharmacokinetics and clinical trial data with regards to both efficacy and safety for apremilast and consider where this new treatment may be positioned in the treatment of PsA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTQ2J8oScirLYtC3U5jeOifW6udTcc2eYn4NswwrQB1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czitl2jtA%253D%253D&md5=afa2fe6ddcb9b00964da43408ab4c306</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1177%2F1759720X16673786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1759720X16673786%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DM.%26aulast%3DCrosbie%26aufirst%3DD.%26atitle%3DApremilast%2520in%2520the%2520Treatment%2520of%2520Psoriatic%2520Arthritis%253A%2520A%2520Perspective%2520Review%26jtitle%3DTher.%2520Adv.%2520Musculoskeletal%2520Dis.%26date%3D2017%26volume%3D9%26spage%3D45%26epage%3D53%26doi%3D10.1177%2F1759720X16673786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Paller, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tom, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenthal, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boguniewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Call, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichenfield, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsha, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spellman, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein Gold, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaenglein, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zane, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebert, A. A.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of Crisaborole Ointment, A Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults</span> <span class="citation_source-journal">J. Am. Acad. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">494</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span><span class="refDoi"> DOI: 10.1016/j.jaad.2016.05.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.jaad.2016.05.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=27417017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKmtbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2016&pages=494-503&author=A.+S.+Pallerauthor=W.+L.+Tomauthor=M.+G.+Lebwohlauthor=R.+L.+Blumenthalauthor=M.+Boguniewiczauthor=R.+S.+Callauthor=L.+F.+Eichenfieldauthor=D.+W.+Forshaauthor=W.+C.+Reesauthor=E.+L.+Simpsonauthor=M.+C.+Spellmanauthor=L.+F.+Stein+Goldauthor=A.+L.+Zaengleinauthor=M.+H.+Hughesauthor=L.+T.+Zaneauthor=A.+A.+Hebert&title=Efficacy+and+Safety+of+Crisaborole+Ointment%2C+A+Novel%2C+Nonsteroidal+Phosphodiesterase+4+%28PDE4%29+Inhibitor+for+the+Topical+Treatment+of+Atopic+Dermatitis+%28AD%29+in+Children+and+Adults&doi=10.1016%2Fj.jaad.2016.05.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults</span></div><div class="casAuthors">Paller, Amy S.; Tom, Wynnis L.; Lebwohl, Mark G.; Blumenthal, Robin L.; Boguniewicz, Mark; Call, Robert S.; Eichenfield, Lawrence F.; Forsha, Douglass W.; Rees, William C.; Simpson, Eric L.; Spellman, Mary C.; Stein Gold, Linda F.; Zaenglein, Andrea L.; Hughes, Matilda H.; Zane, Lee T.; Hebert, Adelaide A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">494-503.e6</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Addnl. topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks.  We sought to assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, in two phase III AD studies (AD-301: NCT02118766; AD-302: NCT02118792).  Two identically designed, vehicle-controlled, double-blind studies enrolled and randomly assigned (2:1, crisaborole:vehicle) patients aged 2 years or older with an Investigator's Static Global Assessment (ISGA) score of mild or moderate for twice-daily application for 28 days.  The primary end point was ISGA score at day 29 of clear (0)/almost clear (1) with 2-grade or greater improvement from baseline.  Addnl. analyses included time to success in ISGA score, percentage of patients achieving clear/almost clear, redn. in severity of AD signs, and time to improvement in pruritus.  More crisaborole- than vehicle-treated patients achieved ISGA score success (clear/almost clear with ≥2-grade improvement; AD-301: 32.8% vs 25.4%, P = .038; AD-302: 31.4% vs 18.0%, P < .001), with a greater percentage with clear/almost clear (51.7% vs 40.6%, P = .005; 48.5% vs 29.7%, P < .001).  Crisaborole-treated patients achieved success in ISGA score and improvement in pruritus earlier than those treated with vehicle (both P ≤ .001).  Treatment-related adverse events were infrequent and mild to moderate in severity.  Short study duration was a limitation.  Crisaborole demonstrated a favorable safety profile and improvement in all measures of efficacy, including overall disease severity, pruritus, and other signs of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD4IlzODC6ebVg90H21EOLACvtfcHk0li7sjF5eNin8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKmtbvP&md5=addbe254ce72db5ae1c96874f70ee1d0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.05.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.05.046%26sid%3Dliteratum%253Aachs%26aulast%3DPaller%26aufirst%3DA.%2BS.%26aulast%3DTom%26aufirst%3DW.%2BL.%26aulast%3DLebwohl%26aufirst%3DM.%2BG.%26aulast%3DBlumenthal%26aufirst%3DR.%2BL.%26aulast%3DBoguniewicz%26aufirst%3DM.%26aulast%3DCall%26aufirst%3DR.%2BS.%26aulast%3DEichenfield%26aufirst%3DL.%2BF.%26aulast%3DForsha%26aufirst%3DD.%2BW.%26aulast%3DRees%26aufirst%3DW.%2BC.%26aulast%3DSimpson%26aufirst%3DE.%2BL.%26aulast%3DSpellman%26aufirst%3DM.%2BC.%26aulast%3DStein%2BGold%26aufirst%3DL.%2BF.%26aulast%3DZaenglein%26aufirst%3DA.%2BL.%26aulast%3DHughes%26aufirst%3DM.%2BH.%26aulast%3DZane%26aufirst%3DL.%2BT.%26aulast%3DHebert%26aufirst%3DA.%2BA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Crisaborole%2520Ointment%252C%2520A%2520Novel%252C%2520Nonsteroidal%2520Phosphodiesterase%25204%2520%2528PDE4%2529%2520Inhibitor%2520for%2520the%2520Topical%2520Treatment%2520of%2520Atopic%2520Dermatitis%2520%2528AD%2529%2520in%2520Children%2520and%2520Adults%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2016%26volume%3D75%26spage%3D494%26epage%3D503%26doi%3D10.1016%2Fj.jaad.2016.05.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span> </span><span class="NLM_article-title">Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-Analysis</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">902</span><span class="NLM_x">–</span> <span class="NLM_lpage">912</span><span class="refDoi"> DOI: 10.1016/j.eururo.2013.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.eururo.2013.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=23395275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFKlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=902-912&author=J.+Yuanauthor=R.+Zhangauthor=Z.+Yangauthor=J.+Leeauthor=Y.+Liuauthor=J.+Tianauthor=X.+Qinauthor=Z.+Renauthor=H.+Dingauthor=Q.+Chenauthor=C.+Maoauthor=J.+Tang&title=Comparative+Effectiveness+and+Safety+of+Oral+Phosphodiesterase+Type+5+Inhibitors+for+Erectile+Dysfunction%3A+A+Systematic+Review+and+Network+Meta-Analysis&doi=10.1016%2Fj.eururo.2013.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis</span></div><div class="casAuthors">Yuan, JinQiu; Zhang, RenJie; Yang, ZuYao; Lee, Jack; Liu, YaLi; Tian, JinHui; Qin, XiWen; Ren, ZhengJia; Ding, Hong; Chen, Qing; Mao, Chen; Tang, JinLing</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">902-912</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphodiesterase type 5 inhibitors (PDE5-Is) are currently the first-line therapy for erectile dysfunction (ED), but available studies investigating the comparative effects of different PDE5-Is are limited.  To compare the efficacy and safety of different classes of oral PDE5-Is for ED.A systematic search was performed in PubMed, Cochrane Library, and Embase to identify randomized controlled trials that compared different PDE5-Is or PDE5-Is with a placebo for ED.  The methodol. quality of included studies was appraised with the Cochrane Collaboration bias appraisal tool, and the quality of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation system.A total of 118 trials (31 195 individuals) were included.  There was no major difference in the results between the traditional meta-anal. and the network meta-anal.  Network meta-anal. demonstrated that PDE5-Is were superior to placebo to improve erectile function.  Compared with tadalafil (relative risk [RR]: 0.61; 95% confidence interval [CI], 0.33-0.90) and vardenafil (RR: 0.63; 95% CI, 0.35-0.92), avanafil was less effective on Global Assessment Questionnaire question 1.  Tadalafil was more effective than vardenafil (mean difference [MD]: 1.49; 95% CI, 0.50-2.50) and udenafil (MD: -1.84; 95% CI, -3.31 to -0.33) as measured by the erectile function domain of the International Index of Erectile Function.  For all efficacy outcomes, the abs. effects and the rank tests indicated that tadalafil and vardenafil were the most effective agents.  After adjusting for dosage, the conclusion remained the same.  Safety anal. showed there was no major difference among different agents.In recommended doses, oral PDE5-Is are more effective than placebo for ED, and tadalafil seems to be the most effective agent, followed by vardenafil.  PDE5-Is are generally safe and well tolerated, and there is no major difference on the safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqibvT0sDtXWbVg90H21EOLACvtfcHk0lhpXPpRaYXJjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFKlsrk%253D&md5=117fac58bd86beccf221376fc919c240</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2013.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2013.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DComparative%2520Effectiveness%2520and%2520Safety%2520of%2520Oral%2520Phosphodiesterase%2520Type%25205%2520Inhibitors%2520for%2520Erectile%2520Dysfunction%253A%2520A%2520Systematic%2520Review%2520and%2520Network%2520Meta-Analysis%26jtitle%3DEur.%2520Urol.%26date%3D2013%26volume%3D63%26spage%3D902%26epage%3D912%26doi%3D10.1016%2Fj.eururo.2013.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Archer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michelakis, E. D.</span><span> </span><span class="NLM_article-title">Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">1864</span><span class="NLM_x">–</span> <span class="NLM_lpage">1871</span><span class="refDoi"> DOI: 10.1056/NEJMct0904473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1056%2FNEJMct0904473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=19890129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2jurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=1864-1871&author=S.+L.+Archerauthor=E.+D.+Michelakis&title=Phosphodiesterase+Type+5+Inhibitors+for+Pulmonary+Arterial+Hypertension&doi=10.1056%2FNEJMct0904473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension</span></div><div class="casAuthors">Archer, Stephen L.; Michelakis, Evangelos D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1864-1871</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  A 46-yr-old woman presents with progressive exertional dyspnea and recurrent exertional syncope.  Her jugular venous pressure is 16 cm of water, and moderate peripheral edema is noted.  Auscultation reveals a pronounced pulmonic component of the second heart sound and a grade 2/6 holosystolic murmur of tricuspid regurgitation.  Echocardiog. shows moderate right ventricular and right atrial enlargement, right ventricular systolic dysfunction, and an estd. right ventricular systolic pressure of 100 mm Hg.  Cardiac catheterization reveals a mean right atrial pressure of 13 mm Hg, a pulmonary-artery pressure of 80/40 mm Hg (mean, 58), a mean pulmonary-capillary wedge pressure of 10 mm Hg, and a cardiac output of 5 L per min.  The results of addnl. studies to detect causes of secondary pulmonary hypertension or assocd. conditions are unremarkable, and she receives a diagnosis of idiopathic pulmonary arterial hypertension.  Her pulmonary-artery pressure does not decrease in response to inhaled nitric oxide.  Therapy with sildenafil is recommended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdhp_AHUygSLVg90H21EOLACvtfcHk0lhpXPpRaYXJjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2jurvI&md5=5477561829a7b9c579c0db54677ab9fe</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMct0904473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMct0904473%26sid%3Dliteratum%253Aachs%26aulast%3DArcher%26aufirst%3DS.%2BL.%26aulast%3DMichelakis%26aufirst%3DE.%2BD.%26atitle%3DPhosphodiesterase%2520Type%25205%2520Inhibitors%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D1864%26epage%3D1871%26doi%3D10.1056%2FNEJMct0904473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Andersson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Groat, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McVary, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lue, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roehrborn, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyndaele, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viktrup, L.</span><span> </span><span class="NLM_article-title">Tadalafil for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Pathophysiology and Mechanism(s) of Action</span> <span class="citation_source-journal">Neurourol. Urodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1002/nau.20999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1002%2Fnau.20999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=21284024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlslOitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=292-301&author=K.+E.+Anderssonauthor=W.+C.+de+Groatauthor=K.+T.+McVaryauthor=T.+F.+Lueauthor=M.+Maggiauthor=C.+G.+Roehrbornauthor=J.+J.+Wyndaeleauthor=T.+Melbyauthor=L.+Viktrup&title=Tadalafil+for+the+Treatment+of+Lower+Urinary+Tract+Symptoms+Secondary+to+Benign+Prostatic+Hyperplasia%3A+Pathophysiology+and+Mechanism%28s%29+of+Action&doi=10.1002%2Fnau.20999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action</span></div><div class="casAuthors">Andersson, Karl-Erik; de Groat, William C.; McVary, Kevin T.; Lue, Tom F.; Maggi, Mario; Roehrborn, Claus G.; Wyndaele, Jean Jacques; Melby, Thomas; Viktrup, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Neurourology and Urodynamics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-301</span>CODEN:
                <span class="NLM_cas:coden">NEUREM</span>;
        ISSN:<span class="NLM_cas:issn">0733-2467</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: The PDE5 inhibitor tadalafil is under investigation for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).  Several clin. studies of tadalafil and other PDE5 inhibitors have reported significant symptom redn. but limited urinary flow rate improvement.  This manuscript reviews the published literature describing the pathophysiol. of male LUTS, with an emphasis on mechanisms that may be modulated or improved by phosphodiesterase type 5 (PDE5) inhibition.  Methods: Literature (through March 2010) was obtained via Medline searches and from the individual reviewers files.  Articles were selected for review based on describing in vitro, preclin., or clin. studies of pathol. processes contributing to LUTS, or possible effects of PDE5 inhibition in the lower urinary tract.  Results: Major mechanisms contributing to LUTS include: reduced nitric oxide/cyclic guanosine monophosphate signaling; increased RhoA kinase pathway activity; autonomic overactivity; increased bladder afferent activity; and pelvic ischemia.  Tadalafil and other PDE5 inhibitors have demonstrated beneficial effects on smooth muscle relaxation, smooth muscle and endothelial cell proliferation, nerve activity, and tissue perfusion that may impact LUTS in men.  Conclusions: The pathophysiol. of male LUTS is complex and not completely understood.  LUTS may occur independently of BPH or secondary to BPH but in both cases involve obstructive or irritative mechanisms with substantial pathophysiol. overlap.  While the precise mechanism remains unclear, inhibition of PDE5 seems to have an effect on several pathways that may impact LUTS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdQl9V0DpcbVg90H21EOLACvtfcHk0lhpXPpRaYXJjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlslOitL4%253D&md5=5705436d6efa5dca6f5d2d755b593ae4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fnau.20999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fnau.20999%26sid%3Dliteratum%253Aachs%26aulast%3DAndersson%26aufirst%3DK.%2BE.%26aulast%3Dde%2BGroat%26aufirst%3DW.%2BC.%26aulast%3DMcVary%26aufirst%3DK.%2BT.%26aulast%3DLue%26aufirst%3DT.%2BF.%26aulast%3DMaggi%26aufirst%3DM.%26aulast%3DRoehrborn%26aufirst%3DC.%2BG.%26aulast%3DWyndaele%26aufirst%3DJ.%2BJ.%26aulast%3DMelby%26aufirst%3DT.%26aulast%3DViktrup%26aufirst%3DL.%26atitle%3DTadalafil%2520for%2520the%2520Treatment%2520of%2520Lower%2520Urinary%2520Tract%2520Symptoms%2520Secondary%2520to%2520Benign%2520Prostatic%2520Hyperplasia%253A%2520Pathophysiology%2520and%2520Mechanism%2528s%2529%2520of%2520Action%26jtitle%3DNeurourol.%2520Urodyn.%26date%3D2011%26volume%3D30%26spage%3D292%26epage%3D301%26doi%3D10.1002%2Fnau.20999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraci, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span> </span><span class="NLM_article-title">Phosphodiesterases in the CNS: Targets for Drug Development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span><span class="refDoi"> DOI: 10.1038/nrd2058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1038%2Fnrd2058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=16883304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFCkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=660-670&author=F.+S.+Mennitiauthor=W.+S.+Faraciauthor=C.+J.+Schmidt&title=Phosphodiesterases+in+the+CNS%3A+Targets+for+Drug+Development&doi=10.1038%2Fnrd2058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterases in the CNS: targets for drug development</span></div><div class="casAuthors">Menniti, Frank S.; Faraci, W. Stephen; Schmidt, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">660-670</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The therapeutic and com. success of phosphodiesterase 5 inhibitors such as Viagra, Levitra and Cialis has sparked renewed interest in the phosphodiesterases as drug discovery targets.  Virtually all the phosphodiesterases are expressed in the CNS, making this gene family a particularly attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders.  Significantly, all neurons express multiple phosphodiesterases, which differ in cyclic nucleotide specificity, affinity, regulatory control and subcellular compartmentalization.  Therefore, phosphodiesterase inhibition represents a mechanism through which it could be possible to precisely modulate neuronal activity.  In this article, we review the current state of the art in the burgeoning field of phosphodiesterase pharmacol. in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa2I3t5o1HibVg90H21EOLACvtfcHk0lhroOgz3hNwFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFCkurg%253D&md5=7c2b421b629efe9ee73999098322e811</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd2058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2058%26sid%3Dliteratum%253Aachs%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DFaraci%26aufirst%3DW.%2BS.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26atitle%3DPhosphodiesterases%2520in%2520the%2520CNS%253A%2520Targets%2520for%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D660%26epage%3D670%26doi%3D10.1038%2Fnrd2058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonseca, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx-LaFrance, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helal, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claffey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuttle, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffman, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanase-Frawley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span> </span><span class="NLM_article-title">Design and Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9045</span><span class="NLM_x">–</span> <span class="NLM_lpage">9054</span><span class="refDoi"> DOI: 10.1021/jm3007799</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3007799" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9045-9054&author=P.+R.+Verhoestauthor=K.+R.+Fonsecaauthor=X.+Houauthor=C.+Proulx-LaFranceauthor=M.+Cormanauthor=C.+J.+Helalauthor=M.+M.+Claffeyauthor=J.+B.+Tuttleauthor=K.+J.+Coffmanauthor=S.+Liuauthor=F.+Nelsonauthor=R.+J.+Kleimanauthor=F.+S.+Mennitiauthor=C.+J.+Schmidtauthor=M.+Vanase-Frawleyauthor=S.+Liras&title=Design+and+Discovery+of+6-%5B%283S%2C4S%29-4-Methyl-1-%28pyrimidin-2-ylmethyl%29pyrrolidin-3-yl%5D-1-%28tetrahydro-2H-pyran-4-yl%29-1%2C5-dihydro-4H-pyrazolo%5B3%2C4-d%5Dpyrimidin-4-one+%28PF-04447943%29%2C+a+Selective+Brain+Penetrant+PDE9A+Inhibitor+for+the+Treatment+of+Cognitive+Disorders&doi=10.1021%2Fjm3007799"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm3007799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3007799%26sid%3Dliteratum%253Aachs%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DProulx-LaFrance%26aufirst%3DC.%26aulast%3DCorman%26aufirst%3DM.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DClaffey%26aufirst%3DM.%2BM.%26aulast%3DTuttle%26aufirst%3DJ.%2BB.%26aulast%3DCoffman%26aufirst%3DK.%2BJ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DF.%26aulast%3DKleiman%26aufirst%3DR.%2BJ.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DVanase-Frawley%26aufirst%3DM.%26aulast%3DLiras%26aufirst%3DS.%26atitle%3DDesign%2520and%2520Discovery%2520of%25206-%255B%25283S%252C4S%2529-4-Methyl-1-%2528pyrimidin-2-ylmethyl%2529pyrrolidin-3-yl%255D-1-%2528tetrahydro-2H-pyran-4-yl%2529-1%252C5-dihydro-4H-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-one%2520%2528PF-04447943%2529%252C%2520a%2520Selective%2520Brain%2520Penetrant%2520PDE9A%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cognitive%2520Disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9045%26epage%3D9054%26doi%3D10.1021%2Fjm3007799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Chappie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helal, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span> </span><span class="NLM_article-title">Current Landscape of Phosphodiesterase 10A (PDE10A) Inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7299</span><span class="NLM_x">–</span> <span class="NLM_lpage">7331</span><span class="refDoi"> DOI: 10.1021/jm3004976</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3004976" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2gsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7299-7331&author=T.+A.+Chappieauthor=C.+J.+Helalauthor=X.+Hou&title=Current+Landscape+of+Phosphodiesterase+10A+%28PDE10A%29+Inhibition&doi=10.1021%2Fjm3004976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Current Landscape of Phosphodiesterase 10A (PDE10A) Inhibition</span></div><div class="casAuthors">Chappie, Thomas A.; Helal, Christopher J.; Hou, Xinjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7299-7331</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  No abstr. required for Perspectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolfNGPFFnnOrVg90H21EOLACvtfcHk0ljOstG3Tkzifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2gsbrF&md5=b50361a522ec669cad0a65b2d33d5dfb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm3004976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3004976%26sid%3Dliteratum%253Aachs%26aulast%3DChappie%26aufirst%3DT.%2BA.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DHou%26aufirst%3DX.%26atitle%3DCurrent%2520Landscape%2520of%2520Phosphodiesterase%252010A%2520%2528PDE10A%2529%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7299%26epage%3D7331%26doi%3D10.1021%2Fjm3004976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beard, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyser, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrick, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wennogle, L. P.</span><span> </span><span class="NLM_article-title">Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1149</span><span class="NLM_x">–</span> <span class="NLM_lpage">1164</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01751</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01751" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1aisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1149-1164&author=P.+Liauthor=H.+Zhengauthor=J.+Zhaoauthor=L.+Zhangauthor=W.+Yaoauthor=H.+Zhuauthor=J.+D.+Beardauthor=K.+Idaauthor=W.+Laneauthor=G.+Snellauthor=S.+Sogabeauthor=C.+J.+Heyserauthor=G.+L.+Snyderauthor=J.+P.+Hendrickauthor=K.+E.+Vanoverauthor=R.+E.+Davisauthor=L.+P.+Wennogle&title=Discovery+of+Potent+and+Selective+Inhibitors+of+Phosphodiesterase+1+for+the+Treatment+of+Cognitive+Impairment+Associated+with+Neurodegenerative+and+Neuropsychiatric+Diseases&doi=10.1021%2Facs.jmedchem.5b01751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases</span></div><div class="casAuthors">Li, Peng; Zheng, Hailin; Zhao, Jun; Zhang, Lei; Yao, Wei; Zhu, Hongwen; Beard, J. David; Ida, Koh; Lane, Weston; Snell, Gyorgy; Sogabe, Satoshi; Heyser, Charles J.; Snyder, Gretchen L.; Hendrick, Joseph P.; Vanover, Kimberly E.; Davis, Robert E.; Wennogle, Lawrence P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1149-1164</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A diverse set of 3-aminopyrazolo[3,4-d]pyrimidinones was designed and synthesized.  The structure-activity relationships of these polycyclic compds. as phosphodiesterase 1 (PDE1) inhibitors were studied along with their physicochem. and pharmacokinetic properties.  Systematic optimizations of this novel scaffold culminated in the identification of a clin. candidate I, which exhibited picomolar inhibitory potency for PDE1, demonstrated excellent selectivity against all other PDE families and showed good efficacy in vivo.  Currently, this investigational new drug is in Phase I clin. development and being considered for the treatment of several indications including cognitive deficits assocd. with schizophrenia and Alzheimer's disease, movement disorders, attention deficit and hyperactivity disorders, and other central nervous system (CNS) and non-CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiqQuMoLsXnbVg90H21EOLACvtfcHk0ljOstG3Tkzifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1aisLk%253D&md5=73741521722dc906869ffa3504ceaf2e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01751%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DBeard%26aufirst%3DJ.%2BD.%26aulast%3DIda%26aufirst%3DK.%26aulast%3DLane%26aufirst%3DW.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DHeyser%26aufirst%3DC.%2BJ.%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DHendrick%26aufirst%3DJ.%2BP.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DWennogle%26aufirst%3DL.%2BP.%26atitle%3DDiscovery%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Phosphodiesterase%25201%2520for%2520the%2520Treatment%2520of%2520Cognitive%2520Impairment%2520Associated%2520with%2520Neurodegenerative%2520and%2520Neuropsychiatric%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1149%26epage%3D1164%26doi%3D10.1021%2Facs.jmedchem.5b01751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lakics, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karran, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boess, F. G.</span><span> </span><span class="NLM_article-title">Quantitative Comparison of Phosphodiesterase mRNA Distribution in Human Brain and Peripheral Tissues</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">374</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2010.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.neuropharm.2010.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=20493887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1SqsLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2010&pages=367-374&author=V.+Lakicsauthor=E.+H.+Karranauthor=F.+G.+Boess&title=Quantitative+Comparison+of+Phosphodiesterase+mRNA+Distribution+in+Human+Brain+and+Peripheral+Tissues&doi=10.1016%2Fj.neuropharm.2010.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues</span></div><div class="casAuthors">Lakics, Viktor; Karran, Eric H.; Boess, Frank G.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">367-374</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cyclic nucleotide-specific phosphodiesterases (PDEs) play a crit. role in signal transduction by regulating the level of adenosine 3',5'-cyclic monophosphate (cAMP) and guanosine 3',5'-cyclic monophosphate (cGMP) in cells.  The gene expression pattern of a PDE provides important information regarding its role in physiol. and pathol. processes.  In this study, we have established the mRNA expression profile all PDE isoenzymes (PDE1A/B/C, 2A, 3A/B, 4A/B/C/D, 5A, 6A/B/C, 7A/B, 8A/B, 9A, 10A, 11A) in a human cDNA collection consisting of 10 brain regions (parietal, frontal, temporal cortex, hippocampus, striatum, thalamus, hypothalamus, substantia nigra, nucleus accumbens, cerebellum), spinal cord, dorsal root ganglia and 12 peripheral tissues (skeletal muscle, heart, thyroid, adrenal gland, pancreas, bladder, kidney, liver, lung, small intestine, spleen, and stomach).  Using quant. real-time polymerase chain reaction and parallel anal. of a carefully selected group of ref. genes, we have detd. the relative expression of each PDE isoenzyme across the 24 selected tissues, and also compared the expression of selected PDEs to each other within a given tissue type.  Several PDEs show strikingly selective expression (e.g. PDE10A and PDE1B mRNA levels in the caudate nucleus are 20-fold higher than in most other tissues; PDE1C and PDE3A are highly expressed in the heart and PDE8B is expressed very strongly in the thyroid gland).  This comprehensive approach provides a coherent and quant. view of the mRNA expression of the PDE gene family and enables an integration of data obtained with other non-quant. methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprGz6OEkRjbLVg90H21EOLACvtfcHk0ljOstG3Tkzifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1SqsLbJ&md5=ee55772f572818eaa7194a1ae3f52f45</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2010.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2010.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DLakics%26aufirst%3DV.%26aulast%3DKarran%26aufirst%3DE.%2BH.%26aulast%3DBoess%26aufirst%3DF.%2BG.%26atitle%3DQuantitative%2520Comparison%2520of%2520Phosphodiesterase%2520mRNA%2520Distribution%2520in%2520Human%2520Brain%2520and%2520Peripheral%2520Tissues%26jtitle%3DNeuropharmacology%26date%3D2010%26volume%3D59%26spage%3D367%26epage%3D374%26doi%3D10.1016%2Fj.neuropharm.2010.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Stephenson, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coskran, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelms, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamowicz, W. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muravnick, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, D.</span><span> </span><span class="NLM_article-title">Immunohistochemical Localization of Phosphodiesterase 2A in Multiple Mammalian Species</span> <span class="citation_source-journal">J. Histochem. Cytochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">949</span><span class="refDoi"> DOI: 10.1369/jhc.2009.953471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1369%2Fjhc.2009.953471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=19506089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOgtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2009&pages=933-949&author=D.+T.+Stephensonauthor=T.+M.+Coskranauthor=M.+B.+Wilhelmsauthor=W.+O.+Adamowiczauthor=M.+M.+O%E2%80%99Donnellauthor=K.+B.+Muravnickauthor=F.+S.+Mennitiauthor=R.+J.+Kleimanauthor=D.+Morton&title=Immunohistochemical+Localization+of+Phosphodiesterase+2A+in+Multiple+Mammalian+Species&doi=10.1369%2Fjhc.2009.953471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species</span></div><div class="casAuthors">Stephenson, Diane T.; Coskran, Tim M.; Wilhelms, Margaret B.; Adamowicz, Wendy O.; O'Donnell, Michele M.; Muravnick, Kathleen B.; Menniti, Frank S.; Kleiman, Robin J.; Morton, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">933-949</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Histochemical Society, Inc.</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a family of enzymes that regulate the levels of cyclic nucleotides, key second messengers that mediate a diverse array of functions.  PDE2A is an evolutionarily conserved cGMP-stimulated cAMP and cGMP PDE.  In the present study, the regional and cellular distribution of PDE2A in tissues of rats, mice, cynomolgus monkeys, dogs, and humans was evaluated by immunohistochem.  A polyclonal antibody directed to the C-terminal portion of PDE2A specifically detected PDE2A by Western blotting and by immunohistochem.  The pattern of PDE2A immunoreactivity (ir) was consistent across all species.  Western blot anal. demonstrated that PDE2A was most abundant in the brain relative to peripheral tissues.  PDE2A ir was heterogeneously distributed within brain and was selectively expressed in particular peripheral tissues.  In the brain, prominent immunoreactivity was apparent in components of the limbic system, including the isocortex, hippocampus, amygdala, habenula, basal ganglia, and interpeduncular nucleus.  Cytoplasmic PDE2A staining was prominent in several peripheral tissues, including the adrenal zona glomerulosa, neurons of enteric ganglia, endothelial cells in all organs, lymphocytes of spleen and lymph nodes, and pituitary.  These studies suggest that PDE2A is evolutionarily conserved across mammalian species and support the hypothesis that the enzyme plays a fundamental role in signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHVQCCm4loO7Vg90H21EOLACvtfcHk0lhn7Vmj3QteTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOgtrrJ&md5=ce1dfa99cc99c02f31ab8071a9e438fd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1369%2Fjhc.2009.953471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1369%252Fjhc.2009.953471%26sid%3Dliteratum%253Aachs%26aulast%3DStephenson%26aufirst%3DD.%2BT.%26aulast%3DCoskran%26aufirst%3DT.%2BM.%26aulast%3DWilhelms%26aufirst%3DM.%2BB.%26aulast%3DAdamowicz%26aufirst%3DW.%2BO.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BM.%26aulast%3DMuravnick%26aufirst%3DK.%2BB.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DKleiman%26aufirst%3DR.%2BJ.%26aulast%3DMorton%26aufirst%3DD.%26atitle%3DImmunohistochemical%2520Localization%2520of%2520Phosphodiesterase%25202A%2520in%2520Multiple%2520Mammalian%2520Species%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2009%26volume%3D57%26spage%3D933%26epage%3D949%26doi%3D10.1369%2Fjhc.2009.953471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Cote, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valeriani, B. A.</span><span> </span><span class="NLM_article-title">Relative Potency of Various Classes of Phosphodiesterase (PDE) Inhibitors for Rod and Cone Photoreceptor PDE</span> <span class="citation_source-journal">Invest. Ophthalmol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1524</span><span class="NLM_x">–</span> <span class="NLM_lpage">1527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=1524-1527&author=R.+H.+Coteauthor=Q.+Fengauthor=B.+A.+Valeriani&title=Relative+Potency+of+Various+Classes+of+Phosphodiesterase+%28PDE%29+Inhibitors+for+Rod+and+Cone+Photoreceptor+PDE"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCote%26aufirst%3DR.%2BH.%26aulast%3DFeng%26aufirst%3DQ.%26aulast%3DValeriani%26aufirst%3DB.%2BA.%26atitle%3DRelative%2520Potency%2520of%2520Various%2520Classes%2520of%2520Phosphodiesterase%2520%2528PDE%2529%2520Inhibitors%2520for%2520Rod%2520and%2520Cone%2520Photoreceptor%2520PDE%26jtitle%3DInvest.%2520Ophthalmol.%26date%3D2003%26volume%3D44%26spage%3D1524%26epage%3D1527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Young, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, A.</span><span> </span><span class="NLM_article-title">Milrinone. A Preliminary Review of Its Pharmacological Properties and Therapeutic Use</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.2165/00003495-198836020-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.2165%2F00003495-198836020-00003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1988&pages=158-192&author=R.+A.+Youngauthor=A.+Ward&title=Milrinone.+A+Preliminary+Review+of+Its+Pharmacological+Properties+and+Therapeutic+Use&doi=10.2165%2F00003495-198836020-00003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2165%2F00003495-198836020-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-198836020-00003%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DWard%26aufirst%3DA.%26atitle%3DMilrinone.%2520A%2520Preliminary%2520Review%2520of%2520Its%2520Pharmacological%2520Properties%2520and%2520Therapeutic%2520Use%26jtitle%3DDrugs%26date%3D1988%26volume%3D36%26spage%3D158%26epage%3D192%26doi%3D10.2165%2F00003495-198836020-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kandel, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, R. D.</span><span> </span><span class="NLM_article-title">Nitric Oxide Signaling Contributes to Late-Phase LTP and CREB Phosphorylation in the Hippocampus</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">10250</span><span class="NLM_x">–</span> <span class="NLM_lpage">10261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1523%2FJNEUROSCI.19-23-10250.1999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10575022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADyaK1MXnslyrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=10250-10261&author=Y.+Luauthor=E.+R.+Kandelauthor=R.+D.+Hawkins&title=Nitric+Oxide+Signaling+Contributes+to+Late-Phase+LTP+and+CREB+Phosphorylation+in+the+Hippocampus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus</span></div><div class="casAuthors">Lu, Yun-Fei; Kandel, Eric R.; Hawkins, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10250-10261</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Long-term potentiation (LTP) in the hippocampus has an early phase (E-LTP) that can be induced by 1- or 2-train tetanization, lasts ∼1 h, and is cAMP-dependent protein kinase A (PKA)- and protein synthesis-independent and a late phase (L-LTP) that can be induced by 3- or 4-train tetanization, lasts >3 h, and is reduced by inhibitors of PKA and of protein or RNA synthesis.  NO is thought to be involved in E-LTP, but until now there has been no information about the role of the NO-signaling pathway in L-LTP.  Here, the authors examd. this question at the Schaffer collateral-CA1 synapses in slices of mouse hippocampus.  An inhibitor of nitric oxide synthase blocked L-LTP induced by 3-train tetanization and reduced L-LTP induced by 4-train tetanization, whereas an inhibitor of PKA was more effective in blocking 4-train L-LTP than 3-train L-LTP.  Three-train L-LTP was also blocked by inhibitors of guanylyl cyclase or cGMP-dependent protein kinase G (PKG).  Conversely, either NO or cGMP analogs paired with 1-train tetanization produced late-phase potentiation, and the cGMP-induced potentiation was blocked by inhibitors of protein or RNA synthesis and an inhibitor of PKG, but not by an inhibitor of PKA.  To test a possible downstream target of PKG, the authors examd. changes in phospho-CRE-binding protein (phospho-CREB) immunofluorescence in the CA1 cell body area and obtained results similar to those of the electrophysiol. expts.  The results suggested that NO contributes to L-LTP by stimulating guanylyl cyclase and PKG, which acts in parallel with PKA to increase phosphorylation of transcription factor CREB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY0i0LYOPf7LVg90H21EOLACvtfcHk0lhn7Vmj3QteTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnslyrt70%253D&md5=6d09b68560c09b81e38354826f7c21b6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.19-23-10250.1999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.19-23-10250.1999%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DKandel%26aufirst%3DE.%2BR.%26aulast%3DHawkins%26aufirst%3DR.%2BD.%26atitle%3DNitric%2520Oxide%2520Signaling%2520Contributes%2520to%2520Late-Phase%2520LTP%2520and%2520CREB%2520Phosphorylation%2520in%2520the%2520Hippocampus%26jtitle%3DJ.%2520Neurosci.%26date%3D1999%26volume%3D19%26spage%3D10250%26epage%3D10261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Sanderson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sher, E.</span><span> </span><span class="NLM_article-title">The Role of Phosphodiesterases in Hippocampal Synaptic Plasticity</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.neuropharm.2013.01.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2013&pages=86-95&author=T.+M.+Sandersonauthor=E.+Sher&title=The+Role+of+Phosphodiesterases+in+Hippocampal+Synaptic+Plasticity&doi=10.1016%2Fj.neuropharm.2013.01.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DT.%2BM.%26aulast%3DSher%26aufirst%3DE.%26atitle%3DThe%2520Role%2520of%2520Phosphodiesterases%2520in%2520Hippocampal%2520Synaptic%2520Plasticity%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D74%26spage%3D86%26epage%3D95%26doi%3D10.1016%2Fj.neuropharm.2013.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Prickaerts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vente, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honig, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbusch, H. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span> </span><span class="NLM_article-title">cGMP, but not cAMP, in Rat Hippocampus Is Involved in Early Stages of Object Memory Consolidation</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">436</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1016/S0014-2999(01)01614-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2FS0014-2999%2801%2901614-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=11834250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtVKrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2002&pages=83-87&author=J.+Prickaertsauthor=J.+de+Venteauthor=W.+Honigauthor=H.+W.+M.+Steinbuschauthor=A.+Blokland&title=cGMP%2C+but+not+cAMP%2C+in+Rat+Hippocampus+Is+Involved+in+Early+Stages+of+Object+Memory+Consolidation&doi=10.1016%2FS0014-2999%2801%2901614-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation</span></div><div class="casAuthors">Prickaerts, Jos; de Vente, Jan; Honig, Wiel; Steinbusch, Harry W. M.; Blokland, Arjan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">436</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">83-87</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The present study investigated the role of cGMP and cAMP on the memory performance in the object recognition task in rats.  The analog, 8-bromo-GMP (8-Br-cGMP) or 8-bromo-cAMP (8-Br-cAMP) was administered bilaterally into the hippocampus (0, 1, 3, and 10 μg in 0.5 μL saline/site) immediately after the exposure to 2 identical objects.  After 24 h, saline-treated animals spent equal times exploring a new and the familiar object demonstrating that they did not recognize the familiar one.  However, a dose-dependent improvement in object recognition was found after injection of 8-Br-cGMP.  In contrast, 8-Br-cAMP did not improve the memory performance at the doses tested.  These results indicate that hippocampal cGMP but not cAMP is involved in early stages of consolidation of object memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtZ18mRPVkf7Vg90H21EOLACvtfcHk0lhn7Vmj3QteTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtVKrtLk%253D&md5=2110ed071d976fc80b634bad0e548804</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901614-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901614-4%26sid%3Dliteratum%253Aachs%26aulast%3DPrickaerts%26aufirst%3DJ.%26aulast%3Dde%2BVente%26aufirst%3DJ.%26aulast%3DHonig%26aufirst%3DW.%26aulast%3DSteinbusch%26aufirst%3DH.%2BW.%2BM.%26aulast%3DBlokland%26aufirst%3DA.%26atitle%3DcGMP%252C%2520but%2520not%2520cAMP%252C%2520in%2520Rat%2520Hippocampus%2520Is%2520Involved%2520in%2520Early%2520Stages%2520of%2520Object%2520Memory%2520Consolidation%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D436%26spage%3D83%26epage%3D87%26doi%3D10.1016%2FS0014-2999%2801%2901614-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Niewoehner, U.; Schauss, D.; Hendrix, M.; Koenig, G.; Boess, F. G.; van der Staay, F. J.; Schreiber, R.; Schlemmer, K. H.; Grosser, R.</span><span> </span><span class="NLM_article-title">Novel Substituted Imidazotriazinones as PDE II-Inhibitors</span>. WO 2002050078, June 27,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=U.+Niewoehner&author=D.+Schauss&author=M.+Hendrix&author=G.+Koenig&author=F.+G.+Boess&author=F.+J.+van+der+Staay&author=R.+Schreiber&author=K.+H.+Schlemmer&author=R.+Grosser&title=Novel+Substituted+Imidazotriazinones+as+PDE+II-Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNiewoehner%26aufirst%3DU.%26atitle%3DNovel%2520Substituted%2520Imidazotriazinones%2520as%2520PDE%2520II-Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Abaarghaz, M.; Biondi, S.; Duranton, J.; Limanton, E.; Mondadori, C.; Wagner, P.</span><span> </span><span class="NLM_article-title">Benzo[1,4]diazepin-2-one Derivatives as Phosphodiesterase PDE2 Inhibitors, Preparation and Therapeutic Use Thereof</span>. WO 2005063723, July 14,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Abaarghaz&author=S.+Biondi&author=J.+Duranton&author=E.+Limanton&author=C.+Mondadori&author=P.+Wagner&title=Benzo%5B1%2C4%5Ddiazepin-2-one+Derivatives+as+Phosphodiesterase+PDE2+Inhibitors%2C+Preparation+and+Therapeutic+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbaarghaz%26aufirst%3DM.%26atitle%3DBenzo%255B1%252C4%255Ddiazepin-2-one%2520Derivatives%2520as%2520Phosphodiesterase%2520PDE2%2520Inhibitors%252C%2520Preparation%2520and%2520Therapeutic%2520Use%2520Thereof%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Buijnsters, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langlois, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rombouts, F. J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanHoof, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Roosbroeck, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrés, J.-I.</span><span> </span><span class="NLM_article-title">Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1049</span><span class="NLM_x">–</span> <span class="NLM_lpage">1053</span><span class="refDoi"> DOI: 10.1021/ml500262u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500262u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1049-1053&author=P.+Buijnstersauthor=M.+De+Angelisauthor=X.+Langloisauthor=F.+J.+R.+Romboutsauthor=W.+Sandersonauthor=G.+Tresadernauthor=A.+Ritchieauthor=A.+A.+Trabancoauthor=G.+VanHoofauthor=Y.+Van+Roosbroeckauthor=J.-I.+Andr%C3%A9s&title=Structure-Based+Design+of+a+Potent%2C+Selective%2C+and+Brain+Penetrating+PDE2+Inhibitor+with+Demonstrated+Target+Engagement&doi=10.1021%2Fml500262u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fml500262u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500262u%26sid%3Dliteratum%253Aachs%26aulast%3DBuijnsters%26aufirst%3DP.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DRombouts%26aufirst%3DF.%2BJ.%2BR.%26aulast%3DSanderson%26aufirst%3DW.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DRitchie%26aufirst%3DA.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DVanHoof%26aufirst%3DG.%26aulast%3DVan%2BRoosbroeck%26aufirst%3DY.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DJ.-I.%26atitle%3DStructure-Based%2520Design%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Brain%2520Penetrating%2520PDE2%2520Inhibitor%2520with%2520Demonstrated%2520Target%2520Engagement%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1049%26epage%3D1053%26doi%3D10.1021%2Fml500262u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Rombouts, F. J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buijnsters, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langlois, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tovar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbrecher, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhoof, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrés, J.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span> </span><span class="NLM_article-title">Pyrido[4,3-<i>e</i>][1,2,4]triazolo[4,3-<i>a</i>]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1021/ml500463t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500463t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVOltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=282-286&author=F.+J.+R.+Romboutsauthor=G.+Tresadernauthor=P.+Buijnstersauthor=X.+Langloisauthor=F.+Tovarauthor=T.+B.+Steinbrecherauthor=G.+Vanhoofauthor=M.+Somersauthor=J.-I.+Andr%C3%A9sauthor=A.+A.+Trabanco&title=Pyrido%5B4%2C3-e%5D%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazines+as+Selective%2C+Brain+Penetrant+Phosphodiesterase+2+%28PDE2%29+Inhibitors&doi=10.1021%2Fml500463t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors</span></div><div class="casAuthors">Rombouts, Frederik J. R.; Tresadern, Gary; Buijnsters, Peter; Langlois, Xavier; Tovar, Fulgencio; Steinbrecher, Thomas B.; Vanhoof, Greet; Somers, Marijke; Andres, Jose-Ignacio; Trabanco, Andres A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">282-286</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines is reported as potent PDE2/PDE10 inhibitors with drug-like properties.  Selectivity for PDE2 was obtained by introducing a linear, lipophilic moiety on the meta-position of the Ph ring pending from the triazole.  The SAR and protein flexibility were explored with free energy perturbation calcns.  Rat pharmacokinetic data and in vivo receptor occupancy data are given for two representative compds. 6 and 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbUtc8164aobVg90H21EOLACvtfcHk0lhDmBiW_5LU7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVOltA%253D%253D&md5=d92a3c22cee3c286c2608d5cf719b14c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fml500463t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500463t%26sid%3Dliteratum%253Aachs%26aulast%3DRombouts%26aufirst%3DF.%2BJ.%2BR.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DBuijnsters%26aufirst%3DP.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DTovar%26aufirst%3DF.%26aulast%3DSteinbrecher%26aufirst%3DT.%2BB.%26aulast%3DVanhoof%26aufirst%3DG.%26aulast%3DSomers%26aufirst%3DM.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DJ.-I.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3DPyrido%255B4%252C3-e%255D%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazines%2520as%2520Selective%252C%2520Brain%2520Penetrant%2520Phosphodiesterase%25202%2520%2528PDE2%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D282%26epage%3D286%26doi%3D10.1021%2Fml500463t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Redrobe, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jørgensen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christoffersen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montezinho, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastlund, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnerup, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bundgaard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerdrup, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plath, N.</span><span> </span><span class="NLM_article-title">In Vitro and In Vivo Characterisation of Lu AF64280, a Novel, Brain Penetrant Phosphodiesterase (PDE) 2A Inhibitor: Potential Relevance to Cognitive Deficits in Schizophrenia</span> <span class="citation_source-journal">Psychopharmacology (Berl)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">3151</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span><span class="refDoi"> DOI: 10.1007/s00213-014-3492-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1007%2Fs00213-014-3492-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=24577516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlKgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=3151-3167&author=J.+P.+Redrobeauthor=M.+J%C3%B8rgensenauthor=C.+T.+Christoffersenauthor=L.+P.+Montezinhoauthor=J.+F.+Bastlundauthor=M.+Carnerupauthor=C.+Bundgaardauthor=L.+Lerdrupauthor=N.+Plath&title=In+Vitro+and+In+Vivo+Characterisation+of+Lu+AF64280%2C+a+Novel%2C+Brain+Penetrant+Phosphodiesterase+%28PDE%29+2A+Inhibitor%3A+Potential+Relevance+to+Cognitive+Deficits+in+Schizophrenia&doi=10.1007%2Fs00213-014-3492-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia</span></div><div class="casAuthors">Redrobe, John P.; Jorgensen, Morten; Christoffersen, Claus T.; Montezinho, Liliana P.; Bastlund, Jesper F.; Carnerup, Martin; Bundgaard, Christoffer; Lerdrup, Linda; Plath, Niels</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3151-3167</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Here, we present the pharmacol. characterization of Lu AF64280, a novel, selective, brain penetrant phosphodiesterase (PDE) 2A inhibitor, in in vitro/in vivo assays indicative of PDE2A inhibition, and in vivo models/assays relevant to cognitive processing or antipsychotic-like activity.  The in vitro selectivity of Lu AF64280 was detd. against a panel of PDE enzymes and 3',5'-cyclic guanosine monophosphate (cGMP) levels in the hippocampus were detd. using in vivo microdialysis.  Lu AF64280 potently inhibited hPDE2A (Ki = 20 nM), 50-fold above moderate inhibition of both hPDE9A (Ki = 1,000 nM) and hPDE10A (Ki = 1,800 nM), and displayed a >250-fold selectivity over all other full-length human recombinant PDE family members (Ki above 5,000 nM).  Lu AF64280 (20 mg/kg) significantly increased cGMP levels in the hippocampus (p < 0.01 vs. vehicle-treated mice), attenuated sub-chronic phencyclidine-induced deficits in novel object exploration in rats (10 mg/kg, p < 0.001 vs. vehicle-treated), blocked early postnatal phencyclidine-induced deficits in the intradimensional/extradimensional shift task in rats (1 and 10 mg/kg, p < 0.001 vs. vehicle-treated) and attenuated spontaneous P20-N40 auditory gating deficits in DBA/2 mice (20 mg/kg, p < 0.05 vs. vehicle-treated).  In contrast, Lu AF64280 failed to attenuate phencyclidine-induced hyperactivity in mice, and was devoid of antipsychotic-like activity in the conditioned avoidance response paradigm in rats, at any dose tested.  Lu AF64280 represents a novel tool compd. for selective PDE2A inhibition that substantiates a crit. role of this enzyme in cognitive processes under normal and pathol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIxqzVL5lb5rVg90H21EOLACvtfcHk0lhDmBiW_5LU7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlKgtr8%253D&md5=74789561beac4e9f901971525e603806</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs00213-014-3492-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-014-3492-7%26sid%3Dliteratum%253Aachs%26aulast%3DRedrobe%26aufirst%3DJ.%2BP.%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DM.%26aulast%3DChristoffersen%26aufirst%3DC.%2BT.%26aulast%3DMontezinho%26aufirst%3DL.%2BP.%26aulast%3DBastlund%26aufirst%3DJ.%2BF.%26aulast%3DCarnerup%26aufirst%3DM.%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DLerdrup%26aufirst%3DL.%26aulast%3DPlath%26aufirst%3DN.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Characterisation%2520of%2520Lu%2520AF64280%252C%2520a%2520Novel%252C%2520Brain%2520Penetrant%2520Phosphodiesterase%2520%2528PDE%2529%25202A%2520Inhibitor%253A%2520Potential%2520Relevance%2520to%2520Cognitive%2520Deficits%2520in%2520Schizophrenia%26jtitle%3DPsychopharmacology%2520%2528Berl%2529%26date%3D2014%26volume%3D231%26spage%3D3151%26epage%3D3167%26doi%3D10.1007%2Fs00213-014-3492-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Helal, C. J.</span><span> </span><span class="NLM_article-title">Identification of a Brain Penetrant, Highly Selective Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Impairment Associated with Schizophrenia (CIAS)</span>. 244th ACS National Meeting & Exposition, Philadelphia, PA, USA, August 19–23, 2012; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+J.+Helal&title=Identification+of+a+Brain+Penetrant%2C+Highly+Selective+Phosphodiesterase+2A+Inhibitor+for+the+Treatment+of+Cognitive+Impairment+Associated+with+Schizophrenia+%28CIAS%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26atitle%3DIdentification%2520of%2520a%2520Brain%2520Penetrant%252C%2520Highly%2520Selective%2520Phosphodiesterase%25202A%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cognitive%2520Impairment%2520Associated%2520with%2520Schizophrenia%2520%2528CIAS%2529%26jtitle%3D244th%2520ACS%2520National%2520Meeting%2520%2526%2520Exposition%252C%2520Philadelphia%252C%2520PA%252C%2520USA%252C%2520August%252019%25E2%2580%259323%252C%25202012%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Gomez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massari, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freestone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoder, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadbent, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barido, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmelzer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neul, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebring, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabatabaei, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenbucher, J. G.</span><span> </span><span class="NLM_article-title">Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2037</span><span class="NLM_x">–</span> <span class="NLM_lpage">2051</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01793</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01793" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1Sjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2037-2051&author=L.+Gomezauthor=M.+E.+Massariauthor=T.+Vickersauthor=G.+Freestoneauthor=W.+Vernierauthor=K.+Lyauthor=R.+Xuauthor=M.+McCarrickauthor=T.+Marroneauthor=M.+Metzauthor=Y.+G.+Yanauthor=Z.+W.+Yoderauthor=R.+Lemusauthor=N.+J.+Broadbentauthor=R.+Baridoauthor=N.+Warrenauthor=K.+Schmelzerauthor=D.+Neulauthor=D.+Leeauthor=C.+B.+Andersenauthor=K.+Sebringauthor=K.+Aertgeertsauthor=X.+Zhouauthor=A.+Tabatabaeiauthor=M.+Petersauthor=J.+G.+Breitenbucher&title=Design+and+Synthesis+of+Novel+and+Selective+Phosphodiesterase+2+%28PDE2a%29+Inhibitors+for+the+Treatment+of+Memory+Disorders&doi=10.1021%2Facs.jmedchem.6b01793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders</span></div><div class="casAuthors">Gomez, Laurent; Massari, Mark Eben; Vickers, Troy; Freestone, Graeme; Vernier, William; Ly, Kiev; Xu, Rui; McCarrick, Margaret; Marrone, Tami; Metz, Markus; Yan, Yingzhou G.; Yoder, Zachary W.; Lemus, Robert; Broadbent, Nicola J.; Barido, Richard; Warren, Noelle; Schmelzer, Kara; Neul, David; Lee, Dong; Andersen, Carsten B.; Sebring, Kristen; Aertgeerts, Kathleen; Zhou, Xianbo; Tabatabaei, Ali; Peters, Marco; Breitenbucher, J. Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2037-2051</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of potent and selective [1,2,4]triazolo[1,5-a]pyrimidine PDE2a inhibitors is reported.  The design and improvement of the binding properties of this series was achieved using X-ray crystal structures in conjunction with careful anal. of electronic and structural requirements for the PDE2a enzyme.  One of the lead compds., compd. I (DNS-8254), was identified as a potent and highly selective PDE2a enzyme inhibitor with favorable rat pharmacokinetic properties.  Interestingly, the increased potency of compd. I was facilitated by the formation of a halogen bond with the oxygen of Tyr827 present in the PDE2a active site.  In vivo, compd. I demonstrated significant memory enhancing effects in a rat model of novel object recognition.  Taken together, these data suggest that compd. I may be a useful tool to explore the pharmacol. of selective PDE2a inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6ML_QxZhnWLVg90H21EOLACvtfcHk0lgsnNf0B1RTtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1Sjuro%253D&md5=fe8df71fbd1f61423352dfcb862d9d53</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01793%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DL.%26aulast%3DMassari%26aufirst%3DM.%2BE.%26aulast%3DVickers%26aufirst%3DT.%26aulast%3DFreestone%26aufirst%3DG.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DLy%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DMcCarrick%26aufirst%3DM.%26aulast%3DMarrone%26aufirst%3DT.%26aulast%3DMetz%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%2BG.%26aulast%3DYoder%26aufirst%3DZ.%2BW.%26aulast%3DLemus%26aufirst%3DR.%26aulast%3DBroadbent%26aufirst%3DN.%2BJ.%26aulast%3DBarido%26aufirst%3DR.%26aulast%3DWarren%26aufirst%3DN.%26aulast%3DSchmelzer%26aufirst%3DK.%26aulast%3DNeul%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DAndersen%26aufirst%3DC.%2BB.%26aulast%3DSebring%26aufirst%3DK.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DTabatabaei%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DM.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520and%2520Selective%2520Phosphodiesterase%25202%2520%2528PDE2a%2529%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Memory%2520Disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2037%26epage%3D2051%26doi%3D10.1021%2Facs.jmedchem.6b01793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Boess, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Staay, F.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erb, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Staveren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vente, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickaerts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koenig, G.</span><span> </span><span class="NLM_article-title">Inhibition of Phosphodiesterase 2 Increases Neuronal cGMP, Synaptic Plasticity and Memory Performance</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1081</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2004.07.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.neuropharm.2004.07.040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1081-1092&author=F.+G.+Boessauthor=M.+Hendrixauthor=F.-J.+van+der+Staayauthor=C.+Erbauthor=R.+Schreiberauthor=W.+van+Staverenauthor=J.+de+Venteauthor=J.+Prickaertsauthor=A.+Bloklandauthor=G.+Koenig&title=Inhibition+of+Phosphodiesterase+2+Increases+Neuronal+cGMP%2C+Synaptic+Plasticity+and+Memory+Performance&doi=10.1016%2Fj.neuropharm.2004.07.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2004.07.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2004.07.040%26sid%3Dliteratum%253Aachs%26aulast%3DBoess%26aufirst%3DF.%2BG.%26aulast%3DHendrix%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BStaay%26aufirst%3DF.-J.%26aulast%3DErb%26aufirst%3DC.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3Dvan%2BStaveren%26aufirst%3DW.%26aulast%3Dde%2BVente%26aufirst%3DJ.%26aulast%3DPrickaerts%26aufirst%3DJ.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DKoenig%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520Phosphodiesterase%25202%2520Increases%2520Neuronal%2520cGMP%252C%2520Synaptic%2520Plasticity%2520and%2520Memory%2520Performance%26jtitle%3DNeuropharmacology%26date%3D2004%26volume%3D47%26spage%3D1081%26epage%3D1092%26doi%3D10.1016%2Fj.neuropharm.2004.07.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Rutten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Donkelaar, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrington, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbusch, H. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, P. A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickaerts, J. H. H. J.</span><span> </span><span class="NLM_article-title">Phosphodiesterase Inhibitors Enhance Object Memory Independent of Cerebral Blood Flow and Glucose Utilization in Rats</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1914</span><span class="NLM_x">–</span> <span class="NLM_lpage">1925</span><span class="refDoi"> DOI: 10.1038/npp.2009.24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1038%2Fnpp.2009.24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=19262466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFSju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=1914-1925&author=K.+Ruttenauthor=E.+L.+Van+Donkelaarauthor=L.+Ferringtonauthor=A.+Bloklandauthor=E.+Bollenauthor=H.+W.+M.+Steinbuschauthor=P.+A.+T.+Kellyauthor=J.+H.+H.+J.+Prickaerts&title=Phosphodiesterase+Inhibitors+Enhance+Object+Memory+Independent+of+Cerebral+Blood+Flow+and+Glucose+Utilization+in+Rats&doi=10.1038%2Fnpp.2009.24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats</span></div><div class="casAuthors">Rutten, Kris; Van Donkelaar, Eva L.; Ferrington, Linda; Blokland, Arjan; Bollen, Eva; Steinbusch, Harry W. M.; Kelly, Paul A. T.; Prickaerts, Jos H. H. J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1914-1925</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) inhibitors prevent the breakdown of the second messengers, cAMP (cAMP) and cyclic GMP (cGMP), and are currently studied as possible targets for cognitive enhancement.  Earlier studies indicated beneficial effects of PDE inhibitors in object recognition.  In this study we tested the effects of three PDE inhibitors on spatial memory as assessed in a place and object recognition task.  Furthermore, as both cAMP and cGMP are known vasodilators, the effects of PDE inhibition on cognitive functions could be explained by enhancement of cerebrovascular function.  We examd. this possibility by measuring the effects of PDE5 and PDE4 inhibitor treatment on local cerebral blood flow and glucose utilization in rats using [14C]-iodoantipyrine and [14C]-2-deoxyglucose quant. autoradiog., resp.  In the spatial location task, PDE5 inhibition (cGMP) with vardenafil enhanced only early phase consolidation, PDE4 inhibition (cAMP) with rolipram enhanced only late phase consolidation, and PDE2 inhibition (cAMP and cGMP) with Bay 60-7550 enhanced both consolidation processes.  Furthermore, PDE5 inhibition had no cerebrovascular effects in hippocampal or rhinal areas.  PDE4 inhibition increased rhinal, but not hippocampal blood flow, whereas it decreased glucose utilization in both areas.  In general, PDE5 inhibition decreased the ratio between blood flow and glucose utilization, indicative of general oligemia; whereas PDE4 inhibition increased this ratio, indicative of general hyperemia.  Both oligemic and hyperemic conditions are detrimental for brain function and do not explain memory enhancement.  These results underscore the specific effects of cAMP and cGMP on memory consolidation (object and spatial memory) and provide evidence that the underlying mechanisms of PDE inhibition on cognition are independent of cerebrovascular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfAElwT0GL1rVg90H21EOLACvtfcHk0lh1DCBl39GyOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFSju7c%253D&md5=506d0fbcb1b4a7a0c25bf92ab08fc270</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2009.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2009.24%26sid%3Dliteratum%253Aachs%26aulast%3DRutten%26aufirst%3DK.%26aulast%3DVan%2BDonkelaar%26aufirst%3DE.%2BL.%26aulast%3DFerrington%26aufirst%3DL.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DBollen%26aufirst%3DE.%26aulast%3DSteinbusch%26aufirst%3DH.%2BW.%2BM.%26aulast%3DKelly%26aufirst%3DP.%2BA.%2BT.%26aulast%3DPrickaerts%26aufirst%3DJ.%2BH.%2BH.%2BJ.%26atitle%3DPhosphodiesterase%2520Inhibitors%2520Enhance%2520Object%2520Memory%2520Independent%2520of%2520Cerebral%2520Blood%2520Flow%2520and%2520Glucose%2520Utilization%2520in%2520Rats%26jtitle%3DNeuropsychopharmacology%26date%3D2009%26volume%3D34%26spage%3D1914%26epage%3D1925%26doi%3D10.1038%2Fnpp.2009.24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Reneerkens, O. A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hage, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbusch, H. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickaerts, J.</span><span> </span><span class="NLM_article-title">Inhibition of Phoshodiesterase Type 2 or Type 10 Reverses Object Memory Deficits Induced by Scopolamine or MK-801</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1016/j.bbr.2012.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.bbr.2012.08.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=2013&pages=16-22&author=O.+A.+H.+Reneerkensauthor=K.+Ruttenauthor=E.+Bollenauthor=T.+Hageauthor=A.+Bloklandauthor=H.+W.+M.+Steinbuschauthor=J.+Prickaerts&title=Inhibition+of+Phoshodiesterase+Type+2+or+Type+10+Reverses+Object+Memory+Deficits+Induced+by+Scopolamine+or+MK-801&doi=10.1016%2Fj.bbr.2012.08.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2012.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2012.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DReneerkens%26aufirst%3DO.%2BA.%2BH.%26aulast%3DRutten%26aufirst%3DK.%26aulast%3DBollen%26aufirst%3DE.%26aulast%3DHage%26aufirst%3DT.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DSteinbusch%26aufirst%3DH.%2BW.%2BM.%26aulast%3DPrickaerts%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520Phoshodiesterase%2520Type%25202%2520or%2520Type%252010%2520Reverses%2520Object%2520Memory%2520Deficits%2520Induced%2520by%2520Scopolamine%2520or%2520MK-801%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2013%26volume%3D236%26spage%3D16%26epage%3D22%26doi%3D10.1016%2Fj.bbr.2012.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Pandit, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillman, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span> </span><span class="NLM_article-title">Mechanism for the Allosteric Regulation of Phosphodiesterase 2A Deduced from the X-ray Structure of a Near Full-Length Construct</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">18225</span><span class="NLM_x">–</span> <span class="NLM_lpage">18230</span><span class="refDoi"> DOI: 10.1073/pnas.0907635106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1073%2Fpnas.0907635106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=19828435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVags7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=18225-18230&author=J.+Panditauthor=M.+D.+Formanauthor=K.+F.+Fennellauthor=K.+S.+Dillmanauthor=F.+S.+Menniti&title=Mechanism+for+the+Allosteric+Regulation+of+Phosphodiesterase+2A+Deduced+from+the+X-ray+Structure+of+a+Near+Full-Length+Construct&doi=10.1073%2Fpnas.0907635106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct</span></div><div class="casAuthors">Pandit, Jayvardhan; Forman, Michael D.; Fennell, Kimberly F.; Dillman, Keith S.; Menniti, Frank S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">18225-18230, S18225/1-S18225/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We report the x-ray crystal structure of a phosphodiesterase (PDE) that includes both catalytic and regulatory domains.  PDE2A (215-900) crystd. as a dimer in which each subunit had an extended organization of regulatory GAF-A and GAF-B and catalytic domains connected by long α-helixes.  The subunits cross at the GAF-B/catalytic domain linker, and each side of the dimer contains in series the GAF-A and GAF-B of one subunit and the catalytic domain of the other subunit.  A dimer interface extends over the entire length of the mol.  The substrate binding pocket of each catalytic domain is occluded by the H-loop.  We deduced from comparisons with structures of isolated, ligand-bound catalytic subunits that the H-loop swings out to allow substrate access.  However, in dimeric PDE2A (215-900), the H-loops of the two catalytic subunits pack against each other at the dimer interface, necessitating movement of the catalytic subunits to allow for H-loop movement.  Comparison of the unliganded GAF-B of PDE2A (215-900) with previous structures of isolated, cGMP-bound GAF domains indicates that cGMP binding induces a significant shift in the GAF-B/catalytic domain linker.  We propose that cGMP binding to GAF-B causes movement, through this linker region, of the catalytic domains, such that the H-loops no longer pack at the dimer interface and are, instead, free to swing out to allow substrate access.  This increase in substrate access is proposed as the basis for PDE2A activation by cGMP and may be a general mechanism for regulation of all PDEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh-kgJc6VX2bVg90H21EOLACvtfcHk0lh1DCBl39GyOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVags7vO&md5=73ddfdb3ffb861674744a1fbeef7c881</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0907635106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0907635106%26sid%3Dliteratum%253Aachs%26aulast%3DPandit%26aufirst%3DJ.%26aulast%3DForman%26aufirst%3DM.%2BD.%26aulast%3DFennell%26aufirst%3DK.%2BF.%26aulast%3DDillman%26aufirst%3DK.%2BS.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26atitle%3DMechanism%2520for%2520the%2520Allosteric%2520Regulation%2520of%2520Phosphodiesterase%25202A%2520Deduced%2520from%2520the%2520X-ray%2520Structure%2520of%2520a%2520Near%2520Full-Length%2520Construct%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D18225%26epage%3D18230%26doi%3D10.1073%2Fpnas.0907635106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Müller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faeh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span> </span><span class="NLM_article-title">Fluorine in Pharmaceuticals: Looking beyond Intuition</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">317</span><span class="NLM_x">, </span> <span class="NLM_fpage">1881</span><span class="NLM_x">–</span> <span class="NLM_lpage">1886</span><span class="refDoi"> DOI: 10.1126/science.1131943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1126%2Fscience.1131943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=17901324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOlt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2007&pages=1881-1886&author=K.+M%C3%BCllerauthor=C.+Faehauthor=F.+Diederich&title=Fluorine+in+Pharmaceuticals%3A+Looking+beyond+Intuition&doi=10.1126%2Fscience.1131943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in Pharmaceuticals: Looking Beyond Intuition</span></div><div class="casAuthors">Mueller, Klaus; Faeh, Christoph; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">5846</span>),
    <span class="NLM_cas:pages">1881-1886</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Fluorine substituents have become a widespread and important drug component, their introduction facilitated by the development of safe and selective fluorinating agents.  Organofluorine affects nearly all phys. and adsorption, distribution, metab., and excretion properties of a lead compd.  Its inductive effects are relatively well understood, enhancing bioavailability, for example, by reducing the basicity of neighboring amines.  In contrast, exploration of the specific influence of carbon-fluorine single bonds on docking interactions, whether through direct contact with the protein or through stereoelectronic effects on mol. conformation of the drug, has only recently begun.  Here, we review exptl. progress in this vein and add complementary anal. based on comprehensive searches in the Cambridge Structural Database and the Protein Data Bank.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwX-YnONRc3LVg90H21EOLACvtfcHk0lh1DCBl39GyOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOlt7rN&md5=f804876c801518e48d0bdb7d87b7fb1c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.1131943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1131943%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DFaeh%26aufirst%3DC.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DFluorine%2520in%2520Pharmaceuticals%253A%2520Looking%2520beyond%2520Intuition%26jtitle%3DScience%26date%3D2007%26volume%3D317%26spage%3D1881%26epage%3D1886%26doi%3D10.1126%2Fscience.1131943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandretto, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span> </span><span class="NLM_article-title">Kinase Inhibitors and the Case for CH···O Hydrogen Bonds in Protein–Ligand Binding</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">–</span> <span class="NLM_lpage">576</span><span class="refDoi"> DOI: 10.1002/prot.10259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1002%2Fprot.10259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2002&pages=567-576&author=A.+C.+Pierceauthor=K.+L.+Sandrettoauthor=G.+W.+Bemis&title=Kinase+Inhibitors+and+the+Case+for+CH%C2%B7%C2%B7%C2%B7O+Hydrogen+Bonds+in+Protein%E2%80%93Ligand+Binding&doi=10.1002%2Fprot.10259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fprot.10259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.10259%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DSandretto%26aufirst%3DK.%2BL.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26atitle%3DKinase%2520Inhibitors%2520and%2520the%2520Case%2520for%2520CH%25C2%25B7%25C2%25B7%25C2%25B7O%2520Hydrogen%2520Bonds%2520in%2520Protein%25E2%2580%2593Ligand%2520Binding%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2002%26volume%3D49%26spage%3D567%26epage%3D576%26doi%3D10.1002%2Fprot.10259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span> </span><span class="NLM_article-title">X-ray Crystal Structure of Phosphodiesterase 2 in Complex with a Highly Selective, Nanomolar Inhibitor Reveals a Binding-Induced Pocket Important for Selectivity</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">11708</span><span class="NLM_x">–</span> <span class="NLM_lpage">11711</span><span class="refDoi"> DOI: 10.1021/ja404449g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja404449g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=11708-11711&author=J.+Zhuauthor=Q.+Yangauthor=D.+Daiauthor=Q.+Huang&title=X-ray+Crystal+Structure+of+Phosphodiesterase+2+in+Complex+with+a+Highly+Selective%2C+Nanomolar+Inhibitor+Reveals+a+Binding-Induced+Pocket+Important+for+Selectivity&doi=10.1021%2Fja404449g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fja404449g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja404449g%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DDai%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DQ.%26atitle%3DX-ray%2520Crystal%2520Structure%2520of%2520Phosphodiesterase%25202%2520in%2520Complex%2520with%2520a%2520Highly%2520Selective%252C%2520Nanomolar%2520Inhibitor%2520Reveals%2520a%2520Binding-Induced%2520Pocket%2520Important%2520for%2520Selectivity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D11708%26epage%3D11711%26doi%3D10.1021%2Fja404449g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, Y.</span><span> </span><span class="NLM_article-title">Kinetic Solubility and Lipophilicity Evaluation Connecting Formulation Technology Strategy Perspective</span> <span class="citation_source-journal">J. Drug Delivery Sci. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span><span class="refDoi"> DOI: 10.1016/j.jddst.2016.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.jddst.2016.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC28XktFers7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=13-18&author=K.+Yamamotoauthor=Y.+Ikeda&title=Kinetic+Solubility+and+Lipophilicity+Evaluation+Connecting+Formulation+Technology+Strategy+Perspective&doi=10.1016%2Fj.jddst.2016.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic solubility and lipophilicity evaluation connecting formulation technology strategy perspective</span></div><div class="casAuthors">Yamamoto, Katsuhiko; Ikeda, Yukihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Delivery Science and Technology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-18</span>CODEN:
                <span class="NLM_cas:coden">JDDSAL</span>;
        ISSN:<span class="NLM_cas:issn">1773-2247</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lipophilicity and soly. are important physicochem. properties of pharmaceutical compds., esp. orally administration drugs.  In this study, we developed a chromatog. distribution coeff. (LogD) detn. method as lipophilicity evaluation and a kinetic soly. procedure with rapid quantitation by HPLC-UV.  Both methods are simple and applicable for use of conventional equipment in early stage of drug discovery and development.  Actually both data of model drugs were collected and discussed to improve the physicochem. properties using formulation technologies such as solubilization and enteric coating.  The parallel measurement and consideration of both sets of data enables not only detail evaluation of the physicochem. properties but also the perspective of the relevant formulation strategies of drugs.  Such rational evaluation will facilitate the development of high quality and effective drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq69TBJfRT8dLVg90H21EOLACvtfcHk0ljREQRHIyqOSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktFers7g%253D&md5=73f97d1fb1447eee30aca663d8686c35</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.jddst.2016.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jddst.2016.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DY.%26atitle%3DKinetic%2520Solubility%2520and%2520Lipophilicity%2520Evaluation%2520Connecting%2520Formulation%2520Technology%2520Strategy%2520Perspective%26jtitle%3DJ.%2520Drug%2520Delivery%2520Sci.%2520Technol.%26date%3D2016%26volume%3D33%26spage%3D13%26epage%3D18%26doi%3D10.1016%2Fj.jddst.2016.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Omori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotera, J.</span><span> </span><span class="NLM_article-title">Overview of PDEs and Their Regulation</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1161/01.RES.0000256354.95791.f1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1161%2F01.RES.0000256354.95791.f1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=17307970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsF2kurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=309-327&author=K.+Omoriauthor=J.+Kotera&title=Overview+of+PDEs+and+Their+Regulation&doi=10.1161%2F01.RES.0000256354.95791.f1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of PDEs and their regulation</span></div><div class="casAuthors">Omori, Kenji; Kotera, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-327</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Contraction and relaxation of vascular smooth muscle and cardiac myocytes are key physiol. events in the cardiovascular system.  These events are regulated by 2nd messengers, cAMP and cGMP, in response to extracellular stimulants.  The strength of signal transduction is controlled by intracellular cyclic nucleotide concns., which are detd. by a balance in the prodn. and degrdn. of cAMP and cGMP.  The degrdn. of cyclic nucleotides is catalyzed by 3',5'-cyclic nucleotide phosphodiesterases (PDEs), and therefore regulation of PDEs hydrolytic activity is important for modulation of cellular functions.  Mammalian PDEs are composed of 21 genes and are categorized into 11 families based on sequence homol., enzymic properties, and sensitivity to inhibitors.  PDE families contain many splice variants that mostly are unique in tissue-expression patterns, gene regulation, enzymic regulation by phosphorylation and regulatory proteins, subcellular localization, and interaction with assocn. proteins.  Each unique variant is closely related to the regulation of a specific cellular signaling.  Thus, multiple PDEs function as a particular modulator of each cardiovascular function and regulate physiol. homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctQ0OjiRTE7Vg90H21EOLACvtfcHk0ljREQRHIyqOSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsF2kurY%253D&md5=932f5158c5ebdd9a75a41317b0b12955</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000256354.95791.f1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000256354.95791.f1%26sid%3Dliteratum%253Aachs%26aulast%3DOmori%26aufirst%3DK.%26aulast%3DKotera%26aufirst%3DJ.%26atitle%3DOverview%2520of%2520PDEs%2520and%2520Their%2520Regulation%26jtitle%3DCirc.%2520Res.%26date%3D2007%26volume%3D100%26spage%3D309%26epage%3D327%26doi%3D10.1161%2F01.RES.0000256354.95791.f1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Martins, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mumby, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beavo, J. A.</span><span> </span><span class="NLM_article-title">Purification and Characterization of a Cyclic GMP-Stimulated Cyclic Nucleotide Phosphodiesterase from Bovine Tissues</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x">, </span> <span class="NLM_fpage">1973</span><span class="NLM_x">–</span> <span class="NLM_lpage">1979</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1982&pages=1973-1979&author=T.+J.+Martinsauthor=M.+C.+Mumbyauthor=J.+A.+Beavo&title=Purification+and+Characterization+of+a+Cyclic+GMP-Stimulated+Cyclic+Nucleotide+Phosphodiesterase+from+Bovine+Tissues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartins%26aufirst%3DT.%2BJ.%26aulast%3DMumby%26aufirst%3DM.%2BC.%26aulast%3DBeavo%26aufirst%3DJ.%2BA.%26atitle%3DPurification%2520and%2520Characterization%2520of%2520a%2520Cyclic%2520GMP-Stimulated%2520Cyclic%2520Nucleotide%2520Phosphodiesterase%2520from%2520Bovine%2520Tissues%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1982%26volume%3D257%26spage%3D1973%26epage%3D1979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Podzuweit, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nennstiel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, A.</span><span> </span><span class="NLM_article-title">Isozyme Selective Inhibition of cGMP-Stimulated Cyclic Nucleotide Phosphodiesterases by Erythro-9-(2-hydroxy-3-nonyl) Adenine</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">738</span><span class="refDoi"> DOI: 10.1016/0898-6568(95)00042-N</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2F0898-6568%2895%2900042-N" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=8519602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADyaK2MXovVaisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1995&pages=733-738&author=T.+Podzuweitauthor=P.+Nennstielauthor=A.+M%C3%BCller&title=Isozyme+Selective+Inhibition+of+cGMP-Stimulated+Cyclic+Nucleotide+Phosphodiesterases+by+Erythro-9-%282-hydroxy-3-nonyl%29+Adenine&doi=10.1016%2F0898-6568%2895%2900042-N"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Isoenzyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine</span></div><div class="casAuthors">Podzuweit, Thomas; Nennstiel, Peter; Mueller, Antje</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">733-8</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), a potent inhibitor of adenosine deaminase (ADA), was tested as an inhibitor of the sol. cyclic nucleotide phosphodiesterase (PDE) isoenzymes from pig and human myocardium.  Four sol. PDE activities were resolved from human papillary muscle exts. using anion exchange chromatog. (DEAE Sepharose CL-6B).  These activities were designated PDE I-IV according to the nomenclature of Beavo.  PDE I was stimulated by Ca2+-calmodulin and PDE II by cGMP (1 μM).  PDE III was inhibited by cGMP (1 μM) as well as by SK&F 94120, and PDE IV was inhibited by both rolipram and Ro 20-1724.  Enzyme kinetics and inhibition consts. were similar with the PDE isoenzymes from pig heart.  However, porcine myocardium lacked Ca2+-calmodulin-stimulated sol. PDE I activity.  The present data reveal that EHNA exerted a concn.-dependent inhibition of the cGMP-stimulated PDE II (cGs-PDE) (IC50: 0.8 μM (human), 2 μM (pig)) but did not inhibit the other PDE isoenzymes (IC50 > 100 μM).  These findings indicate that EHNA is a potent and, as far as cytosolic PDEs are concerned, selective inhibitor of cGMP-stimulated PDEs.  The compd. may lend itself to the rational design of other isoenzyme selective PDE II inhibitors and for examg. the specific biol. functions of cGs-PDEs.  EHNA may be used in systems in which inhibition of ADA is of no concern.  Conversely, dual inhibition of both ADA and cGs-PDE by EHNA may cause accumulation of two inhibitory metabolites, adenosine and cGMP, which may act in synergy to mediate diverse pharmacol. responses, including antiviral, antitumor, and antiarrhythmic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDp9d-Vx26qLVg90H21EOLACvtfcHk0lg0GhnWH2a5_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovVaisL4%253D&md5=af2d50c73a87ae3f3effef1521a2eb86</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2F0898-6568%2895%2900042-N&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0898-6568%252895%252900042-N%26sid%3Dliteratum%253Aachs%26aulast%3DPodzuweit%26aufirst%3DT.%26aulast%3DNennstiel%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26atitle%3DIsozyme%2520Selective%2520Inhibition%2520of%2520cGMP-Stimulated%2520Cyclic%2520Nucleotide%2520Phosphodiesterases%2520by%2520Erythro-9-%25282-hydroxy-3-nonyl%2529%2520Adenine%26jtitle%3DCell.%2520Signalling%26date%3D1995%26volume%3D7%26spage%3D733%26epage%3D738%26doi%3D10.1016%2F0898-6568%2895%2900042-N" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Sugimoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirabayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amano, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriwaki, T.</span><span> </span><span class="NLM_article-title">Quantitative Investigation of the Impact of P-Glycoprotein Inhibition on Drug Transport across Blood-Brain Barrier in Rats</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1124/dmd.110.035774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1124%2Fdmd.110.035774" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=8-14&author=H.+Sugimotoauthor=H.+Hirabayashiauthor=Y.+Kimuraauthor=A.+Furutaauthor=N.+Amanoauthor=T.+Moriwaki&title=Quantitative+Investigation+of+the+Impact+of+P-Glycoprotein+Inhibition+on+Drug+Transport+across+Blood-Brain+Barrier+in+Rats&doi=10.1124%2Fdmd.110.035774"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035774%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DHirabayashi%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DFuruta%26aufirst%3DA.%26aulast%3DAmano%26aufirst%3DN.%26aulast%3DMoriwaki%26aufirst%3DT.%26atitle%3DQuantitative%2520Investigation%2520of%2520the%2520Impact%2520of%2520P-Glycoprotein%2520Inhibition%2520on%2520Drug%2520Transport%2520across%2520Blood-Brain%2520Barrier%2520in%2520Rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D8%26epage%3D14%26doi%3D10.1124%2Fdmd.110.035774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Takeuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshitomi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikemoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahi, S.</span><span> </span><span class="NLM_article-title">Establishment and Characterization of the Transformants Stably-Expressing MDR1 Derived from Various Animal Species in LLC-PK1</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1460</span><span class="NLM_x">–</span> <span class="NLM_lpage">1472</span><span class="refDoi"> DOI: 10.1007/s11095-006-0285-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1007%2Fs11095-006-0285-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=16779700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsFOmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=1460-1472&author=T.+Takeuchiauthor=S.+Yoshitomiauthor=T.+Higuchiauthor=K.+Ikemotoauthor=S.+Niwaauthor=T.+Ebiharaauthor=M.+Katohauthor=T.+Yokoiauthor=S.+Asahi&title=Establishment+and+Characterization+of+the+Transformants+Stably-Expressing+MDR1+Derived+from+Various+Animal+Species+in+LLC-PK1&doi=10.1007%2Fs11095-006-0285-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment and Characterization of the Transformants Stably-Expressing MDR1 Derived from Various Animal Species in LLC-PK1</span></div><div class="casAuthors">Takeuchi, Toshiyuki; Yoshitomi, Sumie; Higuchi, Tomoaki; Ikemoto, Keiko; Niwa, Shin-Ichi; Ebihara, Takuya; Katoh, Miki; Yokoi, Tsuyoshi; Asahi, Satoru</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1460-1472</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Stable transformants expressing human multidrug resistance 1 (MDR1), monkey MDR1, canine MDR1, rat MDR1a, rat MDR1b, mouse mdr1a, and mouse mdr1b in LLC-PK1 were established to investigate species differences in P-glycoprotein (P-gp, ABCB1) mediated efflux activity.  Methods: The seven cDNAs of MDR1 from five animals were cloned, and their transformants stably expressing the series of MDR1 in LLC-PK1 were established.  Transport studies of clarithromycin, daunorubicin, digoxin, erythromycin, etoposide, paclitaxel, propranolol, quinidine, ritonavir, saquinavir, verapamil, and vinblastine were performed by using these cells, and efflux activity was compared among the species.  Results: Except for propranolol, all compds. showed efflux activity in all transformants, and were judged to be substrates of P-gp.  There were slight interspecies and interisoforms differences in the substrate recognition.  However, the efflux ratio among the series of the MDR1 stably expressing cells showed good correlation as represented between human and monkey MDR1, and poor correlation as represented between human MDR1 and mouse mdr1a, and human and canine MDR1.  Conclusions: Results in the present study indicate that all MDR1 stably expressing cells have efflux activity for various P-gp substrates, and that interspecies differences and similarities of the P-gp substrate efflux activity may exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28IPlZqwtHLVg90H21EOLACvtfcHk0lg0GhnWH2a5_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsFOmur0%253D&md5=a21044c202d7ff2eb8ab27c4623909de</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs11095-006-0285-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-006-0285-7%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DYoshitomi%26aufirst%3DS.%26aulast%3DHiguchi%26aufirst%3DT.%26aulast%3DIkemoto%26aufirst%3DK.%26aulast%3DNiwa%26aufirst%3DS.%26aulast%3DEbihara%26aufirst%3DT.%26aulast%3DKatoh%26aufirst%3DM.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DAsahi%26aufirst%3DS.%26atitle%3DEstablishment%2520and%2520Characterization%2520of%2520the%2520Transformants%2520Stably-Expressing%2520MDR1%2520Derived%2520from%2520Various%2520Animal%2520Species%2520in%2520LLC-PK1%26jtitle%3DPharm.%2520Res.%26date%3D2006%26volume%3D23%26spage%3D1460%26epage%3D1472%26doi%3D10.1007%2Fs11095-006-0285-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Iffland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohls, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kothe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellenberger, T.</span><span> </span><span class="NLM_article-title">Structural Determinants for Inhibitor Specificity and Selectivity in PDE2A Using the Wheat Germ in Vitro Translation System</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">8312</span><span class="NLM_x">–</span> <span class="NLM_lpage">8325</span><span class="refDoi"> DOI: 10.1021/bi047313h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi047313h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=8312-8325&author=A.+Ifflandauthor=D.+Kohlsauthor=S.+Lowauthor=J.+Luanauthor=Y.+Zhangauthor=M.+Kotheauthor=Q.+Caoauthor=A.+V.+Kamathauthor=Y.+H.+Dingauthor=T.+Ellenberger&title=Structural+Determinants+for+Inhibitor+Specificity+and+Selectivity+in+PDE2A+Using+the+Wheat+Germ+in+Vitro+Translation+System&doi=10.1021%2Fbi047313h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fbi047313h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi047313h%26sid%3Dliteratum%253Aachs%26aulast%3DIffland%26aufirst%3DA.%26aulast%3DKohls%26aufirst%3DD.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DLuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DDing%26aufirst%3DY.%2BH.%26aulast%3DEllenberger%26aufirst%3DT.%26atitle%3DStructural%2520Determinants%2520for%2520Inhibitor%2520Specificity%2520and%2520Selectivity%2520in%2520PDE2A%2520Using%2520the%2520Wheat%2520Germ%2520in%2520Vitro%2520Translation%2520System%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D8312%26epage%3D8325%26doi%3D10.1021%2Fbi047313h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-Ray Diffraction Data Collected in Oscillation Mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-Ray+Diffraction+Data+Collected+in+Oscillation+Mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lg0GhnWH2a5_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-Ray%2520Diffraction%2520Data%2520Collected%2520in%2520Oscillation%2520Mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Vagin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teplyakov, A.</span><span> </span><span class="NLM_article-title">MOLREP: an Automated Program for Molecular Replacement</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">–</span> <span class="NLM_lpage">1025</span><span class="refDoi"> DOI: 10.1107/S0021889897006766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1107%2FS0021889897006766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1997&pages=1022-1025&author=A.+Vaginauthor=A.+Teplyakov&title=MOLREP%3A+an+Automated+Program+for+Molecular+Replacement&doi=10.1107%2FS0021889897006766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">MOLREP: an automated program for molecular replacement</span></div><div class="casAuthors">Vagin, Alexei; Teplyakov, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1022-1025</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">MOLREP is an automated program for mol. replacement which uses effective new approaches in data processing and rotational and translational searching.  These include an automatic choice of all parameters, scaling by Patterson origin peaks and soft resoln. cutoff.  One of the cornerstones of the program is an original full-symmetry translation function combined with a packing function.  Information from the model already placed in the cell is incorporated in both translation and packing functions.  A no. of tests using exptl. data proved the ability of the program to find the correct soln. in difficult cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkGXdZ-nTKxLVg90H21EOLACvtfcHk0lhtSMrfjWjW2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D&md5=96af64aedd8a8f018c3c18b57a6b4b21</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1107%2FS0021889897006766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889897006766%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DTeplyakov%26aufirst%3DA.%26atitle%3DMOLREP%253A%2520an%2520Automated%2520Program%2520for%2520Molecular%2520Replacement%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1997%26volume%3D30%26spage%3D1022%26epage%3D1025%26doi%3D10.1107%2FS0021889897006766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Collaborative Computational Project Number 4</span><span> </span><span class="NLM_article-title">The CCP4 Suite: Programs for Protein Crystallography</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span><span class="refDoi"> DOI: 10.1107/S0907444994003112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=15299374" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=760-763&author=Collaborative+Computational+Project+Number+4&title=The+CCP4+Suite%3A+Programs+for+Protein+Crystallography&doi=10.1107%2FS0907444994003112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520CCP4%2520Suite%253A%2520Programs%2520for%2520Protein%2520Crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2FS0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and Development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+Development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lhtSMrfjWjW2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520Development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 24 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jiyun Sun, Zhiwei Xiao, Ahmed Haider, Catherine Gebhard, Hao Xu, Hai-Bin Luo, Han-Ting Zhang, Lee Josephson, Lu Wang, <span class="NLM_string-name hlFld-ContribAuthor">Steven H. Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7083-7109. <a href="https://doi.org/10.1021/acs.jmedchem.1c00115" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00115</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00115%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAdvances%252Bin%252BCyclic%252BNucleotide%252BPhosphodiesterase-Targeted%252BPET%252BImaging%252Band%252BDrug%252BDiscovery%26aulast%3DSun%26aufirst%3DJiyun%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D21012021%26date%3D27052021%26volume%3D64%26issue%3D11%26spage%3D7083%26epage%3D7109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ivor Smajlagic, Brenden Carlson, <span class="NLM_string-name hlFld-ContribAuthor">Travis Dudding</span>. </span><span class="cited-content_cbyCitation_article-title">Brønsted Acid Organocatalyzed Three-Component Hydroamidation Reactions of Vinyl Ethers. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (5)
                                     , 4171-4181. <a href="https://doi.org/10.1021/acs.joc.0c03017" title="DOI URL">https://doi.org/10.1021/acs.joc.0c03017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c03017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c03017%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DBr%2525C3%2525B8nsted%252BAcid%252BOrganocatalyzed%252BThree-Component%252BHydroamidation%252BReactions%252Bof%252BVinyl%252BEthers%26aulast%3DSmajlagic%26aufirst%3DIvor%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23122020%26date%3D24022021%26volume%3D86%26issue%3D5%26spage%3D4171%26epage%3D4181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Matthew D. Lloyd</span>. </span><span class="cited-content_cbyCitation_article-title">High-Throughput Screening for the Discovery of Enzyme Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10742-10772. <a href="https://doi.org/10.1021/acs.jmedchem.0c00523" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00523%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHigh-Throughput%252BScreening%252Bfor%252Bthe%252BDiscovery%252Bof%252BEnzyme%252BInhibitors%26aulast%3DLloyd%26aufirst%3DMatthew%2BD.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30032020%26date%3D10062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10742%26epage%3D10772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Juan-Carlos Castillo, Alexis Tigreros, <span class="NLM_string-name hlFld-ContribAuthor">Jaime Portilla</span>. </span><span class="cited-content_cbyCitation_article-title">3-Formylpyrazolo[1,5-a]pyrimidines as Key Intermediates for the Preparation of Functional Fluorophores. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (18)
                                     , 10887-10897. <a href="https://doi.org/10.1021/acs.joc.8b01571" title="DOI URL">https://doi.org/10.1021/acs.joc.8b01571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b01571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b01571%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3D3-Formylpyrazolo%25255B1%25252C5-a%25255Dpyrimidines%252Bas%252BKey%252BIntermediates%252Bfor%252Bthe%252BPreparation%252Bof%252BFunctional%252BFluorophores%26aulast%3DCastillo%26aufirst%3DJuan-Carlos%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D22062018%26date%3D02082018%26date%3D27072018%26volume%3D83%26issue%3D18%26spage%3D10887%26epage%3D10897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antonia F.  Stepan</span>, <span class="hlFld-ContribAuthor ">Tuan P.  Tran</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Helal</span>, <span class="hlFld-ContribAuthor ">Maria S.  Brown</span>, <span class="hlFld-ContribAuthor ">Cheng  Chang</span>, <span class="hlFld-ContribAuthor ">Rebecca E.  O’Connor</span>, <span class="hlFld-ContribAuthor ">Michael  De Vivo</span>, <span class="hlFld-ContribAuthor ">Shawn D.  Doran</span>, <span class="hlFld-ContribAuthor ">Ethan L.  Fisher</span>, <span class="hlFld-ContribAuthor ">Stephen  Jenkinson</span>, <span class="hlFld-ContribAuthor ">David  Karanian</span>, <span class="hlFld-ContribAuthor ">Bethany L.  Kormos</span>, <span class="hlFld-ContribAuthor ">Raman  Sharma</span>, <span class="hlFld-ContribAuthor ">Gregory S.  Walker</span>, <span class="hlFld-ContribAuthor ">Ann S.  Wright</span>, <span class="hlFld-ContribAuthor ">Edward X.  Yang</span>, <span class="hlFld-ContribAuthor ">Michael A.  Brodney</span>, <span class="hlFld-ContribAuthor ">Travis T.  Wager</span>, <span class="hlFld-ContribAuthor ">Patrick R.  Verhoest</span>, and <span class="hlFld-ContribAuthor ">R. Scott  Obach</span>  . </span><span class="cited-content_cbyCitation_article-title">Late-Stage Microsomal Oxidation Reduces Drug–Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (2)
                                     , 68-72. <a href="https://doi.org/10.1021/acsmedchemlett.7b00343" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00343</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00343%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLate-Stage%252BMicrosomal%252BOxidation%252BReduces%252BDrug%2525E2%252580%252593Drug%252BInteraction%252Band%252BIdentifies%252BPhosphodiesterase%252B2A%252BInhibitor%252BPF-06815189%26aulast%3DStepan%26aufirst%3DAntonia%2BF.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D19082017%26date%3D03012018%26date%3D30012018%26date%3D08022018%26date%3D04012018%26volume%3D9%26issue%3D2%26spage%3D68%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satoshi  Mikami</span>, <span class="hlFld-ContribAuthor ">Shinji  Nakamura</span>, <span class="hlFld-ContribAuthor ">Tomoko  Ashizawa</span>, <span class="hlFld-ContribAuthor ">Izumi  Nomura</span>, <span class="hlFld-ContribAuthor ">Masanori  Kawasaki</span>, <span class="hlFld-ContribAuthor ">Shigekazu  Sasaki</span>, <span class="hlFld-ContribAuthor ">Hideyuki  Oki</span>, <span class="hlFld-ContribAuthor ">Hironori  Kokubo</span>, <span class="hlFld-ContribAuthor ">Isaac D.  Hoffman</span>, <span class="hlFld-ContribAuthor ">Hua  Zou</span>, <span class="hlFld-ContribAuthor ">Noriko  Uchiyama</span>, <span class="hlFld-ContribAuthor ">Kosuke  Nakashima</span>, <span class="hlFld-ContribAuthor ">Naomi  Kamiguchi</span>, <span class="hlFld-ContribAuthor ">Haruka  Imada</span>, <span class="hlFld-ContribAuthor ">Noriko  Suzuki</span>, <span class="hlFld-ContribAuthor ">Hiroki  Iwashita</span>, and <span class="hlFld-ContribAuthor ">Takahiko  Taniguchi</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (18)
                                     , 7677-7702. <a href="https://doi.org/10.1021/acs.jmedchem.7b00807" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00807%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BClinical%252BCandidate%252BN-%252528%2525281S%252529-1-%2525283-Fluoro-4-%252528trifluoromethoxy%252529phenyl%252529-2-methoxyethyl%252529-7-methoxy-2-oxo-2%25252C3-dihydropyrido%25255B2%25252C3-b%25255Dpyrazine-4%2525281H%252529-carboxamide%252B%252528TAK-915%252529%25253A%252BA%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BBrain-Penetrating%252BPhosphodiesterase%252B2A%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BCognitive%252BDisorders%26aulast%3DMikami%26aufirst%3DSatoshi%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D02062017%26date%3D05092017%26date%3D28092017%26date%3D10082017%26volume%3D60%26issue%3D18%26spage%3D7677%26epage%3D7702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Liu</span>, <span class="hlFld-ContribAuthor ">Hyejin  Kim</span>, <span class="hlFld-ContribAuthor ">Pingyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Doerte R.  Fricke</span>, <span class="hlFld-ContribAuthor ">Haiying  Chen</span>, <span class="hlFld-ContribAuthor ">Tianzhi  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Shen</span>, <span class="hlFld-ContribAuthor ">Jia  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Further lead optimization on Bax activators: Design, synthesis and pharmacological evaluation of 2-fluoro-fluorene derivatives for the treatment of breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>219 </em>, 113427. <a href="https://doi.org/10.1016/j.ejmech.2021.113427" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113427%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFurther%252Blead%252Boptimization%252Bon%252BBax%252Bactivators%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252B2-fluoro-fluorene%252Bderivatives%252Bfor%252Bthe%252Btreatment%252Bof%252Bbreast%252Bcancer%26aulast%3DLiu%26aufirst%3DGang%26date%3D2021%26volume%3D219%26spage%3D113427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mei-Yan  Jiang</span>, <span class="hlFld-ContribAuthor ">Chuan  Han</span>, <span class="hlFld-ContribAuthor ">Chen  Zhang</span>, <span class="hlFld-ContribAuthor ">Qian  Zhou</span>, <span class="hlFld-ContribAuthor ">Bei  Zhang</span>, <span class="hlFld-ContribAuthor ">Mei-Ling  Le</span>, <span class="hlFld-ContribAuthor ">Meng-Xing  Huang</span>, <span class="hlFld-ContribAuthor ">Yinuo  Wu</span>, <span class="hlFld-ContribAuthor ">Hai-Bin  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>41 </em>, 128016. <a href="https://doi.org/10.1016/j.bmcl.2021.128016" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128016%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Beffective%252Bphosphodiesterase%252B2%252Binhibitors%252Bwith%252Bantioxidant%252Bactivities%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DJiang%26aufirst%3DMei-Yan%26date%3D2021%26volume%3D41%26spage%3D128016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satoshi  Mikami</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Clinical Candidate TAK-915, a Highly Potent, Selective, and Brain Penetrating Novel Phosphodiesterase 2A Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Synthetic Organic Chemistry, Japan</span><span> <strong>2021,</strong> <em>79 </em>
                                    (6)
                                     , 581-591. <a href="https://doi.org/10.5059/yukigoseikyokaishi.79.581" title="DOI URL">https://doi.org/10.5059/yukigoseikyokaishi.79.581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5059/yukigoseikyokaishi.79.581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5059%2Fyukigoseikyokaishi.79.581%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Synthetic%2520Organic%2520Chemistry%252C%2520Japan%26atitle%3DDiscovery%252Bof%252BClinical%252BCandidate%252BTAK-915%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BBrain%252BPenetrating%252BNovel%252BPhosphodiesterase%252B2A%252BInhibitor%26aulast%3DMikami%26aufirst%3DSatoshi%26date%3D2021%26volume%3D79%26issue%3D6%26spage%3D581%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andres  Arias-Gómez</span>, <span class="hlFld-ContribAuthor ">Andrés  Godoy</span>, <span class="hlFld-ContribAuthor ">Jaime  Portilla</span>. </span><span class="cited-content_cbyCitation_article-title">Functional Pyrazolo[1,5-a]pyrimidines: Current Approaches in Synthetic Transformations and Uses as an Antitumor Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (9)
                                     , 2708. <a href="https://doi.org/10.3390/molecules26092708" title="DOI URL">https://doi.org/10.3390/molecules26092708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26092708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26092708%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DFunctional%252BPyrazolo%25255B1%25252C5-a%25255Dpyrimidines%25253A%252BCurrent%252BApproaches%252Bin%252BSynthetic%252BTransformations%252Band%252BUses%252Bas%252Ban%252BAntitumor%252BScaffold%26aulast%3DArias-G%25C3%25B3mez%26aufirst%3DAndres%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D9%26spage%3D2708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathalia Fonseca  Nadur</span>, <span class="hlFld-ContribAuthor ">Luciana Luiz  de Azevedo</span>, <span class="hlFld-ContribAuthor ">Lucas  Caruso</span>, <span class="hlFld-ContribAuthor ">Cedric Stephan  Graebin</span>, <span class="hlFld-ContribAuthor ">Renata Barbosa  Lacerda</span>, <span class="hlFld-ContribAuthor ">Arthur Eugen  Kümmerle</span>. </span><span class="cited-content_cbyCitation_article-title">The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113123. <a href="https://doi.org/10.1016/j.ejmech.2020.113123" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113123%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Blong%252Band%252Bwinding%252Broad%252Bof%252Bdesigning%252Bphosphodiesterase%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bheart%252Bfailure%26aulast%3DNadur%26aufirst%3DNathalia%2BFonseca%26date%3D2021%26volume%3D212%26spage%3D113123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia A.  Elkina</span>, <span class="hlFld-ContribAuthor ">Yanina V.  Burgart</span>, <span class="hlFld-ContribAuthor ">Evgeny V.  Shchegolkov</span>, <span class="hlFld-ContribAuthor ">Olga P.  Krasnykh</span>, <span class="hlFld-ContribAuthor ">Vera V.  Maslova</span>, <span class="hlFld-ContribAuthor ">Galina A.  Triandafilova</span>, <span class="hlFld-ContribAuthor ">Sergey S.  Solodnikov</span>, <span class="hlFld-ContribAuthor ">Anna A.  Muryleva</span>, <span class="hlFld-ContribAuthor ">Maria A.  Misiurina</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Slita</span>, <span class="hlFld-ContribAuthor ">Vladimir V.  Zarubaev</span>, <span class="hlFld-ContribAuthor ">Victor I.  Saloutin</span>. </span><span class="cited-content_cbyCitation_article-title">Competitive routes to cyclizations of polyfluoroalkyl-containing 2-tolylhydrazinylidene-1,3-diketones with 3-aminopyrazoles into bioactive pyrazoloazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2020,</strong> <em>240 </em>, 109648. <a href="https://doi.org/10.1016/j.jfluchem.2020.109648" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2020.109648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2020.109648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2020.109648%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DCompetitive%252Broutes%252Bto%252Bcyclizations%252Bof%252Bpolyfluoroalkyl-containing%252B2-tolylhydrazinylidene-1%25252C3-diketones%252Bwith%252B3-aminopyrazoles%252Binto%252Bbioactive%252Bpyrazoloazines%26aulast%3DElkina%26aufirst%3DNatalia%2BA.%26date%3D2020%26volume%3D240%26spage%3D109648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mirna S.  Sadek</span>, <span class="hlFld-ContribAuthor ">Eleder  Cachorro</span>, <span class="hlFld-ContribAuthor ">Ali  El-Armouche</span>, <span class="hlFld-ContribAuthor ">Susanne  Kämmerer</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (20)
                                     , 7462. <a href="https://doi.org/10.3390/ijms21207462" title="DOI URL">https://doi.org/10.3390/ijms21207462</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21207462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21207462%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTherapeutic%252BImplications%252Bfor%252BPDE2%252Band%252BcGMP%25252FcAMP%252BMediated%252BCrosstalk%252Bin%252BCardiovascular%252BDiseases%26aulast%3DSadek%26aufirst%3DMirna%2BS.%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D20%26spage%3D7462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ritawidya</span>, <span class="hlFld-ContribAuthor ">Wenzel</span>, <span class="hlFld-ContribAuthor ">Teodoro</span>, <span class="hlFld-ContribAuthor ">Toussaint</span>, <span class="hlFld-ContribAuthor ">Kranz</span>, <span class="hlFld-ContribAuthor ">Deuther-Conrad</span>, <span class="hlFld-ContribAuthor ">Dukic-Stefanovic</span>, <span class="hlFld-ContribAuthor ">Ludwig</span>, <span class="hlFld-ContribAuthor ">Scheunemann</span>, <span class="hlFld-ContribAuthor ">Brust</span>. </span><span class="cited-content_cbyCitation_article-title">Radiosynthesis and Biological Investigation of a Novel Fluorine-18 Labeled Benzoimidazotriazine- Based Radioligand for the Imaging of Phosphodiesterase 2A with Positron Emission Tomography. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (22)
                                     , 4149. <a href="https://doi.org/10.3390/molecules24224149" title="DOI URL">https://doi.org/10.3390/molecules24224149</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24224149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24224149%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DRadiosynthesis%252Band%252BBiological%252BInvestigation%252Bof%252Ba%252BNovel%252BFluorine-18%252BLabeled%252BBenzoimidazotriazine-%252BBased%252BRadioligand%252Bfor%252Bthe%252BImaging%252Bof%252BPhosphodiesterase%252B2A%252Bwith%252BPositron%252BEmission%252BTomography%26aulast%3DRitawidya%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D22%26spage%3D4149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">George S.  Baillie</span>, <span class="hlFld-ContribAuthor ">Gonzalo S.  Tejeda</span>, <span class="hlFld-ContribAuthor ">Michy P.  Kelly</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2019,</strong> <em>18 </em>
                                    (10)
                                     , 770-796. <a href="https://doi.org/10.1038/s41573-019-0033-4" title="DOI URL">https://doi.org/10.1038/s41573-019-0033-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-019-0033-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-019-0033-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DTherapeutic%252Btargeting%252Bof%252B3%2525E2%252580%2525B2%25252C5%2525E2%252580%2525B2-cyclic%252Bnucleotide%252Bphosphodiesterases%25253A%252Binhibition%252Band%252Bbeyond%26aulast%3DBaillie%26aufirst%3DGeorge%2BS.%26date%3D2019%26date%3D2019%26volume%3D18%26issue%3D10%26spage%3D770%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sven  Tobisch</span>. </span><span class="cited-content_cbyCitation_article-title">Copper hydride-mediated electrophilic amidation of vinylarenes with dioxazolones – a computational mechanistic study. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2019,</strong> <em>48 </em>
                                    (38)
                                     , 14337-14346. <a href="https://doi.org/10.1039/C9DT02540E" title="DOI URL">https://doi.org/10.1039/C9DT02540E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9DT02540E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9DT02540E%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DCopper%252Bhydride-mediated%252Belectrophilic%252Bamidation%252Bof%252Bvinylarenes%252Bwith%252Bdioxazolones%252B%2525E2%252580%252593%252Ba%252Bcomputational%252Bmechanistic%252Bstudy%26aulast%3DTobisch%26aufirst%3DSven%26date%3D2019%26date%3D2019%26volume%3D48%26issue%3D38%26spage%3D14337%26epage%3D14346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ankita  Mehta</span>, <span class="hlFld-ContribAuthor ">Bhoomika M.  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2019,</strong> <em>230 </em>, 150-161. <a href="https://doi.org/10.1016/j.lfs.2019.05.043" title="DOI URL">https://doi.org/10.1016/j.lfs.2019.05.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2019.05.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2019.05.043%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DTherapeutic%252Bopportunities%252Bin%252Bcolon%252Bcancer%25253A%252BFocus%252Bon%252Bphosphodiesterase%252Binhibitors%26aulast%3DMehta%26aufirst%3DAnkita%26date%3D2019%26volume%3D230%26spage%3D150%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ritawidya</span>, <span class="hlFld-ContribAuthor ">Ludwig</span>, <span class="hlFld-ContribAuthor ">Briel</span>, <span class="hlFld-ContribAuthor ">Brust</span>, <span class="hlFld-ContribAuthor ">Scheunemann</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and In Vitro Evaluation of 8-Pyridinyl-Substituted Benzo[e]imidazo[2,1-c][1,2,4]triazines as Phosphodiesterase 2A Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (15)
                                     , 2791. <a href="https://doi.org/10.3390/molecules24152791" title="DOI URL">https://doi.org/10.3390/molecules24152791</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24152791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24152791%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BIn%252BVitro%252BEvaluation%252Bof%252B8-Pyridinyl-Substituted%252BBenzo%25255Be%25255Dimidazo%25255B2%25252C1-c%25255D%25255B1%25252C2%25252C4%25255Dtriazines%252Bas%252BPhosphodiesterase%252B2A%252BInhibitors%26aulast%3DRitawidya%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D15%26spage%3D2791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  Maurin</span>, <span class="hlFld-ContribAuthor ">Francesca  Melancia</span>, <span class="hlFld-ContribAuthor ">Marielle  Jarjat</span>, <span class="hlFld-ContribAuthor ">Liliana  Castro</span>, <span class="hlFld-ContribAuthor ">Lara  Costa</span>, <span class="hlFld-ContribAuthor ">Sébastien  Delhaye</span>, <span class="hlFld-ContribAuthor ">Anouar  Khayachi</span>, <span class="hlFld-ContribAuthor ">Sara  Castagnola</span>, <span class="hlFld-ContribAuthor ">Elia  Mota</span>, <span class="hlFld-ContribAuthor ">Audrey  Di Giorgio</span>, <span class="hlFld-ContribAuthor ">Michela  Servadio</span>, <span class="hlFld-ContribAuthor ">Malgorzata  Drozd</span>, <span class="hlFld-ContribAuthor ">Gwénola  Poupon</span>, <span class="hlFld-ContribAuthor ">Sara  Schiavi</span>, <span class="hlFld-ContribAuthor ">Lara  Sardone</span>, <span class="hlFld-ContribAuthor ">Stéphane  Azoulay</span>, <span class="hlFld-ContribAuthor ">Lucia  Ciranna</span>, <span class="hlFld-ContribAuthor ">Stéphane  Martin</span>, <span class="hlFld-ContribAuthor ">Pierre  Vincent</span>, <span class="hlFld-ContribAuthor ">Viviana  Trezza</span>, <span class="hlFld-ContribAuthor ">Barbara  Bardoni</span>. </span><span class="cited-content_cbyCitation_article-title">Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome. </span><span class="cited-content_cbyCitation_journal-name">Cerebral Cortex</span><span> <strong>2019,</strong> <em>29 </em>
                                    (8)
                                     , 3241-3252. <a href="https://doi.org/10.1093/cercor/bhy192" title="DOI URL">https://doi.org/10.1093/cercor/bhy192</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/cercor/bhy192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fcercor%2Fbhy192%26sid%3Dliteratum%253Aachs%26jtitle%3DCerebral%2520Cortex%26atitle%3DInvolvement%252Bof%252BPhosphodiesterase%252B2A%252BActivity%252Bin%252Bthe%252BPathophysiology%252Bof%252BFragile%252BX%252BSyndrome%26aulast%3DMaurin%26aufirst%3DThomas%26date%3D2019%26date%3D2018%26volume%3D29%26issue%3D8%26spage%3D3241%26epage%3D3252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maguie  El Boustani</span>, <span class="hlFld-ContribAuthor ">Lucia  De Stefano</span>, <span class="hlFld-ContribAuthor ">Isabella  Caligiuri</span>, <span class="hlFld-ContribAuthor ">Nayla  Mouawad</span>, <span class="hlFld-ContribAuthor ">Carlotta  Granchi</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Canzonieri</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Antonio  Giordano</span>, <span class="hlFld-ContribAuthor ">Flavio  Rizzolio</span>. </span><span class="cited-content_cbyCitation_article-title">A Guide to PIN1 Function and Mutations Across Cancers. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2019,</strong> <em>9 </em><a href="https://doi.org/10.3389/fphar.2018.01477" title="DOI URL">https://doi.org/10.3389/fphar.2018.01477</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2018.01477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2018.01477%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DA%252BGuide%252Bto%252BPIN1%252BFunction%252Band%252BMutations%252BAcross%252BCancers%26aulast%3DEl%2BBoustani%26aufirst%3DMaguie%26date%3D2019%26date%3D2019%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yujing  Zhou</span>, <span class="hlFld-ContribAuthor ">Oliver D.  Engl</span>, <span class="hlFld-ContribAuthor ">Jeffrey S.  Bandar</span>, <span class="hlFld-ContribAuthor ">Emma D.  Chant</span>, <span class="hlFld-ContribAuthor ">Stephen L.  Buchwald</span>. </span><span class="cited-content_cbyCitation_article-title">CuH‐Catalyzed Asymmetric Hydroamidation of Vinylarenes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (22)
                                     , 6782-6785. <a href="https://doi.org/10.1002/ange.201802797" title="DOI URL">https://doi.org/10.1002/ange.201802797</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201802797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201802797%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DCuH%2525E2%252580%252590Catalyzed%252BAsymmetric%252BHydroamidation%252Bof%252BVinylarenes%26aulast%3DZhou%26aufirst%3DYujing%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D22%26spage%3D6782%26epage%3D6785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yujing  Zhou</span>, <span class="hlFld-ContribAuthor ">Oliver D.  Engl</span>, <span class="hlFld-ContribAuthor ">Jeffrey S.  Bandar</span>, <span class="hlFld-ContribAuthor ">Emma D.  Chant</span>, <span class="hlFld-ContribAuthor ">Stephen L.  Buchwald</span>. </span><span class="cited-content_cbyCitation_article-title">CuH‐Catalyzed Asymmetric Hydroamidation of Vinylarenes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (22)
                                     , 6672-6675. <a href="https://doi.org/10.1002/anie.201802797" title="DOI URL">https://doi.org/10.1002/anie.201802797</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201802797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201802797%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DCuH%2525E2%252580%252590Catalyzed%252BAsymmetric%252BHydroamidation%252Bof%252BVinylarenes%26aulast%3DZhou%26aufirst%3DYujing%26date%3D2018%26volume%3D57%26issue%3D22%26spage%3D6672%26epage%3D6675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satoshi  Mikami</span>, <span class="hlFld-ContribAuthor ">Masanori  Kawasaki</span>, <span class="hlFld-ContribAuthor ">Shuhei  Ikeda</span>, <span class="hlFld-ContribAuthor ">Nobuyuki  Negoro</span>, <span class="hlFld-ContribAuthor ">Shinji  Nakamura</span>, <span class="hlFld-ContribAuthor ">Izumi  Nomura</span>, <span class="hlFld-ContribAuthor ">Tomoko  Ashizawa</span>, <span class="hlFld-ContribAuthor ">Hironori  Kokubo</span>, <span class="hlFld-ContribAuthor ">Isaac Dylan  Hoffman</span>, <span class="hlFld-ContribAuthor ">Hua  Zou</span>, <span class="hlFld-ContribAuthor ">Hideyuki  Oki</span>, <span class="hlFld-ContribAuthor ">Noriko  Uchiyama</span>, <span class="hlFld-ContribAuthor ">Yuuto  Hiura</span>, <span class="hlFld-ContribAuthor ">Maki  Miyamoto</span>, <span class="hlFld-ContribAuthor ">Yuuki  Itou</span>, <span class="hlFld-ContribAuthor ">Masato  Nakashima</span>, <span class="hlFld-ContribAuthor ">Hiroki  Iwashita</span>, <span class="hlFld-ContribAuthor ">Takahiko  Taniguchi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders. </span><span class="cited-content_cbyCitation_journal-name">CHEMICAL & PHARMACEUTICAL BULLETIN</span><span> <strong>2017,</strong> <em>65 </em>
                                    (11)
                                     , 1058-1077. <a href="https://doi.org/10.1248/cpb.c17-00564" title="DOI URL">https://doi.org/10.1248/cpb.c17-00564</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c17-00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c17-00564%26sid%3Dliteratum%253Aachs%26jtitle%3DCHEMICAL%2520%2526%2520PHARMACEUTICAL%2520BULLETIN%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BSeries%252Bof%252BPyrazolo%25255B1%25252C5-a%25255Dpyrimidine-Based%252BPhosphodiesterase%252B2A%252BInhibitors%252BStructurally%252BDifferent%252Bfrom%252BN-%252528%2525281S%252529-1-%2525283-Fluoro-4-%252528trifluoromethoxy%252529phenyl%252529-2-methoxyethyl%252529-7-methoxy-2-oxo-2%25252C3-dihydropyrido%25255B2%25252C3-b%25255Dpyrazine-4%2525281H%252529-carboxamide%252B%252528TAK-915%252529%25252C%252Bfor%252Bthe%252BTreatment%252Bof%252BCognitive%252BDisorders%26aulast%3DMikami%26aufirst%3DSatoshi%26date%3D2017%26volume%3D65%26issue%3D11%26spage%3D1058%26epage%3D1077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0001.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selected examples of currently approved PDE inhibitors <b>1</b>–<b>13</b>. Of these, the PDE3 inhibitors milrinone, olprinone, and cilostazol have been approved for the short-term treatment of congestive heart failure<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and the treatment of intermittent claudication,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> respectively. The PDE4 inhibitor roflumilast has entered the market as an oral treatment for reducing the risk of exacerbations in patients with COPD who also have chronic bronchitis.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a> Another PDE4 inhibitors apremilast and crisaborole have been approved for the treatment of psoriasis and psoriatic arthritis<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and the treatment of atopic dermatitis,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> respectively. The PDE5 inhibitors sildenafil, tadalafil, vardenafil, avanafil, udenafil, mirodenafil, and lodenafil are now marketed for the treatment of erectile dysfunction.<a onclick="showRef(event, 'ref5 ref13'); return false;" href="javascript:void(0);" class="ref ref5 ref13">(5, 13)</a> Sildenafil and tadalafil have also been approved as treatments for PAH;<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> moreover, the latter has also been used clinically for the treatment of benign prostatic hyperplasia.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative structures and profiles of reported selective PDE2A inhibitors <b>14</b>–<b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Structure and profile of pyrazolo[1,5-<i>a</i>]pyrimidine hit <b>18</b> from a high-throughput screen. The intramolecular hydrogen bond is indicated in red. (B) SAR approach.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of the amide linker connecting the pyrazolo[1,5-<i>a</i>]pyrimidine core and <i>p</i>-methoxyphenyl moiety on PDE2A inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Analogue designed to test the involvement of intramolecular hydrogen bonding in PDE2A inhibitory activity. The intramolecular hydrogen bond is depicted as a red arc in compound <b>18</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0006.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray crystal structure of <b>38a</b> bound in the PDE2A catalytic site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XKM">5XKM</a>) viewed from the top (A) and the entrance of the catalytic site (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0007.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Increase in mouse brain cGMP (A) and cAMP (B) levels 30 min after oral administration of compound <b>38a</b> at 10, 30, and 100 mg/kg to ICR mice. The prefrontal cortex (PFC), striatum (STR), and hippocampus (HIP) were isolated after microwave irradiation. Data are presented as mean + SEM (<i>n</i> = 7–8); #<i>p</i> < 0.025, ## <i>p</i> < 0.005, ### <i>p</i> < 0.0005 vs vehicle by Williams’ test or Shirley–Williams’ test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Substituted Pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxylic Acids <b>44a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>41a</b> or <b>41b</b>, AcOH, 70–90 °C, 0.5–16 h, 69–87% (for <b>42a</b> and <b>42b</b>); <b>41c</b>, toluene, 100 °C, 16 h, 68% (for <b>42c</b>). (b) 1 or 2 M NaOH aq, MeOH, THF, 50–60 °C, 3 h–overnight, 80–87% (for <b>44a</b>–<b>c</b>). (c) 2 M NaOH aq, EtOH, reflux, 20 h, (taken on crude) (for <b>43a</b>). (d) <b>41d</b> or <b>41e</b> or <b>41f</b>, EtOH, AcOH, 80–100 °C, 1.5–2 h, 68% (for <b>44d</b>), 64% (2 steps from <b>40</b>) (for <b>44e</b>), 75% (for <b>44f</b>).</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of RHS Benzylamine Moieties <b>48</b>, <b>50a</b>, <b>50b</b>, <b>51a</b>, and <b>51b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) oxalyl chloride, cat. DMF, THF, rt, 4 h, then <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride, Et<sub>3</sub>N, DMA, rt, 16 h, 30%. (b) EtMgBr, THF, 0 °C, 2 h, 86%. (c) MeNH<sub>2</sub>, Ti(O<i>i</i>-Pr)<sub>4</sub>, MeOH, rt, 5 h, then NaBH<sub>4</sub>, rt, overnight, 25%. (d) hydroxylammonium chloride, Et<sub>3</sub>N, EtOH, 80 °C, 3–4 h, (taken on crude). (e) H<sub>2</sub>, 10% Pd/C, MeOH or EtOH, rt, overnight, 66–95%. (f) HCl, Et<sub>2</sub>O, EtOAc, rt, 67–91% (2 steps from <b>49a</b>,<b>b</b>).</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives <b>18</b>–<b>23</b>, <b>27</b>, <b>29</b>, and <b>31</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) EDCI·HCl, HOBt·H<sub>2</sub>O, Et<sub>3</sub>N or none, DMF, rt, 2 h–4 days, 44–98%. (b) EDCI, HOBt, DIEA, DMF, rt, overnight, 28–84%. (c) HATU, DIEA, DMF, rt, overnight, 52%. (d) Chiralpak AD, 100% EtOH.</p></p></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives <b>24</b> and <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) cyclopropylboronic acid, Pd(OAc)<sub>2</sub>, Cy<sub>3</sub>P, KO<i>t</i>-Bu, toluene, 100 °C, 16 h, 10% (for <b>24</b>); phenylboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, water, 150 °C (microwave), 20 min, 77% (for <b>25</b>).</p></p></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0012.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives <b>26</b> and <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) POCl<sub>3</sub>, DMF, 0 °C to rt, 3 h, 82%. (b) <b>51a</b>, NaBH(OAc)<sub>3</sub>, AcOH, Et<sub>3</sub>N, CH<sub>3</sub>CN, rt, overnight, 88%. (c) chlorosulfonic acid, 80 °C, 2 h, 26%. (d) <b>51a</b>, DIEA, CH<sub>3</sub>CN, rt, overnight, 97%.</p></p></figure><figure data-id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/medium/jm-2017-007093_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0013.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of 4,5-Dihydro-3<i>H</i>-pyrazolo[4,5,1-<i>ij</i>][1,6]naphthyridin-3-one Derivative <b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-18/acs.jmedchem.7b00709/20170922/images/large/jm-2017-007093_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00709&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) hydroxylamine-<i>O</i>-sulfonic acid, NaHCO<sub>3</sub>, water, MeOH, 0–50 °C, 16 h, then methyl propiolate, K<sub>2</sub>CO<sub>3</sub>, 0 °C to rt, 2 h, 29%. (b) 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1<i>H</i>)-one (Dess–Martin periodinane), CH<sub>3</sub>CN, 0 °C to rt, 2.5 h, (taken on crude). (c) <b>50a</b>, NaBH(OAc)<sub>3</sub>, AcOH, CH<sub>3</sub>CN, 0 °C to rt, 16 h, 79%. (d) 1 M NaOH aq, MeOH, THF, 70 °C, 2 h, 94%. (e) EDCI·HCl, HOBt·H<sub>2</sub>O, DMF, rt, 16 h, 85%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38012" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38012" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Tresguerres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buck, J.</span><span> </span><span class="NLM_article-title">Intracellular cAMP Signaling by Soluble Adenylyl Cyclase</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">1277</span><span class="NLM_x">–</span> <span class="NLM_lpage">1288</span><span class="refDoi"> DOI: 10.1038/ki.2011.95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1038%2Fki.2011.95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=21490586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFyjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=1277-1288&author=M.+Tresguerresauthor=L.+R.+Levinauthor=J.+Buck&title=Intracellular+cAMP+Signaling+by+Soluble+Adenylyl+Cyclase&doi=10.1038%2Fki.2011.95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular cAMP signaling by soluble adenylyl cyclase</span></div><div class="casAuthors">Tresguerres, Martin; Levin, Lonny R.; Buck, Jochen</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1277-1288</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sol. adenylyl cyclase (sAC) is a recently identified source of the ubiquitous second messenger cyclic adenosine 3',5' monophosphate (cAMP). sAC is distinct from the more widely studied source of cAMP, the transmembrane adenylyl cyclases (tmACs); its activity is uniquely regulated by bicarbonate anions, and it is distributed throughout the cytoplasm and in cellular organelles.  Due to its unique localization and regulation, sAC has various functions in a variety of physiol. systems that are distinct from tmACs.  In this review, we detail the known functions of sAC, and we reassess commonly held views of cAMP signaling inside cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyDPAutHDsDLVg90H21EOLACvtfcHk0lj9dcmiRMMq9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFyjsr0%253D&md5=a14f78b3036a5c704c9ff12209bbe92e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fki.2011.95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2011.95%26sid%3Dliteratum%253Aachs%26aulast%3DTresguerres%26aufirst%3DM.%26aulast%3DLevin%26aufirst%3DL.%2BR.%26aulast%3DBuck%26aufirst%3DJ.%26atitle%3DIntracellular%2520cAMP%2520Signaling%2520by%2520Soluble%2520Adenylyl%2520Cyclase%26jtitle%3DKidney%2520Int.%26date%3D2011%26volume%3D79%26spage%3D1277%26epage%3D1288%26doi%3D10.1038%2Fki.2011.95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lucas, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitari, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazerounian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Stewart, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chepenik, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, S. A.</span><span> </span><span class="NLM_article-title">Guanylyl Cyclases and Signaling by Cyclic GMP</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">413</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10977868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2000&pages=375-413&author=K.+A.+Lucasauthor=G.+M.+Pitariauthor=S.+Kazerounianauthor=I.+Ruiz-Stewartauthor=J.+Parkauthor=S.+Schulzauthor=K.+P.+Chepenikauthor=S.+A.+Waldman&title=Guanylyl+Cyclases+and+Signaling+by+Cyclic+GMP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Guanylyl cyclases and signaling by cyclic GMP</span></div><div class="casAuthors">Lucas, Kimberly A.; Pitari, Giovanni M.; Kazerounian, Shiva; Ruiz-Stewart, Inez; Park, Jason; Schulz, Stephanie; Chepenik, Kenneth P.; Waldman, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-413</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review with 393 refs.  Guanylyl cyclases are a family of enzymes that catalyze the conversion of GTP to cGMP.  The family comprises both membrane-bound and sol. isoforms that are expressed in nearly all cell types.  They are regulated by diverse extracellular agonists that include peptide hormones, bacterial toxins, and free radicals, as well as intracellular mols., such as Ca2+ and adenine nucleotides.  Stimulation of guanylyl cyclases and the resultant accumulation of cGMP regulates complex signaling cascades through immediate downstream effectors, including cGMP-dependent protein kinases, cGMP-regulated phosphodiesterases, and cyclic nucleotide-gated ion channels.  Guanylyl cyclases and cGMP-mediated signaling cascades play a central role in the regulation of diverse (patho)physiol. processes, including vascular smooth muscle motility, intestinal fluid and electrolyte homeostasis, and retinal phototransduction.  Topics addressed in this review include the structure and chromosomal localization of the genes for guanylyl cyclases, structure and function of the members of the guanylyl cyclase family, mol. mechanisms regulating enzymic activity, and mol. sequences coupling ligand binding to catalytic activity.  A brief overview is presented of the downstream events controlled by guanylyl cyclases, including the effectors that are regulated by cGMP and the role that guanylyl cyclases play in cell physiol. and pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHStLFSGOzzbVg90H21EOLACvtfcHk0lj9dcmiRMMq9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFCmsbg%253D&md5=0694e83a91440f3fff3c0a2312682b15</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DK.%2BA.%26aulast%3DPitari%26aufirst%3DG.%2BM.%26aulast%3DKazerounian%26aufirst%3DS.%26aulast%3DRuiz-Stewart%26aufirst%3DI.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DChepenik%26aufirst%3DK.%2BP.%26aulast%3DWaldman%26aufirst%3DS.%2BA.%26atitle%3DGuanylyl%2520Cyclases%2520and%2520Signaling%2520by%2520Cyclic%2520GMP%26jtitle%3DPharmacol.%2520Rev.%26date%3D2000%26volume%3D52%26spage%3D375%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Bender, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beavo, J. A.</span><span> </span><span class="NLM_article-title">Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">488</span><span class="NLM_x">–</span> <span class="NLM_lpage">520</span><span class="refDoi"> DOI: 10.1124/pr.58.3.5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1124%2Fpr.58.3.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=16968949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=488-520&author=A.+T.+Benderauthor=J.+A.+Beavo&title=Cyclic+Nucleotide+Phosphodiesterases%3A+Molecular+Regulation+to+Clinical+Use&doi=10.1124%2Fpr.58.3.5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use</span></div><div class="casAuthors">Bender, Andrew T.; Beavo, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-520</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that regulate the cellular levels of the second messengers, cAMP and cGMP, by controlling their rates of degrdn.  There are 11 different PDE families, with each family typically having several different isoforms and splice variants.  These unique PDEs differ in their three-dimensional structure, kinetic properties, modes of regulation, intracellular localization, cellular expression, and inhibitor sensitivities.  Current data suggest that individual isoenzymes modulate distinct regulatory pathways in the cell.  These properties therefore offer the opportunity for selectively targeting specific PDEs for treatment of specific disease states.  The feasibility of these enzymes as drug targets is exemplified by the com. and clin. successes of the erectile dysfunction drugs, sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra).  PDE inhibitors are also currently available or in development for treatment of a variety of other pathol. conditions.  In this review the basic biochem. properties, cellular regulation, expression patterns, and physiol. functions of the different PDE isoforms will be discussed.  How these properties relate to the current and future development of PDE inhibitors as pharmacol. agents is esp. considered.  PDEs hold great promise as drug targets and recent research advances make this an exciting time for the field of PDE research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJl4RDiZ0ugrVg90H21EOLACvtfcHk0lj9dcmiRMMq9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfI&md5=af31cf6952efe7adb428a951779f36bc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fpr.58.3.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.58.3.5%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DBeavo%26aufirst%3DJ.%2BA.%26atitle%3DCyclic%2520Nucleotide%2520Phosphodiesterases%253A%2520Molecular%2520Regulation%2520to%2520Clinical%2520Use%26jtitle%3DPharmacol.%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D488%26epage%3D520%26doi%3D10.1124%2Fpr.58.3.5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Beavo, J. A.</span><span> </span><span class="NLM_article-title">Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms</span> <span class="citation_source-journal">Physiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1995&pages=725-748&author=J.+A.+Beavo&title=Cyclic+Nucleotide+Phosphodiesterases%3A+Functional+Implications+of+Multiple+Isoforms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeavo%26aufirst%3DJ.%2BA.%26atitle%3DCyclic%2520Nucleotide%2520Phosphodiesterases%253A%2520Functional%2520Implications%2520of%2520Multiple%2520Isoforms%26jtitle%3DPhysiol.%2520Rev.%26date%3D1995%26volume%3D75%26spage%3D725%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Maurice, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manganiello, V. C.</span><span> </span><span class="NLM_article-title">Advances in Targeting Cyclic Nucleotide Phosphodiesterases</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">290</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span><span class="refDoi"> DOI: 10.1038/nrd4228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1038%2Fnrd4228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=24687066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=290-314&author=D.+H.+Mauriceauthor=H.+Keauthor=F.+Ahmadauthor=Y.+Wangauthor=J.+Chungauthor=V.+C.+Manganiello&title=Advances+in+Targeting+Cyclic+Nucleotide+Phosphodiesterases&doi=10.1038%2Fnrd4228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in targeting cyclic nucleotide phosphodiesterases</span></div><div class="casAuthors">Maurice, Donald H.; Ke, Hengming; Ahmad, Faiyaz; Wang, Yousheng; Chung, Jay; Manganiello, Vincent C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">290-314</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cyclic GMP, thereby regulating the intracellular concns. of these cyclic nucleotides, their signalling pathways and, consequently, myriad biol. responses in health and disease.  Currently, a small no. of PDE inhibitors are used clin. for treating the pathophysiol. dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease.  However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMRfUs-zUmLVg90H21EOLACvtfcHk0lgszYrNiOpSWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D&md5=410c8d5bb5fbd7d2906e30dc1b5f2876</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd4228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4228%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DD.%2BH.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DManganiello%26aufirst%3DV.%2BC.%26atitle%3DAdvances%2520in%2520Targeting%2520Cyclic%2520Nucleotide%2520Phosphodiesterases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D290%26epage%3D314%26doi%3D10.1038%2Fnrd4228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Packer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carver, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodeheffer, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanhoe, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiBianco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeldis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrix, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bommer, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkayam, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukin, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallis, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sollano, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tandon, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMets, D. L.</span><span> </span><span class="NLM_article-title">Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">325</span><span class="NLM_x">, </span> <span class="NLM_fpage">1468</span><span class="NLM_x">–</span> <span class="NLM_lpage">1475</span><span class="refDoi"> DOI: 10.1056/NEJM199111213252103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1056%2FNEJM199111213252103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1944425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A280%3ADyaK38%252FkvFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=1991&pages=1468-1475&author=M.+Packerauthor=J.+R.+Carverauthor=R.+J.+Rodehefferauthor=R.+J.+Ivanhoeauthor=R.+DiBiancoauthor=S.+M.+Zeldisauthor=G.+H.+Hendrixauthor=W.+J.+Bommerauthor=U.+Elkayamauthor=M.+L.+Kukinauthor=G.+I.+Mallisauthor=J.+A.+Sollanoauthor=J.+Shannonauthor=P.+K.+Tandonauthor=D.+L.+DeMets&title=Effect+of+Oral+Milrinone+on+Mortality+in+Severe+Chronic+Heart+Failure&doi=10.1056%2FNEJM199111213252103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group</span></div><div class="casAuthors">Packer M; Carver J R; Rodeheffer R J; Ivanhoe R J; DiBianco R; Zeldis S M; Hendrix G H; Bommer W J; Elkayam U; Kukin M L</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1468-75</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Milrinone, a phosphodiesterase inhibitor, enhances cardiac contractility by increasing intracellular levels of cyclic AMP, but the long-term effect of this type of positive inotropic agent on the survival of patients with chronic heart failure has not been determined.  METHODS:  We randomly assigned 1,088 patients with severe chronic heart failure (New York Heart Association class III or IV) and advanced left ventricular dysfunction to double-blind treatment with (40 mg of oral milrinone daily (561 patients) or placebo (527 patients).  In addition, all patients received conventional therapy with digoxin, diuretics, and a converting-enzyme inhibitor throughout the trial.  The median period of follow-up was 6.1 months (range, 1 day to 20 months).  RESULTS:  As compared with placebo, milrinone therapy was associated with a 28 percent increase in mortality from all causes (95 percent confidence interval, 1 to 61 percent; P = 0.038) and a 34 percent increase in cardiovascular mortality (95 percent confidence interval, 6 to 69 percent; P = 0.016).  The adverse effect of milrinone was greatest in patients with the most severe symptoms (New York Heart Association class IV), who had a 53 percent increase in mortality (95 percent confidence interval, 13 to 107 percent; P = 0.006).  Milrinone did not have a beneficial effect on the survival of any subgroup.  Patients treated with milrinone had more hospitalizations (44 vs. 39 percent, P = 0.041), were withdrawn from double-blind therapy more frequently (12.7 vs. 8.7 percent, P = 0.041), and had serious adverse cardiovascular reactions, including hypotension (P = 0.006) and syncope (P = 0.002), more often than the patients given placebo.  CONCLUSIONS:  Our findings indicate that despite its beneficial hemodynamic actions, long-term therapy with oral milrinone increases the morbidity and mortality of patients with severe chronic heart failure.  The mechanism by which the drug exerts its deleterious effects is unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGSjQUFbf_0_6AExegM5LLfW6udTcc2eZfELCdOgW2Xrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252FkvFGlsQ%253D%253D&md5=e43d8fc27d240be714ba780e5efd4b28</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJM199111213252103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199111213252103%26sid%3Dliteratum%253Aachs%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DCarver%26aufirst%3DJ.%2BR.%26aulast%3DRodeheffer%26aufirst%3DR.%2BJ.%26aulast%3DIvanhoe%26aufirst%3DR.%2BJ.%26aulast%3DDiBianco%26aufirst%3DR.%26aulast%3DZeldis%26aufirst%3DS.%2BM.%26aulast%3DHendrix%26aufirst%3DG.%2BH.%26aulast%3DBommer%26aufirst%3DW.%2BJ.%26aulast%3DElkayam%26aufirst%3DU.%26aulast%3DKukin%26aufirst%3DM.%2BL.%26aulast%3DMallis%26aufirst%3DG.%2BI.%26aulast%3DSollano%26aufirst%3DJ.%2BA.%26aulast%3DShannon%26aufirst%3DJ.%26aulast%3DTandon%26aufirst%3DP.%2BK.%26aulast%3DDeMets%26aufirst%3DD.%2BL.%26atitle%3DEffect%2520of%2520Oral%2520Milrinone%2520on%2520Mortality%2520in%2520Severe%2520Chronic%2520Heart%2520Failure%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1991%26volume%3D325%26spage%3D1468%26epage%3D1475%26doi%3D10.1056%2FNEJM199111213252103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kanlop, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chattipakorn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chattipakorn, N.</span><span> </span><span class="NLM_article-title">Effects of Cilostazol in the Heart</span> <span class="citation_source-journal">J. Cardiovasc. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.2459/JCM.0b013e3283439746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.2459%2FJCM.0b013e3283439746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A280%3ADC%252BC3M7gvVKntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=88-95&author=N.+Kanlopauthor=S.+Chattipakornauthor=N.+Chattipakorn&title=Effects+of+Cilostazol+in+the+Heart&doi=10.2459%2FJCM.0b013e3283439746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of cilostazol in the heart</span></div><div class="casAuthors">Kanlop Natnicha; Chattipakorn Siriporn; Chattipakorn Nipon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cardiovascular medicine (Hagerstown, Md.)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cilostazol is a selective phosphodiesterase 3 (PDE3) inhibitor approved by the Food and Drug Administration for treatment of intermittent claudication.  It has also been used in bradyarrhythmic patients to increase heart rates.  Recently, cilostazol has been shown to prevent ventricular fibrillation in patients with Brugada syndrome.  Cilostazol is hypothesized to suppress transient outward potassium (Ito) current and increase inward calcium current, thus, maintaining the dome (phase 2) of action potential, decreasing transmural dispersion of repolarization and preventing ventricular fibrillation.  Although many PDE3 inhibitors have been shown to increase cardiac arrhythmia in heart failure, cilostazol has presented effects that are different from other PDE3 inhibitors, especially adenosine uptake inhibition.  Owing to this effect, cilostazol could be an effective cardioprotective drug, with its beneficial effects in preventing arrhythmia.  In this review, the cardiac electrophysiological effects of cilostazol are presented and its possible cardioprotective effects, particularly in preventing ventricular fibrillation, are discussed, with emphasis on the need to further verify its clinical benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxeNJlN3c-uIxhnOQkIHOxfW6udTcc2eZfELCdOgW2Xrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7gvVKntQ%253D%253D&md5=be5f8e4ae942dd783b41e716eae76f4c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2459%2FJCM.0b013e3283439746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2459%252FJCM.0b013e3283439746%26sid%3Dliteratum%253Aachs%26aulast%3DKanlop%26aufirst%3DN.%26aulast%3DChattipakorn%26aufirst%3DS.%26aulast%3DChattipakorn%26aufirst%3DN.%26atitle%3DEffects%2520of%2520Cilostazol%2520in%2520the%2520Heart%26jtitle%3DJ.%2520Cardiovasc.%2520Med.%26date%3D2011%26volume%3D12%26spage%3D88%26epage%3D95%26doi%3D10.2459%2FJCM.0b013e3283439746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Rabe, K. F.</span><span> </span><span class="NLM_article-title">Update on Roflumilast, a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1111%2Fj.1476-5381.2011.01218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=21232047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=53-67&author=K.+F.+Rabe&title=Update+on+Roflumilast%2C+a+Phosphodiesterase+4+Inhibitor+for+the+Treatment+of+Chronic+Obstructive+Pulmonary+Disease&doi=10.1111%2Fj.1476-5381.2011.01218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rabe, Klaus F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-67</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main PDE isoenzyme occurring in cells involved in inflammatory airway disease such as chronic obstructive pulmonary disease (COPD).  COPD is a preventable and treatable disease and is characterized by airflow obstruction that is not fully reversible.  Chronic progressive symptoms, particularly dyspnea, chronic bronchitis and impaired overall health are worse in those who have frequent, acute episodes of symptom exacerbation.  Although several exptl. PDE4 inhibitors are in clin. development, roflumilast, a highly selective PDE4 inhibitor, is the first in its class to be licensed, and has recently been approved in several countries for oral, once-daily treatment of severe COPD.  Clin. trials have demonstrated that roflumilast improves lung function and reduces exacerbation frequency in COPD.  Furthermore, its unique mode of action may offer the potential to target the inflammatory processes underlying COPD.  Roflumilast is effective when used concomitantly with all forms of bronchodilator and even in patients treated with inhaled corticosteroids.  Roflumilast thus represents an important addn. to current therapeutic options for COPD patients with chronic bronchitis, including those who remain symptomatic despite treatment.  This article reviews the current status of PDE4 inhibitors, focusing on the pharmacokinetics, efficacy and safety of roflumilast.  In particular, it provides an overview of the effects of roflumilast on lung function and exacerbations, glucose homoeostasis and wt. loss, and the concomitant use of long-acting beta2-adrenergic receptor agonists and short-acting muscarinic receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryBUcu0ToPGrVg90H21EOLACvtfcHk0ljUVg2E6m2ApQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D&md5=c6ac3310e2d9ff1c7de86aecbd1356bb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01218.x%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DUpdate%2520on%2520Roflumilast%252C%2520a%2520Phosphodiesterase%25204%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D53%26epage%3D67%26doi%3D10.1111%2Fj.1476-5381.2011.01218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Tenor, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatzelmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beume, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethke, T. D.</span><span> </span><span class="NLM_article-title">Pharmacology, Clinical Efficacy, and Tolerability of Phosphodiesterase-4 Inhibitors: Impact of Human Pharmacokinetics</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span><span class="refDoi"> DOI: 10.1007/978-3-642-17969-3_3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1007%2F978-3-642-17969-3_3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2011&pages=85-119&author=H.+Tenorauthor=A.+Hatzelmannauthor=R.+Beumeauthor=G.+Lahuauthor=K.+Zechauthor=T.+D.+Bethke&title=Pharmacology%2C+Clinical+Efficacy%2C+and+Tolerability+of+Phosphodiesterase-4+Inhibitors%3A+Impact+of+Human+Pharmacokinetics&doi=10.1007%2F978-3-642-17969-3_3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitirors: impact of human pharmacokinetics</span></div><div class="casAuthors">Tenor, Hermann; Hatzelmann, Armin; Beume, Rolf; Lahu, Gezim; Zech, Karl; Bethke, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">Phosphodiesterases as Drug Targets</span>),
    <span class="NLM_cas:pages">85-119</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Since more than two decades anti-inflammatory effects of inhibitors of phosphodiesterase-4 have been described in numerous cellular and animal studies and were finally confirmed in clin. trials.  The path from an early, pioneering study with Ro20-1724 showing redn. of psoriatic plaque size in 1979 to modern PDE4 inhibitors such as oral apremilast in development for psoriasis, the inhaled PDE4 inhibitor GSK256066 in development for asthma and COPD and finally roflumilast, the first PDE4 inhibitor approved and currently marketed as an oral, once-daily remedy for severe COPD was marked by large progress in chem. optimization based on improved understanding of PDE4 biol. and drug-like properties detg. the appropriate pharmacokinetic profile.  In this chapter aspects of the pharmacol. and clin. efficacy of PDE4 inhibitors, which have been in clin. development over the years are summarized with specific emphasis on their clin. pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZJeyCYZnL-LVg90H21EOLACvtfcHk0ljUVg2E6m2ApQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChsLnJ&md5=f138b847bfa54d92569f2d7e2f791973</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-17969-3_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-17969-3_3%26sid%3Dliteratum%253Aachs%26aulast%3DTenor%26aufirst%3DH.%26aulast%3DHatzelmann%26aufirst%3DA.%26aulast%3DBeume%26aufirst%3DR.%26aulast%3DLahu%26aufirst%3DG.%26aulast%3DZech%26aufirst%3DK.%26aulast%3DBethke%26aufirst%3DT.%2BD.%26atitle%3DPharmacology%252C%2520Clinical%2520Efficacy%252C%2520and%2520Tolerability%2520of%2520Phosphodiesterase-4%2520Inhibitors%253A%2520Impact%2520of%2520Human%2520Pharmacokinetics%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2011%26volume%3D204%26spage%3D85%26epage%3D119%26doi%3D10.1007%2F978-3-642-17969-3_3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Fabbri, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izquierdo-Alonso, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bundschuh, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabe, K. F.</span><span> </span><span class="NLM_article-title">Roflumilast in Moderate-to-Severe Chronic Obstructive Pulmonary Disease Treated with Longacting Bronchodilators: Two Randomised Clinical Trials</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">703</span><span class="refDoi"> DOI: 10.1016/S0140-6736(09)61252-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2FS0140-6736%2809%2961252-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2009&pages=695-703&author=L.+M.+Fabbriauthor=P.+M.+Calverleyauthor=J.+L.+Izquierdo-Alonsoauthor=D.+S.+Bundschuhauthor=M.+Broseauthor=F.+J.+Martinezauthor=K.+F.+Rabe&title=Roflumilast+in+Moderate-to-Severe+Chronic+Obstructive+Pulmonary+Disease+Treated+with+Longacting+Bronchodilators%3A+Two+Randomised+Clinical+Trials&doi=10.1016%2FS0140-6736%2809%2961252-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2961252-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252961252-6%26sid%3Dliteratum%253Aachs%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26aulast%3DIzquierdo-Alonso%26aufirst%3DJ.%2BL.%26aulast%3DBundschuh%26aufirst%3DD.%2BS.%26aulast%3DBrose%26aufirst%3DM.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DRoflumilast%2520in%2520Moderate-to-Severe%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%2520Treated%2520with%2520Longacting%2520Bronchodilators%253A%2520Two%2520Randomised%2520Clinical%2520Trials%26jtitle%3DLancet%26date%3D2009%26volume%3D374%26spage%3D695%26epage%3D703%26doi%3D10.1016%2FS0140-6736%2809%2961252-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Reed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosbie, D.</span><span> </span><span class="NLM_article-title">Apremilast in the Treatment of Psoriatic Arthritis: A Perspective Review</span> <span class="citation_source-journal">Ther. Adv. Musculoskeletal Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span><span class="refDoi"> DOI: 10.1177/1759720X16673786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1177%2F1759720X16673786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=28255338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A280%3ADC%252BC1czitl2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=45-53&author=M.+Reedauthor=D.+Crosbie&title=Apremilast+in+the+Treatment+of+Psoriatic+Arthritis%3A+A+Perspective+Review&doi=10.1177%2F1759720X16673786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Apremilast in the treatment of psoriatic arthritis: a perspective review</span></div><div class="casAuthors">Reed Michael; Crosbie David</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic advances in musculoskeletal disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">45-53</span>
        ISSN:<span class="NLM_cas:issn">1759-720X</span>.
    </div><div class="casAbstract">Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4).  Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis.  Established therapeutic options have variable effectiveness across the different domains of psoriatic disease.  Whilst biologic therapies have proven to be of significant benefit to many patients, not all patients respond, and others are not eligible or do not tolerate biologic therapy.  We review the mechanism of action, pharmacokinetics and clinical trial data with regards to both efficacy and safety for apremilast and consider where this new treatment may be positioned in the treatment of PsA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTQ2J8oScirLYtC3U5jeOifW6udTcc2eZpITZoAyYU_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czitl2jtA%253D%253D&md5=afa2fe6ddcb9b00964da43408ab4c306</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1177%2F1759720X16673786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1759720X16673786%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DM.%26aulast%3DCrosbie%26aufirst%3DD.%26atitle%3DApremilast%2520in%2520the%2520Treatment%2520of%2520Psoriatic%2520Arthritis%253A%2520A%2520Perspective%2520Review%26jtitle%3DTher.%2520Adv.%2520Musculoskeletal%2520Dis.%26date%3D2017%26volume%3D9%26spage%3D45%26epage%3D53%26doi%3D10.1177%2F1759720X16673786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Paller, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tom, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenthal, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boguniewicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Call, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichenfield, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsha, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spellman, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein Gold, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaenglein, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zane, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebert, A. A.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of Crisaborole Ointment, A Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults</span> <span class="citation_source-journal">J. Am. Acad. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">494</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span><span class="refDoi"> DOI: 10.1016/j.jaad.2016.05.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.jaad.2016.05.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=27417017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKmtbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2016&pages=494-503&author=A.+S.+Pallerauthor=W.+L.+Tomauthor=M.+G.+Lebwohlauthor=R.+L.+Blumenthalauthor=M.+Boguniewiczauthor=R.+S.+Callauthor=L.+F.+Eichenfieldauthor=D.+W.+Forshaauthor=W.+C.+Reesauthor=E.+L.+Simpsonauthor=M.+C.+Spellmanauthor=L.+F.+Stein+Goldauthor=A.+L.+Zaengleinauthor=M.+H.+Hughesauthor=L.+T.+Zaneauthor=A.+A.+Hebert&title=Efficacy+and+Safety+of+Crisaborole+Ointment%2C+A+Novel%2C+Nonsteroidal+Phosphodiesterase+4+%28PDE4%29+Inhibitor+for+the+Topical+Treatment+of+Atopic+Dermatitis+%28AD%29+in+Children+and+Adults&doi=10.1016%2Fj.jaad.2016.05.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults</span></div><div class="casAuthors">Paller, Amy S.; Tom, Wynnis L.; Lebwohl, Mark G.; Blumenthal, Robin L.; Boguniewicz, Mark; Call, Robert S.; Eichenfield, Lawrence F.; Forsha, Douglass W.; Rees, William C.; Simpson, Eric L.; Spellman, Mary C.; Stein Gold, Linda F.; Zaenglein, Andrea L.; Hughes, Matilda H.; Zane, Lee T.; Hebert, Adelaide A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">494-503.e6</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Addnl. topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks.  We sought to assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, in two phase III AD studies (AD-301: NCT02118766; AD-302: NCT02118792).  Two identically designed, vehicle-controlled, double-blind studies enrolled and randomly assigned (2:1, crisaborole:vehicle) patients aged 2 years or older with an Investigator's Static Global Assessment (ISGA) score of mild or moderate for twice-daily application for 28 days.  The primary end point was ISGA score at day 29 of clear (0)/almost clear (1) with 2-grade or greater improvement from baseline.  Addnl. analyses included time to success in ISGA score, percentage of patients achieving clear/almost clear, redn. in severity of AD signs, and time to improvement in pruritus.  More crisaborole- than vehicle-treated patients achieved ISGA score success (clear/almost clear with ≥2-grade improvement; AD-301: 32.8% vs 25.4%, P = .038; AD-302: 31.4% vs 18.0%, P < .001), with a greater percentage with clear/almost clear (51.7% vs 40.6%, P = .005; 48.5% vs 29.7%, P < .001).  Crisaborole-treated patients achieved success in ISGA score and improvement in pruritus earlier than those treated with vehicle (both P ≤ .001).  Treatment-related adverse events were infrequent and mild to moderate in severity.  Short study duration was a limitation.  Crisaborole demonstrated a favorable safety profile and improvement in all measures of efficacy, including overall disease severity, pruritus, and other signs of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD4IlzODC6ebVg90H21EOLACvtfcHk0lh1eR3wlHv4mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKmtbvP&md5=addbe254ce72db5ae1c96874f70ee1d0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.05.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.05.046%26sid%3Dliteratum%253Aachs%26aulast%3DPaller%26aufirst%3DA.%2BS.%26aulast%3DTom%26aufirst%3DW.%2BL.%26aulast%3DLebwohl%26aufirst%3DM.%2BG.%26aulast%3DBlumenthal%26aufirst%3DR.%2BL.%26aulast%3DBoguniewicz%26aufirst%3DM.%26aulast%3DCall%26aufirst%3DR.%2BS.%26aulast%3DEichenfield%26aufirst%3DL.%2BF.%26aulast%3DForsha%26aufirst%3DD.%2BW.%26aulast%3DRees%26aufirst%3DW.%2BC.%26aulast%3DSimpson%26aufirst%3DE.%2BL.%26aulast%3DSpellman%26aufirst%3DM.%2BC.%26aulast%3DStein%2BGold%26aufirst%3DL.%2BF.%26aulast%3DZaenglein%26aufirst%3DA.%2BL.%26aulast%3DHughes%26aufirst%3DM.%2BH.%26aulast%3DZane%26aufirst%3DL.%2BT.%26aulast%3DHebert%26aufirst%3DA.%2BA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Crisaborole%2520Ointment%252C%2520A%2520Novel%252C%2520Nonsteroidal%2520Phosphodiesterase%25204%2520%2528PDE4%2529%2520Inhibitor%2520for%2520the%2520Topical%2520Treatment%2520of%2520Atopic%2520Dermatitis%2520%2528AD%2529%2520in%2520Children%2520and%2520Adults%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2016%26volume%3D75%26spage%3D494%26epage%3D503%26doi%3D10.1016%2Fj.jaad.2016.05.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span> </span><span class="NLM_article-title">Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-Analysis</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">902</span><span class="NLM_x">–</span> <span class="NLM_lpage">912</span><span class="refDoi"> DOI: 10.1016/j.eururo.2013.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.eururo.2013.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=23395275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFKlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=902-912&author=J.+Yuanauthor=R.+Zhangauthor=Z.+Yangauthor=J.+Leeauthor=Y.+Liuauthor=J.+Tianauthor=X.+Qinauthor=Z.+Renauthor=H.+Dingauthor=Q.+Chenauthor=C.+Maoauthor=J.+Tang&title=Comparative+Effectiveness+and+Safety+of+Oral+Phosphodiesterase+Type+5+Inhibitors+for+Erectile+Dysfunction%3A+A+Systematic+Review+and+Network+Meta-Analysis&doi=10.1016%2Fj.eururo.2013.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis</span></div><div class="casAuthors">Yuan, JinQiu; Zhang, RenJie; Yang, ZuYao; Lee, Jack; Liu, YaLi; Tian, JinHui; Qin, XiWen; Ren, ZhengJia; Ding, Hong; Chen, Qing; Mao, Chen; Tang, JinLing</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">902-912</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphodiesterase type 5 inhibitors (PDE5-Is) are currently the first-line therapy for erectile dysfunction (ED), but available studies investigating the comparative effects of different PDE5-Is are limited.  To compare the efficacy and safety of different classes of oral PDE5-Is for ED.A systematic search was performed in PubMed, Cochrane Library, and Embase to identify randomized controlled trials that compared different PDE5-Is or PDE5-Is with a placebo for ED.  The methodol. quality of included studies was appraised with the Cochrane Collaboration bias appraisal tool, and the quality of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation system.A total of 118 trials (31 195 individuals) were included.  There was no major difference in the results between the traditional meta-anal. and the network meta-anal.  Network meta-anal. demonstrated that PDE5-Is were superior to placebo to improve erectile function.  Compared with tadalafil (relative risk [RR]: 0.61; 95% confidence interval [CI], 0.33-0.90) and vardenafil (RR: 0.63; 95% CI, 0.35-0.92), avanafil was less effective on Global Assessment Questionnaire question 1.  Tadalafil was more effective than vardenafil (mean difference [MD]: 1.49; 95% CI, 0.50-2.50) and udenafil (MD: -1.84; 95% CI, -3.31 to -0.33) as measured by the erectile function domain of the International Index of Erectile Function.  For all efficacy outcomes, the abs. effects and the rank tests indicated that tadalafil and vardenafil were the most effective agents.  After adjusting for dosage, the conclusion remained the same.  Safety anal. showed there was no major difference among different agents.In recommended doses, oral PDE5-Is are more effective than placebo for ED, and tadalafil seems to be the most effective agent, followed by vardenafil.  PDE5-Is are generally safe and well tolerated, and there is no major difference on the safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqibvT0sDtXWbVg90H21EOLACvtfcHk0lhDKQbFknBBIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFKlsrk%253D&md5=117fac58bd86beccf221376fc919c240</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2013.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2013.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DComparative%2520Effectiveness%2520and%2520Safety%2520of%2520Oral%2520Phosphodiesterase%2520Type%25205%2520Inhibitors%2520for%2520Erectile%2520Dysfunction%253A%2520A%2520Systematic%2520Review%2520and%2520Network%2520Meta-Analysis%26jtitle%3DEur.%2520Urol.%26date%3D2013%26volume%3D63%26spage%3D902%26epage%3D912%26doi%3D10.1016%2Fj.eururo.2013.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Archer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michelakis, E. D.</span><span> </span><span class="NLM_article-title">Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">1864</span><span class="NLM_x">–</span> <span class="NLM_lpage">1871</span><span class="refDoi"> DOI: 10.1056/NEJMct0904473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1056%2FNEJMct0904473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=19890129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2jurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=1864-1871&author=S.+L.+Archerauthor=E.+D.+Michelakis&title=Phosphodiesterase+Type+5+Inhibitors+for+Pulmonary+Arterial+Hypertension&doi=10.1056%2FNEJMct0904473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension</span></div><div class="casAuthors">Archer, Stephen L.; Michelakis, Evangelos D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1864-1871</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  A 46-yr-old woman presents with progressive exertional dyspnea and recurrent exertional syncope.  Her jugular venous pressure is 16 cm of water, and moderate peripheral edema is noted.  Auscultation reveals a pronounced pulmonic component of the second heart sound and a grade 2/6 holosystolic murmur of tricuspid regurgitation.  Echocardiog. shows moderate right ventricular and right atrial enlargement, right ventricular systolic dysfunction, and an estd. right ventricular systolic pressure of 100 mm Hg.  Cardiac catheterization reveals a mean right atrial pressure of 13 mm Hg, a pulmonary-artery pressure of 80/40 mm Hg (mean, 58), a mean pulmonary-capillary wedge pressure of 10 mm Hg, and a cardiac output of 5 L per min.  The results of addnl. studies to detect causes of secondary pulmonary hypertension or assocd. conditions are unremarkable, and she receives a diagnosis of idiopathic pulmonary arterial hypertension.  Her pulmonary-artery pressure does not decrease in response to inhaled nitric oxide.  Therapy with sildenafil is recommended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdhp_AHUygSLVg90H21EOLACvtfcHk0lhDKQbFknBBIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2jurvI&md5=5477561829a7b9c579c0db54677ab9fe</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMct0904473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMct0904473%26sid%3Dliteratum%253Aachs%26aulast%3DArcher%26aufirst%3DS.%2BL.%26aulast%3DMichelakis%26aufirst%3DE.%2BD.%26atitle%3DPhosphodiesterase%2520Type%25205%2520Inhibitors%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D1864%26epage%3D1871%26doi%3D10.1056%2FNEJMct0904473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Andersson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Groat, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McVary, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lue, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roehrborn, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyndaele, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viktrup, L.</span><span> </span><span class="NLM_article-title">Tadalafil for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Pathophysiology and Mechanism(s) of Action</span> <span class="citation_source-journal">Neurourol. Urodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1002/nau.20999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1002%2Fnau.20999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=21284024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlslOitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=292-301&author=K.+E.+Anderssonauthor=W.+C.+de+Groatauthor=K.+T.+McVaryauthor=T.+F.+Lueauthor=M.+Maggiauthor=C.+G.+Roehrbornauthor=J.+J.+Wyndaeleauthor=T.+Melbyauthor=L.+Viktrup&title=Tadalafil+for+the+Treatment+of+Lower+Urinary+Tract+Symptoms+Secondary+to+Benign+Prostatic+Hyperplasia%3A+Pathophysiology+and+Mechanism%28s%29+of+Action&doi=10.1002%2Fnau.20999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action</span></div><div class="casAuthors">Andersson, Karl-Erik; de Groat, William C.; McVary, Kevin T.; Lue, Tom F.; Maggi, Mario; Roehrborn, Claus G.; Wyndaele, Jean Jacques; Melby, Thomas; Viktrup, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Neurourology and Urodynamics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-301</span>CODEN:
                <span class="NLM_cas:coden">NEUREM</span>;
        ISSN:<span class="NLM_cas:issn">0733-2467</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: The PDE5 inhibitor tadalafil is under investigation for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).  Several clin. studies of tadalafil and other PDE5 inhibitors have reported significant symptom redn. but limited urinary flow rate improvement.  This manuscript reviews the published literature describing the pathophysiol. of male LUTS, with an emphasis on mechanisms that may be modulated or improved by phosphodiesterase type 5 (PDE5) inhibition.  Methods: Literature (through March 2010) was obtained via Medline searches and from the individual reviewers files.  Articles were selected for review based on describing in vitro, preclin., or clin. studies of pathol. processes contributing to LUTS, or possible effects of PDE5 inhibition in the lower urinary tract.  Results: Major mechanisms contributing to LUTS include: reduced nitric oxide/cyclic guanosine monophosphate signaling; increased RhoA kinase pathway activity; autonomic overactivity; increased bladder afferent activity; and pelvic ischemia.  Tadalafil and other PDE5 inhibitors have demonstrated beneficial effects on smooth muscle relaxation, smooth muscle and endothelial cell proliferation, nerve activity, and tissue perfusion that may impact LUTS in men.  Conclusions: The pathophysiol. of male LUTS is complex and not completely understood.  LUTS may occur independently of BPH or secondary to BPH but in both cases involve obstructive or irritative mechanisms with substantial pathophysiol. overlap.  While the precise mechanism remains unclear, inhibition of PDE5 seems to have an effect on several pathways that may impact LUTS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdQl9V0DpcbVg90H21EOLACvtfcHk0lhDKQbFknBBIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlslOitL4%253D&md5=5705436d6efa5dca6f5d2d755b593ae4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fnau.20999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fnau.20999%26sid%3Dliteratum%253Aachs%26aulast%3DAndersson%26aufirst%3DK.%2BE.%26aulast%3Dde%2BGroat%26aufirst%3DW.%2BC.%26aulast%3DMcVary%26aufirst%3DK.%2BT.%26aulast%3DLue%26aufirst%3DT.%2BF.%26aulast%3DMaggi%26aufirst%3DM.%26aulast%3DRoehrborn%26aufirst%3DC.%2BG.%26aulast%3DWyndaele%26aufirst%3DJ.%2BJ.%26aulast%3DMelby%26aufirst%3DT.%26aulast%3DViktrup%26aufirst%3DL.%26atitle%3DTadalafil%2520for%2520the%2520Treatment%2520of%2520Lower%2520Urinary%2520Tract%2520Symptoms%2520Secondary%2520to%2520Benign%2520Prostatic%2520Hyperplasia%253A%2520Pathophysiology%2520and%2520Mechanism%2528s%2529%2520of%2520Action%26jtitle%3DNeurourol.%2520Urodyn.%26date%3D2011%26volume%3D30%26spage%3D292%26epage%3D301%26doi%3D10.1002%2Fnau.20999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraci, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span> </span><span class="NLM_article-title">Phosphodiesterases in the CNS: Targets for Drug Development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span><span class="refDoi"> DOI: 10.1038/nrd2058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1038%2Fnrd2058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=16883304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFCkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=660-670&author=F.+S.+Mennitiauthor=W.+S.+Faraciauthor=C.+J.+Schmidt&title=Phosphodiesterases+in+the+CNS%3A+Targets+for+Drug+Development&doi=10.1038%2Fnrd2058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterases in the CNS: targets for drug development</span></div><div class="casAuthors">Menniti, Frank S.; Faraci, W. Stephen; Schmidt, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">660-670</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The therapeutic and com. success of phosphodiesterase 5 inhibitors such as Viagra, Levitra and Cialis has sparked renewed interest in the phosphodiesterases as drug discovery targets.  Virtually all the phosphodiesterases are expressed in the CNS, making this gene family a particularly attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders.  Significantly, all neurons express multiple phosphodiesterases, which differ in cyclic nucleotide specificity, affinity, regulatory control and subcellular compartmentalization.  Therefore, phosphodiesterase inhibition represents a mechanism through which it could be possible to precisely modulate neuronal activity.  In this article, we review the current state of the art in the burgeoning field of phosphodiesterase pharmacol. in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa2I3t5o1HibVg90H21EOLACvtfcHk0lg5gteFTXkG1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFCkurg%253D&md5=7c2b421b629efe9ee73999098322e811</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd2058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2058%26sid%3Dliteratum%253Aachs%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DFaraci%26aufirst%3DW.%2BS.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26atitle%3DPhosphodiesterases%2520in%2520the%2520CNS%253A%2520Targets%2520for%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D660%26epage%3D670%26doi%3D10.1038%2Fnrd2058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonseca, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx-LaFrance, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helal, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claffey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuttle, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffman, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanase-Frawley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span> </span><span class="NLM_article-title">Design and Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9045</span><span class="NLM_x">–</span> <span class="NLM_lpage">9054</span><span class="refDoi"> DOI: 10.1021/jm3007799</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3007799" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9045-9054&author=P.+R.+Verhoestauthor=K.+R.+Fonsecaauthor=X.+Houauthor=C.+Proulx-LaFranceauthor=M.+Cormanauthor=C.+J.+Helalauthor=M.+M.+Claffeyauthor=J.+B.+Tuttleauthor=K.+J.+Coffmanauthor=S.+Liuauthor=F.+Nelsonauthor=R.+J.+Kleimanauthor=F.+S.+Mennitiauthor=C.+J.+Schmidtauthor=M.+Vanase-Frawleyauthor=S.+Liras&title=Design+and+Discovery+of+6-%5B%283S%2C4S%29-4-Methyl-1-%28pyrimidin-2-ylmethyl%29pyrrolidin-3-yl%5D-1-%28tetrahydro-2H-pyran-4-yl%29-1%2C5-dihydro-4H-pyrazolo%5B3%2C4-d%5Dpyrimidin-4-one+%28PF-04447943%29%2C+a+Selective+Brain+Penetrant+PDE9A+Inhibitor+for+the+Treatment+of+Cognitive+Disorders&doi=10.1021%2Fjm3007799"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm3007799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3007799%26sid%3Dliteratum%253Aachs%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DProulx-LaFrance%26aufirst%3DC.%26aulast%3DCorman%26aufirst%3DM.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DClaffey%26aufirst%3DM.%2BM.%26aulast%3DTuttle%26aufirst%3DJ.%2BB.%26aulast%3DCoffman%26aufirst%3DK.%2BJ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DF.%26aulast%3DKleiman%26aufirst%3DR.%2BJ.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DVanase-Frawley%26aufirst%3DM.%26aulast%3DLiras%26aufirst%3DS.%26atitle%3DDesign%2520and%2520Discovery%2520of%25206-%255B%25283S%252C4S%2529-4-Methyl-1-%2528pyrimidin-2-ylmethyl%2529pyrrolidin-3-yl%255D-1-%2528tetrahydro-2H-pyran-4-yl%2529-1%252C5-dihydro-4H-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-one%2520%2528PF-04447943%2529%252C%2520a%2520Selective%2520Brain%2520Penetrant%2520PDE9A%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cognitive%2520Disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9045%26epage%3D9054%26doi%3D10.1021%2Fjm3007799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Chappie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helal, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span> </span><span class="NLM_article-title">Current Landscape of Phosphodiesterase 10A (PDE10A) Inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7299</span><span class="NLM_x">–</span> <span class="NLM_lpage">7331</span><span class="refDoi"> DOI: 10.1021/jm3004976</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3004976" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2gsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7299-7331&author=T.+A.+Chappieauthor=C.+J.+Helalauthor=X.+Hou&title=Current+Landscape+of+Phosphodiesterase+10A+%28PDE10A%29+Inhibition&doi=10.1021%2Fjm3004976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Current Landscape of Phosphodiesterase 10A (PDE10A) Inhibition</span></div><div class="casAuthors">Chappie, Thomas A.; Helal, Christopher J.; Hou, Xinjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7299-7331</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  No abstr. required for Perspectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolfNGPFFnnOrVg90H21EOLACvtfcHk0lg5gteFTXkG1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2gsbrF&md5=b50361a522ec669cad0a65b2d33d5dfb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm3004976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3004976%26sid%3Dliteratum%253Aachs%26aulast%3DChappie%26aufirst%3DT.%2BA.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DHou%26aufirst%3DX.%26atitle%3DCurrent%2520Landscape%2520of%2520Phosphodiesterase%252010A%2520%2528PDE10A%2529%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7299%26epage%3D7331%26doi%3D10.1021%2Fjm3004976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beard, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyser, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrick, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wennogle, L. P.</span><span> </span><span class="NLM_article-title">Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1149</span><span class="NLM_x">–</span> <span class="NLM_lpage">1164</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01751</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01751" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1aisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1149-1164&author=P.+Liauthor=H.+Zhengauthor=J.+Zhaoauthor=L.+Zhangauthor=W.+Yaoauthor=H.+Zhuauthor=J.+D.+Beardauthor=K.+Idaauthor=W.+Laneauthor=G.+Snellauthor=S.+Sogabeauthor=C.+J.+Heyserauthor=G.+L.+Snyderauthor=J.+P.+Hendrickauthor=K.+E.+Vanoverauthor=R.+E.+Davisauthor=L.+P.+Wennogle&title=Discovery+of+Potent+and+Selective+Inhibitors+of+Phosphodiesterase+1+for+the+Treatment+of+Cognitive+Impairment+Associated+with+Neurodegenerative+and+Neuropsychiatric+Diseases&doi=10.1021%2Facs.jmedchem.5b01751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases</span></div><div class="casAuthors">Li, Peng; Zheng, Hailin; Zhao, Jun; Zhang, Lei; Yao, Wei; Zhu, Hongwen; Beard, J. David; Ida, Koh; Lane, Weston; Snell, Gyorgy; Sogabe, Satoshi; Heyser, Charles J.; Snyder, Gretchen L.; Hendrick, Joseph P.; Vanover, Kimberly E.; Davis, Robert E.; Wennogle, Lawrence P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1149-1164</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A diverse set of 3-aminopyrazolo[3,4-d]pyrimidinones was designed and synthesized.  The structure-activity relationships of these polycyclic compds. as phosphodiesterase 1 (PDE1) inhibitors were studied along with their physicochem. and pharmacokinetic properties.  Systematic optimizations of this novel scaffold culminated in the identification of a clin. candidate I, which exhibited picomolar inhibitory potency for PDE1, demonstrated excellent selectivity against all other PDE families and showed good efficacy in vivo.  Currently, this investigational new drug is in Phase I clin. development and being considered for the treatment of several indications including cognitive deficits assocd. with schizophrenia and Alzheimer's disease, movement disorders, attention deficit and hyperactivity disorders, and other central nervous system (CNS) and non-CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiqQuMoLsXnbVg90H21EOLACvtfcHk0lhFLvFTF-edEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1aisLk%253D&md5=73741521722dc906869ffa3504ceaf2e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01751%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DBeard%26aufirst%3DJ.%2BD.%26aulast%3DIda%26aufirst%3DK.%26aulast%3DLane%26aufirst%3DW.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DHeyser%26aufirst%3DC.%2BJ.%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DHendrick%26aufirst%3DJ.%2BP.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DWennogle%26aufirst%3DL.%2BP.%26atitle%3DDiscovery%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Phosphodiesterase%25201%2520for%2520the%2520Treatment%2520of%2520Cognitive%2520Impairment%2520Associated%2520with%2520Neurodegenerative%2520and%2520Neuropsychiatric%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1149%26epage%3D1164%26doi%3D10.1021%2Facs.jmedchem.5b01751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lakics, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karran, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boess, F. G.</span><span> </span><span class="NLM_article-title">Quantitative Comparison of Phosphodiesterase mRNA Distribution in Human Brain and Peripheral Tissues</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">374</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2010.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.neuropharm.2010.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=20493887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1SqsLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2010&pages=367-374&author=V.+Lakicsauthor=E.+H.+Karranauthor=F.+G.+Boess&title=Quantitative+Comparison+of+Phosphodiesterase+mRNA+Distribution+in+Human+Brain+and+Peripheral+Tissues&doi=10.1016%2Fj.neuropharm.2010.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues</span></div><div class="casAuthors">Lakics, Viktor; Karran, Eric H.; Boess, Frank G.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">367-374</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cyclic nucleotide-specific phosphodiesterases (PDEs) play a crit. role in signal transduction by regulating the level of adenosine 3',5'-cyclic monophosphate (cAMP) and guanosine 3',5'-cyclic monophosphate (cGMP) in cells.  The gene expression pattern of a PDE provides important information regarding its role in physiol. and pathol. processes.  In this study, we have established the mRNA expression profile all PDE isoenzymes (PDE1A/B/C, 2A, 3A/B, 4A/B/C/D, 5A, 6A/B/C, 7A/B, 8A/B, 9A, 10A, 11A) in a human cDNA collection consisting of 10 brain regions (parietal, frontal, temporal cortex, hippocampus, striatum, thalamus, hypothalamus, substantia nigra, nucleus accumbens, cerebellum), spinal cord, dorsal root ganglia and 12 peripheral tissues (skeletal muscle, heart, thyroid, adrenal gland, pancreas, bladder, kidney, liver, lung, small intestine, spleen, and stomach).  Using quant. real-time polymerase chain reaction and parallel anal. of a carefully selected group of ref. genes, we have detd. the relative expression of each PDE isoenzyme across the 24 selected tissues, and also compared the expression of selected PDEs to each other within a given tissue type.  Several PDEs show strikingly selective expression (e.g. PDE10A and PDE1B mRNA levels in the caudate nucleus are 20-fold higher than in most other tissues; PDE1C and PDE3A are highly expressed in the heart and PDE8B is expressed very strongly in the thyroid gland).  This comprehensive approach provides a coherent and quant. view of the mRNA expression of the PDE gene family and enables an integration of data obtained with other non-quant. methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprGz6OEkRjbLVg90H21EOLACvtfcHk0lhFLvFTF-edEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1SqsLbJ&md5=ee55772f572818eaa7194a1ae3f52f45</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2010.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2010.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DLakics%26aufirst%3DV.%26aulast%3DKarran%26aufirst%3DE.%2BH.%26aulast%3DBoess%26aufirst%3DF.%2BG.%26atitle%3DQuantitative%2520Comparison%2520of%2520Phosphodiesterase%2520mRNA%2520Distribution%2520in%2520Human%2520Brain%2520and%2520Peripheral%2520Tissues%26jtitle%3DNeuropharmacology%26date%3D2010%26volume%3D59%26spage%3D367%26epage%3D374%26doi%3D10.1016%2Fj.neuropharm.2010.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Stephenson, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coskran, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelms, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamowicz, W. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muravnick, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, D.</span><span> </span><span class="NLM_article-title">Immunohistochemical Localization of Phosphodiesterase 2A in Multiple Mammalian Species</span> <span class="citation_source-journal">J. Histochem. Cytochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">949</span><span class="refDoi"> DOI: 10.1369/jhc.2009.953471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1369%2Fjhc.2009.953471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=19506089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOgtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2009&pages=933-949&author=D.+T.+Stephensonauthor=T.+M.+Coskranauthor=M.+B.+Wilhelmsauthor=W.+O.+Adamowiczauthor=M.+M.+O%E2%80%99Donnellauthor=K.+B.+Muravnickauthor=F.+S.+Mennitiauthor=R.+J.+Kleimanauthor=D.+Morton&title=Immunohistochemical+Localization+of+Phosphodiesterase+2A+in+Multiple+Mammalian+Species&doi=10.1369%2Fjhc.2009.953471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species</span></div><div class="casAuthors">Stephenson, Diane T.; Coskran, Tim M.; Wilhelms, Margaret B.; Adamowicz, Wendy O.; O'Donnell, Michele M.; Muravnick, Kathleen B.; Menniti, Frank S.; Kleiman, Robin J.; Morton, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">933-949</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Histochemical Society, Inc.</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a family of enzymes that regulate the levels of cyclic nucleotides, key second messengers that mediate a diverse array of functions.  PDE2A is an evolutionarily conserved cGMP-stimulated cAMP and cGMP PDE.  In the present study, the regional and cellular distribution of PDE2A in tissues of rats, mice, cynomolgus monkeys, dogs, and humans was evaluated by immunohistochem.  A polyclonal antibody directed to the C-terminal portion of PDE2A specifically detected PDE2A by Western blotting and by immunohistochem.  The pattern of PDE2A immunoreactivity (ir) was consistent across all species.  Western blot anal. demonstrated that PDE2A was most abundant in the brain relative to peripheral tissues.  PDE2A ir was heterogeneously distributed within brain and was selectively expressed in particular peripheral tissues.  In the brain, prominent immunoreactivity was apparent in components of the limbic system, including the isocortex, hippocampus, amygdala, habenula, basal ganglia, and interpeduncular nucleus.  Cytoplasmic PDE2A staining was prominent in several peripheral tissues, including the adrenal zona glomerulosa, neurons of enteric ganglia, endothelial cells in all organs, lymphocytes of spleen and lymph nodes, and pituitary.  These studies suggest that PDE2A is evolutionarily conserved across mammalian species and support the hypothesis that the enzyme plays a fundamental role in signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHVQCCm4loO7Vg90H21EOLACvtfcHk0lhFLvFTF-edEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOgtrrJ&md5=ce1dfa99cc99c02f31ab8071a9e438fd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1369%2Fjhc.2009.953471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1369%252Fjhc.2009.953471%26sid%3Dliteratum%253Aachs%26aulast%3DStephenson%26aufirst%3DD.%2BT.%26aulast%3DCoskran%26aufirst%3DT.%2BM.%26aulast%3DWilhelms%26aufirst%3DM.%2BB.%26aulast%3DAdamowicz%26aufirst%3DW.%2BO.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BM.%26aulast%3DMuravnick%26aufirst%3DK.%2BB.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DKleiman%26aufirst%3DR.%2BJ.%26aulast%3DMorton%26aufirst%3DD.%26atitle%3DImmunohistochemical%2520Localization%2520of%2520Phosphodiesterase%25202A%2520in%2520Multiple%2520Mammalian%2520Species%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2009%26volume%3D57%26spage%3D933%26epage%3D949%26doi%3D10.1369%2Fjhc.2009.953471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Cote, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valeriani, B. A.</span><span> </span><span class="NLM_article-title">Relative Potency of Various Classes of Phosphodiesterase (PDE) Inhibitors for Rod and Cone Photoreceptor PDE</span> <span class="citation_source-journal">Invest. Ophthalmol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1524</span><span class="NLM_x">–</span> <span class="NLM_lpage">1527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=1524-1527&author=R.+H.+Coteauthor=Q.+Fengauthor=B.+A.+Valeriani&title=Relative+Potency+of+Various+Classes+of+Phosphodiesterase+%28PDE%29+Inhibitors+for+Rod+and+Cone+Photoreceptor+PDE"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCote%26aufirst%3DR.%2BH.%26aulast%3DFeng%26aufirst%3DQ.%26aulast%3DValeriani%26aufirst%3DB.%2BA.%26atitle%3DRelative%2520Potency%2520of%2520Various%2520Classes%2520of%2520Phosphodiesterase%2520%2528PDE%2529%2520Inhibitors%2520for%2520Rod%2520and%2520Cone%2520Photoreceptor%2520PDE%26jtitle%3DInvest.%2520Ophthalmol.%26date%3D2003%26volume%3D44%26spage%3D1524%26epage%3D1527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Young, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, A.</span><span> </span><span class="NLM_article-title">Milrinone. A Preliminary Review of Its Pharmacological Properties and Therapeutic Use</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.2165/00003495-198836020-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.2165%2F00003495-198836020-00003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1988&pages=158-192&author=R.+A.+Youngauthor=A.+Ward&title=Milrinone.+A+Preliminary+Review+of+Its+Pharmacological+Properties+and+Therapeutic+Use&doi=10.2165%2F00003495-198836020-00003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2165%2F00003495-198836020-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-198836020-00003%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DWard%26aufirst%3DA.%26atitle%3DMilrinone.%2520A%2520Preliminary%2520Review%2520of%2520Its%2520Pharmacological%2520Properties%2520and%2520Therapeutic%2520Use%26jtitle%3DDrugs%26date%3D1988%26volume%3D36%26spage%3D158%26epage%3D192%26doi%3D10.2165%2F00003495-198836020-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kandel, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, R. D.</span><span> </span><span class="NLM_article-title">Nitric Oxide Signaling Contributes to Late-Phase LTP and CREB Phosphorylation in the Hippocampus</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">10250</span><span class="NLM_x">–</span> <span class="NLM_lpage">10261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1523%2FJNEUROSCI.19-23-10250.1999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10575022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADyaK1MXnslyrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=10250-10261&author=Y.+Luauthor=E.+R.+Kandelauthor=R.+D.+Hawkins&title=Nitric+Oxide+Signaling+Contributes+to+Late-Phase+LTP+and+CREB+Phosphorylation+in+the+Hippocampus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus</span></div><div class="casAuthors">Lu, Yun-Fei; Kandel, Eric R.; Hawkins, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10250-10261</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Long-term potentiation (LTP) in the hippocampus has an early phase (E-LTP) that can be induced by 1- or 2-train tetanization, lasts ∼1 h, and is cAMP-dependent protein kinase A (PKA)- and protein synthesis-independent and a late phase (L-LTP) that can be induced by 3- or 4-train tetanization, lasts >3 h, and is reduced by inhibitors of PKA and of protein or RNA synthesis.  NO is thought to be involved in E-LTP, but until now there has been no information about the role of the NO-signaling pathway in L-LTP.  Here, the authors examd. this question at the Schaffer collateral-CA1 synapses in slices of mouse hippocampus.  An inhibitor of nitric oxide synthase blocked L-LTP induced by 3-train tetanization and reduced L-LTP induced by 4-train tetanization, whereas an inhibitor of PKA was more effective in blocking 4-train L-LTP than 3-train L-LTP.  Three-train L-LTP was also blocked by inhibitors of guanylyl cyclase or cGMP-dependent protein kinase G (PKG).  Conversely, either NO or cGMP analogs paired with 1-train tetanization produced late-phase potentiation, and the cGMP-induced potentiation was blocked by inhibitors of protein or RNA synthesis and an inhibitor of PKG, but not by an inhibitor of PKA.  To test a possible downstream target of PKG, the authors examd. changes in phospho-CRE-binding protein (phospho-CREB) immunofluorescence in the CA1 cell body area and obtained results similar to those of the electrophysiol. expts.  The results suggested that NO contributes to L-LTP by stimulating guanylyl cyclase and PKG, which acts in parallel with PKA to increase phosphorylation of transcription factor CREB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY0i0LYOPf7LVg90H21EOLACvtfcHk0liOuxtaEU6O4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnslyrt70%253D&md5=6d09b68560c09b81e38354826f7c21b6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.19-23-10250.1999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.19-23-10250.1999%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DKandel%26aufirst%3DE.%2BR.%26aulast%3DHawkins%26aufirst%3DR.%2BD.%26atitle%3DNitric%2520Oxide%2520Signaling%2520Contributes%2520to%2520Late-Phase%2520LTP%2520and%2520CREB%2520Phosphorylation%2520in%2520the%2520Hippocampus%26jtitle%3DJ.%2520Neurosci.%26date%3D1999%26volume%3D19%26spage%3D10250%26epage%3D10261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Sanderson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sher, E.</span><span> </span><span class="NLM_article-title">The Role of Phosphodiesterases in Hippocampal Synaptic Plasticity</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.neuropharm.2013.01.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2013&pages=86-95&author=T.+M.+Sandersonauthor=E.+Sher&title=The+Role+of+Phosphodiesterases+in+Hippocampal+Synaptic+Plasticity&doi=10.1016%2Fj.neuropharm.2013.01.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DT.%2BM.%26aulast%3DSher%26aufirst%3DE.%26atitle%3DThe%2520Role%2520of%2520Phosphodiesterases%2520in%2520Hippocampal%2520Synaptic%2520Plasticity%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D74%26spage%3D86%26epage%3D95%26doi%3D10.1016%2Fj.neuropharm.2013.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Prickaerts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vente, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honig, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbusch, H. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span> </span><span class="NLM_article-title">cGMP, but not cAMP, in Rat Hippocampus Is Involved in Early Stages of Object Memory Consolidation</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">436</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1016/S0014-2999(01)01614-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2FS0014-2999%2801%2901614-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=11834250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtVKrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2002&pages=83-87&author=J.+Prickaertsauthor=J.+de+Venteauthor=W.+Honigauthor=H.+W.+M.+Steinbuschauthor=A.+Blokland&title=cGMP%2C+but+not+cAMP%2C+in+Rat+Hippocampus+Is+Involved+in+Early+Stages+of+Object+Memory+Consolidation&doi=10.1016%2FS0014-2999%2801%2901614-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation</span></div><div class="casAuthors">Prickaerts, Jos; de Vente, Jan; Honig, Wiel; Steinbusch, Harry W. M.; Blokland, Arjan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">436</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">83-87</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The present study investigated the role of cGMP and cAMP on the memory performance in the object recognition task in rats.  The analog, 8-bromo-GMP (8-Br-cGMP) or 8-bromo-cAMP (8-Br-cAMP) was administered bilaterally into the hippocampus (0, 1, 3, and 10 μg in 0.5 μL saline/site) immediately after the exposure to 2 identical objects.  After 24 h, saline-treated animals spent equal times exploring a new and the familiar object demonstrating that they did not recognize the familiar one.  However, a dose-dependent improvement in object recognition was found after injection of 8-Br-cGMP.  In contrast, 8-Br-cAMP did not improve the memory performance at the doses tested.  These results indicate that hippocampal cGMP but not cAMP is involved in early stages of consolidation of object memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtZ18mRPVkf7Vg90H21EOLACvtfcHk0liOuxtaEU6O4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtVKrtLk%253D&md5=2110ed071d976fc80b634bad0e548804</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901614-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901614-4%26sid%3Dliteratum%253Aachs%26aulast%3DPrickaerts%26aufirst%3DJ.%26aulast%3Dde%2BVente%26aufirst%3DJ.%26aulast%3DHonig%26aufirst%3DW.%26aulast%3DSteinbusch%26aufirst%3DH.%2BW.%2BM.%26aulast%3DBlokland%26aufirst%3DA.%26atitle%3DcGMP%252C%2520but%2520not%2520cAMP%252C%2520in%2520Rat%2520Hippocampus%2520Is%2520Involved%2520in%2520Early%2520Stages%2520of%2520Object%2520Memory%2520Consolidation%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D436%26spage%3D83%26epage%3D87%26doi%3D10.1016%2FS0014-2999%2801%2901614-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Niewoehner, U.; Schauss, D.; Hendrix, M.; Koenig, G.; Boess, F. G.; van der Staay, F. J.; Schreiber, R.; Schlemmer, K. H.; Grosser, R.</span><span> </span><span class="NLM_article-title">Novel Substituted Imidazotriazinones as PDE II-Inhibitors</span>. WO 2002050078, June 27,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=U.+Niewoehner&author=D.+Schauss&author=M.+Hendrix&author=G.+Koenig&author=F.+G.+Boess&author=F.+J.+van+der+Staay&author=R.+Schreiber&author=K.+H.+Schlemmer&author=R.+Grosser&title=Novel+Substituted+Imidazotriazinones+as+PDE+II-Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNiewoehner%26aufirst%3DU.%26atitle%3DNovel%2520Substituted%2520Imidazotriazinones%2520as%2520PDE%2520II-Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Abaarghaz, M.; Biondi, S.; Duranton, J.; Limanton, E.; Mondadori, C.; Wagner, P.</span><span> </span><span class="NLM_article-title">Benzo[1,4]diazepin-2-one Derivatives as Phosphodiesterase PDE2 Inhibitors, Preparation and Therapeutic Use Thereof</span>. WO 2005063723, July 14,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Abaarghaz&author=S.+Biondi&author=J.+Duranton&author=E.+Limanton&author=C.+Mondadori&author=P.+Wagner&title=Benzo%5B1%2C4%5Ddiazepin-2-one+Derivatives+as+Phosphodiesterase+PDE2+Inhibitors%2C+Preparation+and+Therapeutic+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbaarghaz%26aufirst%3DM.%26atitle%3DBenzo%255B1%252C4%255Ddiazepin-2-one%2520Derivatives%2520as%2520Phosphodiesterase%2520PDE2%2520Inhibitors%252C%2520Preparation%2520and%2520Therapeutic%2520Use%2520Thereof%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Buijnsters, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langlois, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rombouts, F. J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanHoof, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Roosbroeck, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrés, J.-I.</span><span> </span><span class="NLM_article-title">Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1049</span><span class="NLM_x">–</span> <span class="NLM_lpage">1053</span><span class="refDoi"> DOI: 10.1021/ml500262u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500262u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1049-1053&author=P.+Buijnstersauthor=M.+De+Angelisauthor=X.+Langloisauthor=F.+J.+R.+Romboutsauthor=W.+Sandersonauthor=G.+Tresadernauthor=A.+Ritchieauthor=A.+A.+Trabancoauthor=G.+VanHoofauthor=Y.+Van+Roosbroeckauthor=J.-I.+Andr%C3%A9s&title=Structure-Based+Design+of+a+Potent%2C+Selective%2C+and+Brain+Penetrating+PDE2+Inhibitor+with+Demonstrated+Target+Engagement&doi=10.1021%2Fml500262u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fml500262u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500262u%26sid%3Dliteratum%253Aachs%26aulast%3DBuijnsters%26aufirst%3DP.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DRombouts%26aufirst%3DF.%2BJ.%2BR.%26aulast%3DSanderson%26aufirst%3DW.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DRitchie%26aufirst%3DA.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DVanHoof%26aufirst%3DG.%26aulast%3DVan%2BRoosbroeck%26aufirst%3DY.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DJ.-I.%26atitle%3DStructure-Based%2520Design%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Brain%2520Penetrating%2520PDE2%2520Inhibitor%2520with%2520Demonstrated%2520Target%2520Engagement%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1049%26epage%3D1053%26doi%3D10.1021%2Fml500262u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Rombouts, F. J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresadern, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buijnsters, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langlois, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tovar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbrecher, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhoof, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrés, J.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span> </span><span class="NLM_article-title">Pyrido[4,3-<i>e</i>][1,2,4]triazolo[4,3-<i>a</i>]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1021/ml500463t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500463t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVOltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=282-286&author=F.+J.+R.+Romboutsauthor=G.+Tresadernauthor=P.+Buijnstersauthor=X.+Langloisauthor=F.+Tovarauthor=T.+B.+Steinbrecherauthor=G.+Vanhoofauthor=M.+Somersauthor=J.-I.+Andr%C3%A9sauthor=A.+A.+Trabanco&title=Pyrido%5B4%2C3-e%5D%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazines+as+Selective%2C+Brain+Penetrant+Phosphodiesterase+2+%28PDE2%29+Inhibitors&doi=10.1021%2Fml500463t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors</span></div><div class="casAuthors">Rombouts, Frederik J. R.; Tresadern, Gary; Buijnsters, Peter; Langlois, Xavier; Tovar, Fulgencio; Steinbrecher, Thomas B.; Vanhoof, Greet; Somers, Marijke; Andres, Jose-Ignacio; Trabanco, Andres A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">282-286</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines is reported as potent PDE2/PDE10 inhibitors with drug-like properties.  Selectivity for PDE2 was obtained by introducing a linear, lipophilic moiety on the meta-position of the Ph ring pending from the triazole.  The SAR and protein flexibility were explored with free energy perturbation calcns.  Rat pharmacokinetic data and in vivo receptor occupancy data are given for two representative compds. 6 and 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbUtc8164aobVg90H21EOLACvtfcHk0ljXMgAOouL1NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVOltA%253D%253D&md5=d92a3c22cee3c286c2608d5cf719b14c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fml500463t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500463t%26sid%3Dliteratum%253Aachs%26aulast%3DRombouts%26aufirst%3DF.%2BJ.%2BR.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DBuijnsters%26aufirst%3DP.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DTovar%26aufirst%3DF.%26aulast%3DSteinbrecher%26aufirst%3DT.%2BB.%26aulast%3DVanhoof%26aufirst%3DG.%26aulast%3DSomers%26aufirst%3DM.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DJ.-I.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3DPyrido%255B4%252C3-e%255D%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazines%2520as%2520Selective%252C%2520Brain%2520Penetrant%2520Phosphodiesterase%25202%2520%2528PDE2%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D282%26epage%3D286%26doi%3D10.1021%2Fml500463t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Redrobe, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jørgensen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christoffersen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montezinho, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastlund, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnerup, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bundgaard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerdrup, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plath, N.</span><span> </span><span class="NLM_article-title">In Vitro and In Vivo Characterisation of Lu AF64280, a Novel, Brain Penetrant Phosphodiesterase (PDE) 2A Inhibitor: Potential Relevance to Cognitive Deficits in Schizophrenia</span> <span class="citation_source-journal">Psychopharmacology (Berl)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">3151</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span><span class="refDoi"> DOI: 10.1007/s00213-014-3492-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1007%2Fs00213-014-3492-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=24577516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlKgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=3151-3167&author=J.+P.+Redrobeauthor=M.+J%C3%B8rgensenauthor=C.+T.+Christoffersenauthor=L.+P.+Montezinhoauthor=J.+F.+Bastlundauthor=M.+Carnerupauthor=C.+Bundgaardauthor=L.+Lerdrupauthor=N.+Plath&title=In+Vitro+and+In+Vivo+Characterisation+of+Lu+AF64280%2C+a+Novel%2C+Brain+Penetrant+Phosphodiesterase+%28PDE%29+2A+Inhibitor%3A+Potential+Relevance+to+Cognitive+Deficits+in+Schizophrenia&doi=10.1007%2Fs00213-014-3492-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia</span></div><div class="casAuthors">Redrobe, John P.; Jorgensen, Morten; Christoffersen, Claus T.; Montezinho, Liliana P.; Bastlund, Jesper F.; Carnerup, Martin; Bundgaard, Christoffer; Lerdrup, Linda; Plath, Niels</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3151-3167</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Here, we present the pharmacol. characterization of Lu AF64280, a novel, selective, brain penetrant phosphodiesterase (PDE) 2A inhibitor, in in vitro/in vivo assays indicative of PDE2A inhibition, and in vivo models/assays relevant to cognitive processing or antipsychotic-like activity.  The in vitro selectivity of Lu AF64280 was detd. against a panel of PDE enzymes and 3',5'-cyclic guanosine monophosphate (cGMP) levels in the hippocampus were detd. using in vivo microdialysis.  Lu AF64280 potently inhibited hPDE2A (Ki = 20 nM), 50-fold above moderate inhibition of both hPDE9A (Ki = 1,000 nM) and hPDE10A (Ki = 1,800 nM), and displayed a >250-fold selectivity over all other full-length human recombinant PDE family members (Ki above 5,000 nM).  Lu AF64280 (20 mg/kg) significantly increased cGMP levels in the hippocampus (p < 0.01 vs. vehicle-treated mice), attenuated sub-chronic phencyclidine-induced deficits in novel object exploration in rats (10 mg/kg, p < 0.001 vs. vehicle-treated), blocked early postnatal phencyclidine-induced deficits in the intradimensional/extradimensional shift task in rats (1 and 10 mg/kg, p < 0.001 vs. vehicle-treated) and attenuated spontaneous P20-N40 auditory gating deficits in DBA/2 mice (20 mg/kg, p < 0.05 vs. vehicle-treated).  In contrast, Lu AF64280 failed to attenuate phencyclidine-induced hyperactivity in mice, and was devoid of antipsychotic-like activity in the conditioned avoidance response paradigm in rats, at any dose tested.  Lu AF64280 represents a novel tool compd. for selective PDE2A inhibition that substantiates a crit. role of this enzyme in cognitive processes under normal and pathol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIxqzVL5lb5rVg90H21EOLACvtfcHk0ljXMgAOouL1NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlKgtr8%253D&md5=74789561beac4e9f901971525e603806</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs00213-014-3492-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-014-3492-7%26sid%3Dliteratum%253Aachs%26aulast%3DRedrobe%26aufirst%3DJ.%2BP.%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DM.%26aulast%3DChristoffersen%26aufirst%3DC.%2BT.%26aulast%3DMontezinho%26aufirst%3DL.%2BP.%26aulast%3DBastlund%26aufirst%3DJ.%2BF.%26aulast%3DCarnerup%26aufirst%3DM.%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DLerdrup%26aufirst%3DL.%26aulast%3DPlath%26aufirst%3DN.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Characterisation%2520of%2520Lu%2520AF64280%252C%2520a%2520Novel%252C%2520Brain%2520Penetrant%2520Phosphodiesterase%2520%2528PDE%2529%25202A%2520Inhibitor%253A%2520Potential%2520Relevance%2520to%2520Cognitive%2520Deficits%2520in%2520Schizophrenia%26jtitle%3DPsychopharmacology%2520%2528Berl%2529%26date%3D2014%26volume%3D231%26spage%3D3151%26epage%3D3167%26doi%3D10.1007%2Fs00213-014-3492-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Helal, C. J.</span><span> </span><span class="NLM_article-title">Identification of a Brain Penetrant, Highly Selective Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Impairment Associated with Schizophrenia (CIAS)</span>. 244th ACS National Meeting & Exposition, Philadelphia, PA, USA, August 19–23, 2012; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+J.+Helal&title=Identification+of+a+Brain+Penetrant%2C+Highly+Selective+Phosphodiesterase+2A+Inhibitor+for+the+Treatment+of+Cognitive+Impairment+Associated+with+Schizophrenia+%28CIAS%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26atitle%3DIdentification%2520of%2520a%2520Brain%2520Penetrant%252C%2520Highly%2520Selective%2520Phosphodiesterase%25202A%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cognitive%2520Impairment%2520Associated%2520with%2520Schizophrenia%2520%2528CIAS%2529%26jtitle%3D244th%2520ACS%2520National%2520Meeting%2520%2526%2520Exposition%252C%2520Philadelphia%252C%2520PA%252C%2520USA%252C%2520August%252019%25E2%2580%259323%252C%25202012%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Gomez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massari, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freestone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoder, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadbent, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barido, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmelzer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neul, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebring, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabatabaei, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenbucher, J. G.</span><span> </span><span class="NLM_article-title">Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2037</span><span class="NLM_x">–</span> <span class="NLM_lpage">2051</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01793</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01793" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1Sjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2037-2051&author=L.+Gomezauthor=M.+E.+Massariauthor=T.+Vickersauthor=G.+Freestoneauthor=W.+Vernierauthor=K.+Lyauthor=R.+Xuauthor=M.+McCarrickauthor=T.+Marroneauthor=M.+Metzauthor=Y.+G.+Yanauthor=Z.+W.+Yoderauthor=R.+Lemusauthor=N.+J.+Broadbentauthor=R.+Baridoauthor=N.+Warrenauthor=K.+Schmelzerauthor=D.+Neulauthor=D.+Leeauthor=C.+B.+Andersenauthor=K.+Sebringauthor=K.+Aertgeertsauthor=X.+Zhouauthor=A.+Tabatabaeiauthor=M.+Petersauthor=J.+G.+Breitenbucher&title=Design+and+Synthesis+of+Novel+and+Selective+Phosphodiesterase+2+%28PDE2a%29+Inhibitors+for+the+Treatment+of+Memory+Disorders&doi=10.1021%2Facs.jmedchem.6b01793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders</span></div><div class="casAuthors">Gomez, Laurent; Massari, Mark Eben; Vickers, Troy; Freestone, Graeme; Vernier, William; Ly, Kiev; Xu, Rui; McCarrick, Margaret; Marrone, Tami; Metz, Markus; Yan, Yingzhou G.; Yoder, Zachary W.; Lemus, Robert; Broadbent, Nicola J.; Barido, Richard; Warren, Noelle; Schmelzer, Kara; Neul, David; Lee, Dong; Andersen, Carsten B.; Sebring, Kristen; Aertgeerts, Kathleen; Zhou, Xianbo; Tabatabaei, Ali; Peters, Marco; Breitenbucher, J. Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2037-2051</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of potent and selective [1,2,4]triazolo[1,5-a]pyrimidine PDE2a inhibitors is reported.  The design and improvement of the binding properties of this series was achieved using X-ray crystal structures in conjunction with careful anal. of electronic and structural requirements for the PDE2a enzyme.  One of the lead compds., compd. I (DNS-8254), was identified as a potent and highly selective PDE2a enzyme inhibitor with favorable rat pharmacokinetic properties.  Interestingly, the increased potency of compd. I was facilitated by the formation of a halogen bond with the oxygen of Tyr827 present in the PDE2a active site.  In vivo, compd. I demonstrated significant memory enhancing effects in a rat model of novel object recognition.  Taken together, these data suggest that compd. I may be a useful tool to explore the pharmacol. of selective PDE2a inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6ML_QxZhnWLVg90H21EOLACvtfcHk0lhuTaSn-auk1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1Sjuro%253D&md5=fe8df71fbd1f61423352dfcb862d9d53</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01793%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DL.%26aulast%3DMassari%26aufirst%3DM.%2BE.%26aulast%3DVickers%26aufirst%3DT.%26aulast%3DFreestone%26aufirst%3DG.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DLy%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DMcCarrick%26aufirst%3DM.%26aulast%3DMarrone%26aufirst%3DT.%26aulast%3DMetz%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%2BG.%26aulast%3DYoder%26aufirst%3DZ.%2BW.%26aulast%3DLemus%26aufirst%3DR.%26aulast%3DBroadbent%26aufirst%3DN.%2BJ.%26aulast%3DBarido%26aufirst%3DR.%26aulast%3DWarren%26aufirst%3DN.%26aulast%3DSchmelzer%26aufirst%3DK.%26aulast%3DNeul%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DAndersen%26aufirst%3DC.%2BB.%26aulast%3DSebring%26aufirst%3DK.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DTabatabaei%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DM.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520and%2520Selective%2520Phosphodiesterase%25202%2520%2528PDE2a%2529%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Memory%2520Disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2037%26epage%3D2051%26doi%3D10.1021%2Facs.jmedchem.6b01793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Boess, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Staay, F.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erb, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Staveren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vente, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickaerts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koenig, G.</span><span> </span><span class="NLM_article-title">Inhibition of Phosphodiesterase 2 Increases Neuronal cGMP, Synaptic Plasticity and Memory Performance</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1081</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2004.07.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.neuropharm.2004.07.040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1081-1092&author=F.+G.+Boessauthor=M.+Hendrixauthor=F.-J.+van+der+Staayauthor=C.+Erbauthor=R.+Schreiberauthor=W.+van+Staverenauthor=J.+de+Venteauthor=J.+Prickaertsauthor=A.+Bloklandauthor=G.+Koenig&title=Inhibition+of+Phosphodiesterase+2+Increases+Neuronal+cGMP%2C+Synaptic+Plasticity+and+Memory+Performance&doi=10.1016%2Fj.neuropharm.2004.07.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2004.07.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2004.07.040%26sid%3Dliteratum%253Aachs%26aulast%3DBoess%26aufirst%3DF.%2BG.%26aulast%3DHendrix%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BStaay%26aufirst%3DF.-J.%26aulast%3DErb%26aufirst%3DC.%26aulast%3DSchreiber%26aufirst%3DR.%26aulast%3Dvan%2BStaveren%26aufirst%3DW.%26aulast%3Dde%2BVente%26aufirst%3DJ.%26aulast%3DPrickaerts%26aufirst%3DJ.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DKoenig%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520Phosphodiesterase%25202%2520Increases%2520Neuronal%2520cGMP%252C%2520Synaptic%2520Plasticity%2520and%2520Memory%2520Performance%26jtitle%3DNeuropharmacology%26date%3D2004%26volume%3D47%26spage%3D1081%26epage%3D1092%26doi%3D10.1016%2Fj.neuropharm.2004.07.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Rutten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Donkelaar, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrington, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbusch, H. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, P. A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickaerts, J. H. H. J.</span><span> </span><span class="NLM_article-title">Phosphodiesterase Inhibitors Enhance Object Memory Independent of Cerebral Blood Flow and Glucose Utilization in Rats</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1914</span><span class="NLM_x">–</span> <span class="NLM_lpage">1925</span><span class="refDoi"> DOI: 10.1038/npp.2009.24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1038%2Fnpp.2009.24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=19262466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFSju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=1914-1925&author=K.+Ruttenauthor=E.+L.+Van+Donkelaarauthor=L.+Ferringtonauthor=A.+Bloklandauthor=E.+Bollenauthor=H.+W.+M.+Steinbuschauthor=P.+A.+T.+Kellyauthor=J.+H.+H.+J.+Prickaerts&title=Phosphodiesterase+Inhibitors+Enhance+Object+Memory+Independent+of+Cerebral+Blood+Flow+and+Glucose+Utilization+in+Rats&doi=10.1038%2Fnpp.2009.24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats</span></div><div class="casAuthors">Rutten, Kris; Van Donkelaar, Eva L.; Ferrington, Linda; Blokland, Arjan; Bollen, Eva; Steinbusch, Harry W. M.; Kelly, Paul A. T.; Prickaerts, Jos H. H. J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1914-1925</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) inhibitors prevent the breakdown of the second messengers, cAMP (cAMP) and cyclic GMP (cGMP), and are currently studied as possible targets for cognitive enhancement.  Earlier studies indicated beneficial effects of PDE inhibitors in object recognition.  In this study we tested the effects of three PDE inhibitors on spatial memory as assessed in a place and object recognition task.  Furthermore, as both cAMP and cGMP are known vasodilators, the effects of PDE inhibition on cognitive functions could be explained by enhancement of cerebrovascular function.  We examd. this possibility by measuring the effects of PDE5 and PDE4 inhibitor treatment on local cerebral blood flow and glucose utilization in rats using [14C]-iodoantipyrine and [14C]-2-deoxyglucose quant. autoradiog., resp.  In the spatial location task, PDE5 inhibition (cGMP) with vardenafil enhanced only early phase consolidation, PDE4 inhibition (cAMP) with rolipram enhanced only late phase consolidation, and PDE2 inhibition (cAMP and cGMP) with Bay 60-7550 enhanced both consolidation processes.  Furthermore, PDE5 inhibition had no cerebrovascular effects in hippocampal or rhinal areas.  PDE4 inhibition increased rhinal, but not hippocampal blood flow, whereas it decreased glucose utilization in both areas.  In general, PDE5 inhibition decreased the ratio between blood flow and glucose utilization, indicative of general oligemia; whereas PDE4 inhibition increased this ratio, indicative of general hyperemia.  Both oligemic and hyperemic conditions are detrimental for brain function and do not explain memory enhancement.  These results underscore the specific effects of cAMP and cGMP on memory consolidation (object and spatial memory) and provide evidence that the underlying mechanisms of PDE inhibition on cognition are independent of cerebrovascular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfAElwT0GL1rVg90H21EOLACvtfcHk0ljRF8HeEQkpMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFSju7c%253D&md5=506d0fbcb1b4a7a0c25bf92ab08fc270</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2009.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2009.24%26sid%3Dliteratum%253Aachs%26aulast%3DRutten%26aufirst%3DK.%26aulast%3DVan%2BDonkelaar%26aufirst%3DE.%2BL.%26aulast%3DFerrington%26aufirst%3DL.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DBollen%26aufirst%3DE.%26aulast%3DSteinbusch%26aufirst%3DH.%2BW.%2BM.%26aulast%3DKelly%26aufirst%3DP.%2BA.%2BT.%26aulast%3DPrickaerts%26aufirst%3DJ.%2BH.%2BH.%2BJ.%26atitle%3DPhosphodiesterase%2520Inhibitors%2520Enhance%2520Object%2520Memory%2520Independent%2520of%2520Cerebral%2520Blood%2520Flow%2520and%2520Glucose%2520Utilization%2520in%2520Rats%26jtitle%3DNeuropsychopharmacology%26date%3D2009%26volume%3D34%26spage%3D1914%26epage%3D1925%26doi%3D10.1038%2Fnpp.2009.24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Reneerkens, O. A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hage, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbusch, H. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickaerts, J.</span><span> </span><span class="NLM_article-title">Inhibition of Phoshodiesterase Type 2 or Type 10 Reverses Object Memory Deficits Induced by Scopolamine or MK-801</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1016/j.bbr.2012.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.bbr.2012.08.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=2013&pages=16-22&author=O.+A.+H.+Reneerkensauthor=K.+Ruttenauthor=E.+Bollenauthor=T.+Hageauthor=A.+Bloklandauthor=H.+W.+M.+Steinbuschauthor=J.+Prickaerts&title=Inhibition+of+Phoshodiesterase+Type+2+or+Type+10+Reverses+Object+Memory+Deficits+Induced+by+Scopolamine+or+MK-801&doi=10.1016%2Fj.bbr.2012.08.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2012.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2012.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DReneerkens%26aufirst%3DO.%2BA.%2BH.%26aulast%3DRutten%26aufirst%3DK.%26aulast%3DBollen%26aufirst%3DE.%26aulast%3DHage%26aufirst%3DT.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DSteinbusch%26aufirst%3DH.%2BW.%2BM.%26aulast%3DPrickaerts%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520Phoshodiesterase%2520Type%25202%2520or%2520Type%252010%2520Reverses%2520Object%2520Memory%2520Deficits%2520Induced%2520by%2520Scopolamine%2520or%2520MK-801%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2013%26volume%3D236%26spage%3D16%26epage%3D22%26doi%3D10.1016%2Fj.bbr.2012.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Pandit, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillman, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span> </span><span class="NLM_article-title">Mechanism for the Allosteric Regulation of Phosphodiesterase 2A Deduced from the X-ray Structure of a Near Full-Length Construct</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">18225</span><span class="NLM_x">–</span> <span class="NLM_lpage">18230</span><span class="refDoi"> DOI: 10.1073/pnas.0907635106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1073%2Fpnas.0907635106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=19828435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVags7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=18225-18230&author=J.+Panditauthor=M.+D.+Formanauthor=K.+F.+Fennellauthor=K.+S.+Dillmanauthor=F.+S.+Menniti&title=Mechanism+for+the+Allosteric+Regulation+of+Phosphodiesterase+2A+Deduced+from+the+X-ray+Structure+of+a+Near+Full-Length+Construct&doi=10.1073%2Fpnas.0907635106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct</span></div><div class="casAuthors">Pandit, Jayvardhan; Forman, Michael D.; Fennell, Kimberly F.; Dillman, Keith S.; Menniti, Frank S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">18225-18230, S18225/1-S18225/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We report the x-ray crystal structure of a phosphodiesterase (PDE) that includes both catalytic and regulatory domains.  PDE2A (215-900) crystd. as a dimer in which each subunit had an extended organization of regulatory GAF-A and GAF-B and catalytic domains connected by long α-helixes.  The subunits cross at the GAF-B/catalytic domain linker, and each side of the dimer contains in series the GAF-A and GAF-B of one subunit and the catalytic domain of the other subunit.  A dimer interface extends over the entire length of the mol.  The substrate binding pocket of each catalytic domain is occluded by the H-loop.  We deduced from comparisons with structures of isolated, ligand-bound catalytic subunits that the H-loop swings out to allow substrate access.  However, in dimeric PDE2A (215-900), the H-loops of the two catalytic subunits pack against each other at the dimer interface, necessitating movement of the catalytic subunits to allow for H-loop movement.  Comparison of the unliganded GAF-B of PDE2A (215-900) with previous structures of isolated, cGMP-bound GAF domains indicates that cGMP binding induces a significant shift in the GAF-B/catalytic domain linker.  We propose that cGMP binding to GAF-B causes movement, through this linker region, of the catalytic domains, such that the H-loops no longer pack at the dimer interface and are, instead, free to swing out to allow substrate access.  This increase in substrate access is proposed as the basis for PDE2A activation by cGMP and may be a general mechanism for regulation of all PDEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh-kgJc6VX2bVg90H21EOLACvtfcHk0ljRF8HeEQkpMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVags7vO&md5=73ddfdb3ffb861674744a1fbeef7c881</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0907635106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0907635106%26sid%3Dliteratum%253Aachs%26aulast%3DPandit%26aufirst%3DJ.%26aulast%3DForman%26aufirst%3DM.%2BD.%26aulast%3DFennell%26aufirst%3DK.%2BF.%26aulast%3DDillman%26aufirst%3DK.%2BS.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26atitle%3DMechanism%2520for%2520the%2520Allosteric%2520Regulation%2520of%2520Phosphodiesterase%25202A%2520Deduced%2520from%2520the%2520X-ray%2520Structure%2520of%2520a%2520Near%2520Full-Length%2520Construct%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D18225%26epage%3D18230%26doi%3D10.1073%2Fpnas.0907635106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Müller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faeh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span> </span><span class="NLM_article-title">Fluorine in Pharmaceuticals: Looking beyond Intuition</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">317</span><span class="NLM_x">, </span> <span class="NLM_fpage">1881</span><span class="NLM_x">–</span> <span class="NLM_lpage">1886</span><span class="refDoi"> DOI: 10.1126/science.1131943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1126%2Fscience.1131943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=17901324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOlt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2007&pages=1881-1886&author=K.+M%C3%BCllerauthor=C.+Faehauthor=F.+Diederich&title=Fluorine+in+Pharmaceuticals%3A+Looking+beyond+Intuition&doi=10.1126%2Fscience.1131943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in Pharmaceuticals: Looking Beyond Intuition</span></div><div class="casAuthors">Mueller, Klaus; Faeh, Christoph; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">5846</span>),
    <span class="NLM_cas:pages">1881-1886</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Fluorine substituents have become a widespread and important drug component, their introduction facilitated by the development of safe and selective fluorinating agents.  Organofluorine affects nearly all phys. and adsorption, distribution, metab., and excretion properties of a lead compd.  Its inductive effects are relatively well understood, enhancing bioavailability, for example, by reducing the basicity of neighboring amines.  In contrast, exploration of the specific influence of carbon-fluorine single bonds on docking interactions, whether through direct contact with the protein or through stereoelectronic effects on mol. conformation of the drug, has only recently begun.  Here, we review exptl. progress in this vein and add complementary anal. based on comprehensive searches in the Cambridge Structural Database and the Protein Data Bank.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwX-YnONRc3LVg90H21EOLACvtfcHk0ljRF8HeEQkpMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOlt7rN&md5=f804876c801518e48d0bdb7d87b7fb1c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.1131943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1131943%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DFaeh%26aufirst%3DC.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DFluorine%2520in%2520Pharmaceuticals%253A%2520Looking%2520beyond%2520Intuition%26jtitle%3DScience%26date%3D2007%26volume%3D317%26spage%3D1881%26epage%3D1886%26doi%3D10.1126%2Fscience.1131943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandretto, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span> </span><span class="NLM_article-title">Kinase Inhibitors and the Case for CH···O Hydrogen Bonds in Protein–Ligand Binding</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">–</span> <span class="NLM_lpage">576</span><span class="refDoi"> DOI: 10.1002/prot.10259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1002%2Fprot.10259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2002&pages=567-576&author=A.+C.+Pierceauthor=K.+L.+Sandrettoauthor=G.+W.+Bemis&title=Kinase+Inhibitors+and+the+Case+for+CH%C2%B7%C2%B7%C2%B7O+Hydrogen+Bonds+in+Protein%E2%80%93Ligand+Binding&doi=10.1002%2Fprot.10259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fprot.10259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.10259%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DSandretto%26aufirst%3DK.%2BL.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26atitle%3DKinase%2520Inhibitors%2520and%2520the%2520Case%2520for%2520CH%25C2%25B7%25C2%25B7%25C2%25B7O%2520Hydrogen%2520Bonds%2520in%2520Protein%25E2%2580%2593Ligand%2520Binding%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2002%26volume%3D49%26spage%3D567%26epage%3D576%26doi%3D10.1002%2Fprot.10259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span> </span><span class="NLM_article-title">X-ray Crystal Structure of Phosphodiesterase 2 in Complex with a Highly Selective, Nanomolar Inhibitor Reveals a Binding-Induced Pocket Important for Selectivity</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">11708</span><span class="NLM_x">–</span> <span class="NLM_lpage">11711</span><span class="refDoi"> DOI: 10.1021/ja404449g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja404449g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=11708-11711&author=J.+Zhuauthor=Q.+Yangauthor=D.+Daiauthor=Q.+Huang&title=X-ray+Crystal+Structure+of+Phosphodiesterase+2+in+Complex+with+a+Highly+Selective%2C+Nanomolar+Inhibitor+Reveals+a+Binding-Induced+Pocket+Important+for+Selectivity&doi=10.1021%2Fja404449g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fja404449g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja404449g%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DDai%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DQ.%26atitle%3DX-ray%2520Crystal%2520Structure%2520of%2520Phosphodiesterase%25202%2520in%2520Complex%2520with%2520a%2520Highly%2520Selective%252C%2520Nanomolar%2520Inhibitor%2520Reveals%2520a%2520Binding-Induced%2520Pocket%2520Important%2520for%2520Selectivity%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D11708%26epage%3D11711%26doi%3D10.1021%2Fja404449g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, Y.</span><span> </span><span class="NLM_article-title">Kinetic Solubility and Lipophilicity Evaluation Connecting Formulation Technology Strategy Perspective</span> <span class="citation_source-journal">J. Drug Delivery Sci. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span><span class="refDoi"> DOI: 10.1016/j.jddst.2016.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2Fj.jddst.2016.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC28XktFers7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=13-18&author=K.+Yamamotoauthor=Y.+Ikeda&title=Kinetic+Solubility+and+Lipophilicity+Evaluation+Connecting+Formulation+Technology+Strategy+Perspective&doi=10.1016%2Fj.jddst.2016.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic solubility and lipophilicity evaluation connecting formulation technology strategy perspective</span></div><div class="casAuthors">Yamamoto, Katsuhiko; Ikeda, Yukihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Delivery Science and Technology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-18</span>CODEN:
                <span class="NLM_cas:coden">JDDSAL</span>;
        ISSN:<span class="NLM_cas:issn">1773-2247</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lipophilicity and soly. are important physicochem. properties of pharmaceutical compds., esp. orally administration drugs.  In this study, we developed a chromatog. distribution coeff. (LogD) detn. method as lipophilicity evaluation and a kinetic soly. procedure with rapid quantitation by HPLC-UV.  Both methods are simple and applicable for use of conventional equipment in early stage of drug discovery and development.  Actually both data of model drugs were collected and discussed to improve the physicochem. properties using formulation technologies such as solubilization and enteric coating.  The parallel measurement and consideration of both sets of data enables not only detail evaluation of the physicochem. properties but also the perspective of the relevant formulation strategies of drugs.  Such rational evaluation will facilitate the development of high quality and effective drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq69TBJfRT8dLVg90H21EOLACvtfcHk0lijvE0Y3D7IUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktFers7g%253D&md5=73f97d1fb1447eee30aca663d8686c35</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.jddst.2016.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jddst.2016.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DY.%26atitle%3DKinetic%2520Solubility%2520and%2520Lipophilicity%2520Evaluation%2520Connecting%2520Formulation%2520Technology%2520Strategy%2520Perspective%26jtitle%3DJ.%2520Drug%2520Delivery%2520Sci.%2520Technol.%26date%3D2016%26volume%3D33%26spage%3D13%26epage%3D18%26doi%3D10.1016%2Fj.jddst.2016.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Omori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotera, J.</span><span> </span><span class="NLM_article-title">Overview of PDEs and Their Regulation</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1161/01.RES.0000256354.95791.f1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1161%2F01.RES.0000256354.95791.f1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=17307970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsF2kurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=309-327&author=K.+Omoriauthor=J.+Kotera&title=Overview+of+PDEs+and+Their+Regulation&doi=10.1161%2F01.RES.0000256354.95791.f1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of PDEs and their regulation</span></div><div class="casAuthors">Omori, Kenji; Kotera, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-327</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Contraction and relaxation of vascular smooth muscle and cardiac myocytes are key physiol. events in the cardiovascular system.  These events are regulated by 2nd messengers, cAMP and cGMP, in response to extracellular stimulants.  The strength of signal transduction is controlled by intracellular cyclic nucleotide concns., which are detd. by a balance in the prodn. and degrdn. of cAMP and cGMP.  The degrdn. of cyclic nucleotides is catalyzed by 3',5'-cyclic nucleotide phosphodiesterases (PDEs), and therefore regulation of PDEs hydrolytic activity is important for modulation of cellular functions.  Mammalian PDEs are composed of 21 genes and are categorized into 11 families based on sequence homol., enzymic properties, and sensitivity to inhibitors.  PDE families contain many splice variants that mostly are unique in tissue-expression patterns, gene regulation, enzymic regulation by phosphorylation and regulatory proteins, subcellular localization, and interaction with assocn. proteins.  Each unique variant is closely related to the regulation of a specific cellular signaling.  Thus, multiple PDEs function as a particular modulator of each cardiovascular function and regulate physiol. homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctQ0OjiRTE7Vg90H21EOLACvtfcHk0lijvE0Y3D7IUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsF2kurY%253D&md5=932f5158c5ebdd9a75a41317b0b12955</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000256354.95791.f1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000256354.95791.f1%26sid%3Dliteratum%253Aachs%26aulast%3DOmori%26aufirst%3DK.%26aulast%3DKotera%26aufirst%3DJ.%26atitle%3DOverview%2520of%2520PDEs%2520and%2520Their%2520Regulation%26jtitle%3DCirc.%2520Res.%26date%3D2007%26volume%3D100%26spage%3D309%26epage%3D327%26doi%3D10.1161%2F01.RES.0000256354.95791.f1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Martins, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mumby, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beavo, J. A.</span><span> </span><span class="NLM_article-title">Purification and Characterization of a Cyclic GMP-Stimulated Cyclic Nucleotide Phosphodiesterase from Bovine Tissues</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x">, </span> <span class="NLM_fpage">1973</span><span class="NLM_x">–</span> <span class="NLM_lpage">1979</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1982&pages=1973-1979&author=T.+J.+Martinsauthor=M.+C.+Mumbyauthor=J.+A.+Beavo&title=Purification+and+Characterization+of+a+Cyclic+GMP-Stimulated+Cyclic+Nucleotide+Phosphodiesterase+from+Bovine+Tissues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartins%26aufirst%3DT.%2BJ.%26aulast%3DMumby%26aufirst%3DM.%2BC.%26aulast%3DBeavo%26aufirst%3DJ.%2BA.%26atitle%3DPurification%2520and%2520Characterization%2520of%2520a%2520Cyclic%2520GMP-Stimulated%2520Cyclic%2520Nucleotide%2520Phosphodiesterase%2520from%2520Bovine%2520Tissues%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1982%26volume%3D257%26spage%3D1973%26epage%3D1979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Podzuweit, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nennstiel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, A.</span><span> </span><span class="NLM_article-title">Isozyme Selective Inhibition of cGMP-Stimulated Cyclic Nucleotide Phosphodiesterases by Erythro-9-(2-hydroxy-3-nonyl) Adenine</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">738</span><span class="refDoi"> DOI: 10.1016/0898-6568(95)00042-N</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2F0898-6568%2895%2900042-N" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=8519602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADyaK2MXovVaisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1995&pages=733-738&author=T.+Podzuweitauthor=P.+Nennstielauthor=A.+M%C3%BCller&title=Isozyme+Selective+Inhibition+of+cGMP-Stimulated+Cyclic+Nucleotide+Phosphodiesterases+by+Erythro-9-%282-hydroxy-3-nonyl%29+Adenine&doi=10.1016%2F0898-6568%2895%2900042-N"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Isoenzyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine</span></div><div class="casAuthors">Podzuweit, Thomas; Nennstiel, Peter; Mueller, Antje</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">733-8</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), a potent inhibitor of adenosine deaminase (ADA), was tested as an inhibitor of the sol. cyclic nucleotide phosphodiesterase (PDE) isoenzymes from pig and human myocardium.  Four sol. PDE activities were resolved from human papillary muscle exts. using anion exchange chromatog. (DEAE Sepharose CL-6B).  These activities were designated PDE I-IV according to the nomenclature of Beavo.  PDE I was stimulated by Ca2+-calmodulin and PDE II by cGMP (1 μM).  PDE III was inhibited by cGMP (1 μM) as well as by SK&F 94120, and PDE IV was inhibited by both rolipram and Ro 20-1724.  Enzyme kinetics and inhibition consts. were similar with the PDE isoenzymes from pig heart.  However, porcine myocardium lacked Ca2+-calmodulin-stimulated sol. PDE I activity.  The present data reveal that EHNA exerted a concn.-dependent inhibition of the cGMP-stimulated PDE II (cGs-PDE) (IC50: 0.8 μM (human), 2 μM (pig)) but did not inhibit the other PDE isoenzymes (IC50 > 100 μM).  These findings indicate that EHNA is a potent and, as far as cytosolic PDEs are concerned, selective inhibitor of cGMP-stimulated PDEs.  The compd. may lend itself to the rational design of other isoenzyme selective PDE II inhibitors and for examg. the specific biol. functions of cGs-PDEs.  EHNA may be used in systems in which inhibition of ADA is of no concern.  Conversely, dual inhibition of both ADA and cGs-PDE by EHNA may cause accumulation of two inhibitory metabolites, adenosine and cGMP, which may act in synergy to mediate diverse pharmacol. responses, including antiviral, antitumor, and antiarrhythmic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDp9d-Vx26qLVg90H21EOLACvtfcHk0li_oApnpQhKDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovVaisL4%253D&md5=af2d50c73a87ae3f3effef1521a2eb86</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2F0898-6568%2895%2900042-N&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0898-6568%252895%252900042-N%26sid%3Dliteratum%253Aachs%26aulast%3DPodzuweit%26aufirst%3DT.%26aulast%3DNennstiel%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26atitle%3DIsozyme%2520Selective%2520Inhibition%2520of%2520cGMP-Stimulated%2520Cyclic%2520Nucleotide%2520Phosphodiesterases%2520by%2520Erythro-9-%25282-hydroxy-3-nonyl%2529%2520Adenine%26jtitle%3DCell.%2520Signalling%26date%3D1995%26volume%3D7%26spage%3D733%26epage%3D738%26doi%3D10.1016%2F0898-6568%2895%2900042-N" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Sugimoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirabayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amano, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriwaki, T.</span><span> </span><span class="NLM_article-title">Quantitative Investigation of the Impact of P-Glycoprotein Inhibition on Drug Transport across Blood-Brain Barrier in Rats</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1124/dmd.110.035774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1124%2Fdmd.110.035774" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=8-14&author=H.+Sugimotoauthor=H.+Hirabayashiauthor=Y.+Kimuraauthor=A.+Furutaauthor=N.+Amanoauthor=T.+Moriwaki&title=Quantitative+Investigation+of+the+Impact+of+P-Glycoprotein+Inhibition+on+Drug+Transport+across+Blood-Brain+Barrier+in+Rats&doi=10.1124%2Fdmd.110.035774"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035774%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DHirabayashi%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DFuruta%26aufirst%3DA.%26aulast%3DAmano%26aufirst%3DN.%26aulast%3DMoriwaki%26aufirst%3DT.%26atitle%3DQuantitative%2520Investigation%2520of%2520the%2520Impact%2520of%2520P-Glycoprotein%2520Inhibition%2520on%2520Drug%2520Transport%2520across%2520Blood-Brain%2520Barrier%2520in%2520Rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D8%26epage%3D14%26doi%3D10.1124%2Fdmd.110.035774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Takeuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshitomi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikemoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahi, S.</span><span> </span><span class="NLM_article-title">Establishment and Characterization of the Transformants Stably-Expressing MDR1 Derived from Various Animal Species in LLC-PK1</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1460</span><span class="NLM_x">–</span> <span class="NLM_lpage">1472</span><span class="refDoi"> DOI: 10.1007/s11095-006-0285-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1007%2Fs11095-006-0285-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=16779700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsFOmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=1460-1472&author=T.+Takeuchiauthor=S.+Yoshitomiauthor=T.+Higuchiauthor=K.+Ikemotoauthor=S.+Niwaauthor=T.+Ebiharaauthor=M.+Katohauthor=T.+Yokoiauthor=S.+Asahi&title=Establishment+and+Characterization+of+the+Transformants+Stably-Expressing+MDR1+Derived+from+Various+Animal+Species+in+LLC-PK1&doi=10.1007%2Fs11095-006-0285-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment and Characterization of the Transformants Stably-Expressing MDR1 Derived from Various Animal Species in LLC-PK1</span></div><div class="casAuthors">Takeuchi, Toshiyuki; Yoshitomi, Sumie; Higuchi, Tomoaki; Ikemoto, Keiko; Niwa, Shin-Ichi; Ebihara, Takuya; Katoh, Miki; Yokoi, Tsuyoshi; Asahi, Satoru</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1460-1472</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Stable transformants expressing human multidrug resistance 1 (MDR1), monkey MDR1, canine MDR1, rat MDR1a, rat MDR1b, mouse mdr1a, and mouse mdr1b in LLC-PK1 were established to investigate species differences in P-glycoprotein (P-gp, ABCB1) mediated efflux activity.  Methods: The seven cDNAs of MDR1 from five animals were cloned, and their transformants stably expressing the series of MDR1 in LLC-PK1 were established.  Transport studies of clarithromycin, daunorubicin, digoxin, erythromycin, etoposide, paclitaxel, propranolol, quinidine, ritonavir, saquinavir, verapamil, and vinblastine were performed by using these cells, and efflux activity was compared among the species.  Results: Except for propranolol, all compds. showed efflux activity in all transformants, and were judged to be substrates of P-gp.  There were slight interspecies and interisoforms differences in the substrate recognition.  However, the efflux ratio among the series of the MDR1 stably expressing cells showed good correlation as represented between human and monkey MDR1, and poor correlation as represented between human MDR1 and mouse mdr1a, and human and canine MDR1.  Conclusions: Results in the present study indicate that all MDR1 stably expressing cells have efflux activity for various P-gp substrates, and that interspecies differences and similarities of the P-gp substrate efflux activity may exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr28IPlZqwtHLVg90H21EOLACvtfcHk0li_oApnpQhKDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsFOmur0%253D&md5=a21044c202d7ff2eb8ab27c4623909de</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs11095-006-0285-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-006-0285-7%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DYoshitomi%26aufirst%3DS.%26aulast%3DHiguchi%26aufirst%3DT.%26aulast%3DIkemoto%26aufirst%3DK.%26aulast%3DNiwa%26aufirst%3DS.%26aulast%3DEbihara%26aufirst%3DT.%26aulast%3DKatoh%26aufirst%3DM.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DAsahi%26aufirst%3DS.%26atitle%3DEstablishment%2520and%2520Characterization%2520of%2520the%2520Transformants%2520Stably-Expressing%2520MDR1%2520Derived%2520from%2520Various%2520Animal%2520Species%2520in%2520LLC-PK1%26jtitle%3DPharm.%2520Res.%26date%3D2006%26volume%3D23%26spage%3D1460%26epage%3D1472%26doi%3D10.1007%2Fs11095-006-0285-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Iffland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohls, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kothe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellenberger, T.</span><span> </span><span class="NLM_article-title">Structural Determinants for Inhibitor Specificity and Selectivity in PDE2A Using the Wheat Germ in Vitro Translation System</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">8312</span><span class="NLM_x">–</span> <span class="NLM_lpage">8325</span><span class="refDoi"> DOI: 10.1021/bi047313h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi047313h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=8312-8325&author=A.+Ifflandauthor=D.+Kohlsauthor=S.+Lowauthor=J.+Luanauthor=Y.+Zhangauthor=M.+Kotheauthor=Q.+Caoauthor=A.+V.+Kamathauthor=Y.+H.+Dingauthor=T.+Ellenberger&title=Structural+Determinants+for+Inhibitor+Specificity+and+Selectivity+in+PDE2A+Using+the+Wheat+Germ+in+Vitro+Translation+System&doi=10.1021%2Fbi047313h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fbi047313h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi047313h%26sid%3Dliteratum%253Aachs%26aulast%3DIffland%26aufirst%3DA.%26aulast%3DKohls%26aufirst%3DD.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DLuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DDing%26aufirst%3DY.%2BH.%26aulast%3DEllenberger%26aufirst%3DT.%26atitle%3DStructural%2520Determinants%2520for%2520Inhibitor%2520Specificity%2520and%2520Selectivity%2520in%2520PDE2A%2520Using%2520the%2520Wheat%2520Germ%2520in%2520Vitro%2520Translation%2520System%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D8312%26epage%3D8325%26doi%3D10.1021%2Fbi047313h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-Ray Diffraction Data Collected in Oscillation Mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-Ray+Diffraction+Data+Collected+in+Oscillation+Mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0li_oApnpQhKDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-Ray%2520Diffraction%2520Data%2520Collected%2520in%2520Oscillation%2520Mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Vagin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teplyakov, A.</span><span> </span><span class="NLM_article-title">MOLREP: an Automated Program for Molecular Replacement</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">–</span> <span class="NLM_lpage">1025</span><span class="refDoi"> DOI: 10.1107/S0021889897006766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1107%2FS0021889897006766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1997&pages=1022-1025&author=A.+Vaginauthor=A.+Teplyakov&title=MOLREP%3A+an+Automated+Program+for+Molecular+Replacement&doi=10.1107%2FS0021889897006766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">MOLREP: an automated program for molecular replacement</span></div><div class="casAuthors">Vagin, Alexei; Teplyakov, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1022-1025</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">MOLREP is an automated program for mol. replacement which uses effective new approaches in data processing and rotational and translational searching.  These include an automatic choice of all parameters, scaling by Patterson origin peaks and soft resoln. cutoff.  One of the cornerstones of the program is an original full-symmetry translation function combined with a packing function.  Information from the model already placed in the cell is incorporated in both translation and packing functions.  A no. of tests using exptl. data proved the ability of the program to find the correct soln. in difficult cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkGXdZ-nTKxLVg90H21EOLACvtfcHk0lix_z-CqvYCuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D&md5=96af64aedd8a8f018c3c18b57a6b4b21</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1107%2FS0021889897006766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889897006766%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DTeplyakov%26aufirst%3DA.%26atitle%3DMOLREP%253A%2520an%2520Automated%2520Program%2520for%2520Molecular%2520Replacement%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1997%26volume%3D30%26spage%3D1022%26epage%3D1025%26doi%3D10.1107%2FS0021889897006766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Collaborative Computational Project Number 4</span><span> </span><span class="NLM_article-title">The CCP4 Suite: Programs for Protein Crystallography</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span><span class="refDoi"> DOI: 10.1107/S0907444994003112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=15299374" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=760-763&author=Collaborative+Computational+Project+Number+4&title=The+CCP4+Suite%3A+Programs+for+Protein+Crystallography&doi=10.1107%2FS0907444994003112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520CCP4%2520Suite%253A%2520Programs%2520for%2520Protein%2520Crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2FS0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and Development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+Development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lix_z-CqvYCuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520Development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XKM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XKM','PDB','5XKM'); return false;">PDB: 5XKM</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i80"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00709">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_06167"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00709">10.1021/acs.jmedchem.7b00709</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">X-ray data collection and refinement statistics for the crystal structure of PDE2A in complex with compound <b>38a</b> and molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00709/suppl_file/jm7b00709_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00709/suppl_file/jm7b00709_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00709/suppl_file/jm7b00709_si_001.pdf">jm7b00709_si_001.pdf (129.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00709/suppl_file/jm7b00709_si_002.csv">jm7b00709_si_002.csv (1.12 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates of the crystal structure of PDE2A in complex with compound <b>38a</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XKM">5XKM</a>) have been deposited in the Protein Data Bank. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00709&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00709%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-18%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00709" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679abff70ac33c04","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
